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Colorectal cancer surgery and adhesions 
Surgical trauma, invasive pathogens, and tumors are all known triggers for an inflammatory reaction 
of the peritoneum, thus, can potentially cause adhesion formation. Not surprisingly, colorectal 
surgery is associated with high risk of adhesions and adhesion-related complications.1-3 In colorectal 
resection, large wound surfaces are created on the lateral abdominal wall, retroperitoneum, and 
occasionally, the omentum and pelvic organs loosening attachments and dividing mesentery. 
Colorectal surgery always involves some degree of contamination of the peritoneal cavity, even in 
elective surgery. In addition, a substantial number of colorectal surgical procedures are performed 
because of a perforation: this enhances the risk of various levels of contamination. Colorectal cancer 
is the main indication for colorectal surgery, with approximately 7,000 colon and 2,500 rectum 
operations for primary colorectal cancer performed annually in the Netherlands.4 
Adhesion-related complications have a significant adverse effect on patients’ health, and lead to an 
increased workload in clinical practice. After an abdominal surgical procedure, many patients 
develop an episode of small bowel obstruction, which is usually caused by adhesions. This often 
requires emergency surgery with adhesiolysis.5-7 Adhesiolysis in elective repeat surgery is associated 
with inadvertent bowel injury, longer operating time, and conversion to an open approach in 
laparoscopic procedures.8, 9 Other consequences of adhesions include decreased pregnancy rates, 
increased fertility treatments, and chronic abdominal pain.10 
 
Adhesions and laparoscopy 
The majority of studies on adhesion formation and adhesion-related complications focus on open 
surgery. The question of the extent of the adhesion problem in laparoscopic surgery arises. 
Laparoscopy limits parietal peritoneal injury due to the use of smaller incisions. In laparoscopy, tissue 
manipulation is minimized (e.g. no retractors, no gloves), blood loss is less, and the closed peritoneal 
cavity prohibits the introduction of large swabs, which are factors that are known stimuli in adhesion 
formation.11, 12 In two nationwide surveys in the Netherlands, both gynecologists and surgeons were 
found to believe that laparoscopic technique reduces adhesions.13, 14 However, the evidence that 
supports this assumption is limited to a few comparative studies that have reported lower composite 
adhesion scores after laparoscopic colorectal surgery in small series.15-18 More studies have been 
published on the incidence of adhesion-related clinical endpoints after laparoscopic colorectal 
surgery. In recent years, two large, population-based register studies, showed a lower risk for 
adhesion-related readmissions and small bowel obstruction after laparoscopic colorectal surgery, 
compared to open colorectal surgery.19, 20 A meta-analysis of non-randomized studies showed that 
laparoscopy, in general, seems to have a lower incidence of small bowel obstruction.21 Although it 
seems plausible that these advantages of laparoscopic surgery could be the result of less adhesion 
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formation, reliable data on differences in incidence of adhesions after laparoscopic or open surgery is 
lacking. 
Even in modern, minimally invasive surgery, adhesion formation remains relevant, because 
adhesions are a risk factor for conversion from minimally invasive to open colectomy.22 Laparoscopic 
conversion itself is associated with more postoperative complications, and even with worse overall 
survival rates.23, 24  
 
Adhesions and oncologic resection 
Patients undergoing colorectal cancer surgery frequently have a history of abdominal surgery, and 
consequential intra-abdominal adhesions.8 If adhesions surround the tumor, identifying structures 
and avoiding iatrogenic injury might be difficult and could compromise the resection. As a result, the 
extent of colorectal resection may be jeopardized, with possibly smaller or even incomplete 
resection margins.  Narrow resection margins have been identified as risk factors for poor lymph 
node harvest, alongside patient-related factors, such as male gender and increasing age.25 A lower 
number of lymph nodes harvested results in under-staging and subsequent under-treatment of 
patients.26 More extensive nodal dissection is associated with improved survival, although the causal 
relation between the number of nodes and outcome remains a topic of debate.26, 27 Influence of 
repeat surgery on oncological parameters has scarcely been reported. Two retrospective studies 
showed no difference in number of harvested lymph nodes and resection margin between patients 
with- or without previous abdominal surgery.28, 29 Both studies comprised low numbers of patients 
and both reported the overall mean number of lymph nodes harvested at less than 10. This low 
number of lymph nodes harvested possibly reflects inadequate surgical resection or inadequate 
quality of histopathological examination of the specimens that could confound conclusions on the 
impact of previous abdominal surgery. Importantly, these studies provided no information on 
adhesion formation as a cause of poorer oncologic resection quality. If pre-existing adhesions in 
colorectal surgery jeopardize oncologic resection, this would seriously further increase the burden of 
adhesions, with possibly the same negative effect in oncologic reoperation for (recurrent) liver 
metastases, local recurrence, or peritoneal metastases.30, 31  
 
Adhesion prevention 
The ultimate aim of adhesion preventive measures and products is to increase the number of 
patients without any adhesion formation to 100 percent, as no adhesions means no adhesion related 
complications. With good surgical techniques (e.g. minimization of surgical trauma, avoiding 
introduction of foreign materials), adhesions can be reduced, but not prevented.11 Adhesion barriers 
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seem necessary to increase the number of patients without any adhesion after both open- and 
laparoscopic surgery. In open colorectal surgery, incidence of adhesions can be reduced by 45% 
through the use of an adhesion barrier.32 Today, more than 65% of colorectal resections are 
performed by laparoscopic approach.4 The effect of an adhesion barrier on the incidence of 
adhesions after laparoscopic colorectal surgery is unknown; limited data is present of reduction in 
extent and severity of adhesions. Accurate data on incidence of adhesions after laparoscopic surgery 
is required for optimal design of studies on the effect of adhesion barriers in laparoscopic 
procedures. 
Existing cost-effectiveness calculations of adhesion barriers are based on open surgery and do not 
suffice for current colorectal practice with over 50 percent laparoscopic procedures.33 Many 
colorectal surgeons question cost-effectiveness of barriers in laparoscopic surgery beforehand. New 
data, for example, that derived from modeling and prospective studies of adhesion barriers, will give 
better insight into the question of whether or not  adhesion barriers are safe and (cost-) effective in 
laparoscopic colorectal surgery. 
 
Aims of this thesis 
- To assess the incidence of postoperative adhesions after both open and minimally invasive 
colorectal surgery.  
- To assess the influence of previous abdominal surgery on clinical and histopathological outcome 
of colorectal cancer surgery. 
- To study the possible gain for adhesion barriers in colorectal surgery in the minimally invasive era, 
and if it is expedient. 
 
Outline of the thesis 
In Chapter 2 the response of the peritoneum involved in intraperitoneal inflammation, adhesion 
formation, sepsis, and tumor growth are discussed. Regardless of the specific process, injury to the 
peritoneal mesothelial cells results in activation of an inflammatory response to heal the wound. The 
inflammatory reaction comprises of four interacting pathways: immunological, humoral, coagulation, 
and neurological.  Colorectal cancer surgery is associated with all mentioned noxa to the peritoneum 
and peritoneal cavity.  
In Chapter 3 the impact of adhesiolysis on the clinical outcomes of colorectal surgery and 
histopathological results of colorectal cancer surgery are determined. A total of 249 colorectal 
procedures were selected from the earlier prospective cohort study of adhesiolysis-related problems. 
The incidence of bowel injury, morbidity, costs, and the histopathology between patients undergoing 
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elective colorectal surgery with or without adhesiolysis is also compared. 
In Chapter 4, the evaluation of the effect of prior abdominal surgery on the outcome of colorectal 
cancer surgery is described. The large Dutch Surgical Colorectal Cancer Audit (DSCA) prospective 
database of more than 25, 000 colorectal cancer patients was used. Outcome of primary colorectal 
cancer resection was compared between patients with and patients without prior abdominal surgery. 
Primary outcome measures were: number of lymph nodes harvested; circumferential rectal resection 
margin (CRM); CRM positivity; and completeness of resection in colon cancer. Secondary outcome 
measures were postoperative complications and 30-day mortality. 
Laparoscopic technique is generally thought to decrease the impact of colorectal resection, with 
regard to post-operative recovery, but also with regard to adhesion formation. To date, there is no 
sound evidence to substantiate this assertion.  
In Chapter 5, the incidence of adhesions after laparoscopic versus open colorectal cancer resection is 
investigated. A multicenter prospective study was performed, in which adhesions were scored during 
151 liver resections for colorectal metastases. Comparison was made between prior laparoscopic and 
open colorectal resection on the incidence of adhesions to the ventral abdominal wall around the 
site of the original incision. Secondary outcomes were incidence of any adhesions, extent and 
severity of adhesions, as well as morbidity related to adhesions or adhesiolysis. 
Since minimally invasive techniques are not expected to completely prevent adhesion formation, 
evidence regarding efficacy and safety of adhesion barriers continue to be of interest in the 
laparoscopic era.  
In Chapter 6, adhesion barriers that are approved for clinical use by the Food and Drug 
Administration (FDA) are systematically reviewed and meta-analyzed. Outcome measures were: 
reoperation for adhesive small bowel obstruction; serious adverse events; overall incidence of 
adhesions; operation time; small bowel obstruction by any cause; site-specific incidence of 
adhesions; and adhesion score.  
Despite the efficacy of adhesion barriers and the burden of adhesions, adhesion barriers are seldom 
applied. In a nationwide survey in The Netherlands, only 13.4% of surgeons indicated to have used 
any adhesion barrier in the previous year.13 The survey revealed that surgeons do not believe in the 
efficacy of anti-adhesive agents, lack clarity about when to use the barriers, and think that the costs 
do not outweigh the benefits for the patient.  
In Chapter 7, the expediency of the use of adhesion barriers in colorectal surgery is determined. A 
decision-tree model was developed to determine health costs of treatment strategies with- and 
without the use of adhesion barriers, for both open and laparoscopic operative techniques. 
Probabilities were derived from recently published literature. Only direct healthcare costs were 
included. 
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In Chapter 8, the study protocol is described for a randomized controlled trial to assess efficacy and 
safety of C-Qur™ Film adhesion barrier. This study aimed to add to the evidence on the use of 
adhesion barriers in open and laparoscopic colorectal surgery. The primary endpoint was incidence 
of adhesions at repeat surgery, since it is believed to be the most valuable surrogate endpoint for 
clinically relevant adhesion prevention.  When complete adhesion reduction in a patient is 
accomplished, small bowel obstruction and adhesiolysis at repeat surgery are not likely to occur. 
In Chapter 9 a summary of the thesis and a general discussion are presented. 
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In Chapter 8, the study protocol is described for a randomized controlled trial to assess efficacy and 
safety of C-Qur™ Film adhesion barrier. This study aimed to add to the evidence on the use of 
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of adhesions at repeat surgery, since it is believed to be the most valuable surrogate endpoint for 
clinically relevant adhesion prevention.  When complete adhesion reduction in a patient is 
accomplished, small bowel obstruction and adhesiolysis at repeat surgery are not likely to occur. 
In Chapter 9 a summary of the thesis and a general discussion are presented. 
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Abstract 
The peritoneum is one of the commonest sites for pathological processes in pediatric surgery. Its 
response to pathological processes is characterized by an inammatory reaction with specic 
pathways depending on the type of injury or peritoneal process involved. This review discusses the 
current understanding of peritoneal inammation, adhesion formation, intra-abdominal sepsis, 
peritoneal metastasis, and ascites and briey reviews new therapeutic strategies to treat or prevent 
these pathological entities. Recent studies have improved the understanding of peritoneal responses, 
resulting in possible new targets for prevention and therapy. 
 
Introduction 
The peritoneal cavity is a conned space between the parietal peritoneum lining the abdominal wall, 
the retroperitoneum, and the visceral peritoneum covering the abdominal organs. Its total surface 
area is almost equal to the body surface area of the skin.1 The peritoneum is a serous membrane of 
mesodermal origin, consisting of a monolayer of at mesothelial cells anchored to the basement 
membrane. The subjacent connective tissue consists mainly of loose collagen bers, including 
broblasts, blood and lymphatic vessels, as well as nerve bers.  The mesothelial cells play an active 
role in the physiological function as well as in pathological processes of the peritoneum. The 
peritoneal cavity contains less than 100 ml of serous uid, an ultra-ltrate of plasma, which together 
with hyaluronan and a surfactant, produced by mesothelial cells, facilitates frictionless movement of 
the abdominal organs.2 The peritoneum acts as a bidirectional semipermeable membrane. The 
peritoneal mesothelial cells are interrupted by intermesothelial gaps (stomata of von 
Recklinghausen), which adapt to pathological conditions by retraction of the cell margins in response 
to pathological stimuli and in relation with diaphragmatic movements. At these stomata the 
peritoneal cavity is directly exposed to the extracellular matrix.3 The action of the diaphragm 
generates a cephalad ow of peritoneal uid through the stomata.4 Under normal circumstances, 
approximately one-third of the peritoneal uid drains through the diaphragmatic stomata into the 
main thoracic lymphatic ducts, the remainder exits through the parietal peritoneum. 
The peritoneal defense mechanism can be triggered by various types of pathological processes 
“injuring” the peritoneum. Apart from (surgical) trauma, injury can be caused by invasive pathogens 
and tumor. The peritoneum responds to injury with an inammatory reaction. This inammatory 
reaction comprises four interacting pathways: immunological, humoral, coagulation, and  
neurological. In this article, we aim to give a comprehensive overview of the response to pathological 
processes in the peritoneal cavity. 
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General peritoneal response to injury 
Injury of the peritoneum, whether surgical, inammatory, or ischemic, causes a complex 
inammatory reaction.  This response has an integral role in wound healing and tissue repair to heal 
any sustained damage. The disruption of the cellular membrane, through apoptosis or necrosis, 
causes a release of intracellular molecules such as DNA, ATP, and IL-1α in the extracellular space.5–7 
These have been named as Damage-Associated Molecular Pattern molecules (DAMPs), but the 
mechanisms by which they generate an inammatory response are not fully understood. The DAMPs 
induce a local cascade through activating receptors on mesothelial and local inammatory cells. The 
mesothelial and local inammatory cells produce chemoattractants (IL-8 and MCP-1), cytokines (TNF 
α, IL-1β, and IL-6), and growth factors (TGF β, IGF-1, and PDGF), which result in neutrophil 
extravasation which inltrate the damaged area.8 Mast cells are abundantly present around bowel 
mucosa and are believed to play an important role in the inammatory response of the peritoneum 
by inducing vasodilation through release of histamine. They can also be activated by DAMPs and 
activate several local immunological and endothelial cells and nerve bers.9 Neutrophils persist at the 
injured site for 1–2 days and are followed by monocytes recruited in the same manner; these 
differentiate into macrophages which contribute to the inammatory reaction. The primary injury of 
the peritoneum not only leaves a denuded area with damaged mesothelial cells but also causes 
bleeding and extravasation of plasma proteins. Coagulation is up-regulated through the expression of 
tissue factor (TF) by macrophages and mesothelial cells. Interaction of TF with plasma proteins and 
thrombocytes forms a transient brinous matrix. The formation of an extensive brinous matrix is 
possible because the balance between coagulation and brinolysis is disturbed. The brinogen split 
products are known to promote pleural mesothelial proliferation,  this might also  be  the  case with 
peritoneal mesothelial cells.10 Fibrinolysis, however, is decreased because there is an up-regulation 
of plasminogen activator inhibitor 1 (PAI-1) and a down-regulation of tissue-type plasminogen 
activator (t-PA). There is increasing evidence that inammation and coagulation signicantly affect 
each other. Coagulation is induced by inammatory cytokines, while the coagulation-induced 
modulation of inammatory activity is driven by specic cell receptors on inammatory cells and 
endothelial cells.7 Moreover, thrombocytes play their part in inammation through storage and 
release of the pro- and anti-inammatory factors TGF β and IL-1.5 
The neurological pathway of the inammatory response of the peritoneum is activated by IL-1 
binding to paraganglia cells. The “inammatory reex” is formed by signaling through afferent bers 
of the vagus nerve to parasympathetic regions in the brainstem, leading to the release of 
neuropeptides from efferent   
nerve bers and a resultant feedback on inammation.11 Different neuropeptides can lead to either 
anti-inammatory (e.g., acetylcholine) or proinammatory (e.g., substance P) effects on 
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inammation. 
While in the past resolution of inammation has always been seen as a passive process, the discovery 
of locally acting mediators (pro-resolving mediators) has changed this view.12 These proresolving 
mediators are produced via transcellular biosynthesis (i.e., between neutrophils and thrombocytes) 
and down-regulate the inammatory reaction. 
 
Adhesion formation 
Healing of the injured peritoneum can result in the formation of peritoneal adhesions. As mentioned, 
injury of the peritoneum leads to a denuded surface with submesothelial damage evoking an 
inammatory response. Simultaneously the coagulation cascade is activated and brin deposited at 
the site. A serosanguinous exudate rich in inammatory cells, bronectin, glycosaminoglycans, and 
proteoglycans is secreted through increased vascular permeability. This results in brin deposits that 
form an adhesion between two formerly unconnected structures. Under normal circumstances, 
these brin deposits are degraded by brinolysis. This process of brinolysis is driven by the enzyme 
plasmin produced by macrophages and mesothelial cells. Plasmin is derived from its inactive 
substrate plasminogen by tissue-type plasminogen activator (t-PA) and urokinase-like plasminogen 
activator (u-PA). In its turn, t-PA is inhibited in its reaction by plasminogen activator inhibitor 1 (PAI-
1) to keep the balance. However, peritoneal trauma leads to the absence of adequate brinolytic 
activity of the mesothelium and a mismatch in the brinolytic balance in favor of the persistence of 
brin clots.13 Neighboring organs or the abdominal wall ma y adhere, generating a brin bridge 
between the attached tissues.14 Under the actions of various cytokines, these brin bands are 
transformed into granulation tissue by the ingrowth of capillaries and broblasts and subsequently 
converted into permanent, collagenous, and highly organized tissue containing nerve bers and 
vessels. 
Adhesions frequently cause long-term complications after abdominal and pelvic surgery.  After 
pediatric  abdominal  surgery, the incidence of adhesive small bowel obstruction can be as high as 
15.6%, for example, after treatment of gastroschisis and omphalocele in neonates.15,16 Other 
important clinical consequences of adhesions include infertility, chronic abdominal pain, 
malabsorption, and technical difculties at reoperation. Many pharmacological methods and barriers 
have been used for adhesion prevention but only few have been proven to be successful. Prevention 
of adherence of adjacent structures by keeping them apart seems most efcacious. In a recent 
systematic review, the efcacy and safety of the four adhesion barriers approved for use in Europe 
and the USA were evaluated, showing evidence that membranes of oxidized regenerated cellulose 
and hyaluronate carboxymethylcellulose reduce adhesion formation.17 Moreover, there is evidence 
that hyaluronate carboxymethylcellulose reduces the number of reoperations for adhesive small 
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bowel obstruction. Evidence for efcacy on other clinically critical outcomes is lacking. Of the liquid 
adhesion barriers that are available in the market, icodextrin 4% solution is the most widely used. 
There is, however, limited evidence for the benecial effect of icodextrin on the incidence of small 
bowel obstruction or other adhesion-related complications.17,18 
An understanding of the pathological processes enables the modulation of the peritoneal 
environment and brinolytic capacity, which seems to harbor a therapeutic opportunity to prevent 
postsurgical adhesion formation. Intraperitoneal treatment with recombinant human plasminogen 
activator (rPA) was effective in preventing postoperative adhesion formation in experimental 
studies.13 A pilot study in humans, however, showed no reduction of adhesions.19 Since there was no 
measurable elevation of plasma t-PA level in the treatment group, this negative result was ascribed 
to too small a dosage. 
An interesting option to potentially combine anti-inammatory, anti-coagulatory, and probrinolytic 
properties is the use of statins. Beside their cholesterol-lowering capacity, there is accumulating 
evidence that statins effectively lower plasma levels of CRP, have potent anti-inammatory 
properties, and are effective stimulators of brinolytic activity by increasing t-PA and lowering PAI-
1.20,21 Also, the use of an angiotensin-II receptor blocker has potential efcacy in adhesion prevention 
through decreasing TGF β. The intraperitoneal administration of these agents alone and combined 
effectively reduced postsurgical adhesions in mice.22 However, no data on efcacy in humans are 
available yet. Another potentially viable therapeutic target is substance P (a specic proinammatory 
neuropeptide).23 The effects associated with substance P are increasing inammatory cytokine mRNA 
expression, stimulating angiogenesis, and proliferation of broblasts. This is mainly mediated 
through binding to neurokinin-1 receptor. Binding to the neurokinin-1 receptor can be inhibited 
through intraperitoneal administration of a neurokinin-1 receptor antagonist. In rats, interference 
with the actions of substance P with this antagonist showed early effects on the mRNA expression of 
several key mediators of adhesiogenesis.24 
 
Intra-abdominal infection, abscess formation, and peritonitis 
Intra-abdominal infection encompasses all forms of bacterial peritonitis, intra-abdominal abscesses, 
and infections of intra-abdominal organs. Perforation of a hollow organ is the leading cause of intra-
abdominal infection, followed by postoperative peritonitis, ischemic damage of the bowel wall, 
infection of intra-abdominal organs, and translocation in nonbacterial peritonitis.25 
Within minutes of bacterial invasion, a substantial proportion of the bacteria are absorbed from the 
peritoneal cavity through the stomata of  von  Recklinghausen  in  the  diaphragmatic  peritoneum 
and into the thoracic lymphatics.26 At the same time, the bacteria activate the local response 
triggered by reaction of mesothelial cells and peritoneal macrophages, very similar to the response 
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inammation. 
While in the past resolution of inammation has always been seen as a passive process, the discovery 
of locally acting mediators (pro-resolving mediators) has changed this view.12 These proresolving 
mediators are produced via transcellular biosynthesis (i.e., between neutrophils and thrombocytes) 
and down-regulate the inammatory reaction. 
 
Adhesion formation 
Healing of the injured peritoneum can result in the formation of peritoneal adhesions. As mentioned, 
injury of the peritoneum leads to a denuded surface with submesothelial damage evoking an 
inammatory response. Simultaneously the coagulation cascade is activated and brin deposited at 
the site. A serosanguinous exudate rich in inammatory cells, bronectin, glycosaminoglycans, and 
proteoglycans is secreted through increased vascular permeability. This results in brin deposits that 
form an adhesion between two formerly unconnected structures. Under normal circumstances, 
these brin deposits are degraded by brinolysis. This process of brinolysis is driven by the enzyme 
plasmin produced by macrophages and mesothelial cells. Plasmin is derived from its inactive 
substrate plasminogen by tissue-type plasminogen activator (t-PA) and urokinase-like plasminogen 
activator (u-PA). In its turn, t-PA is inhibited in its reaction by plasminogen activator inhibitor 1 (PAI-
1) to keep the balance. However, peritoneal trauma leads to the absence of adequate brinolytic 
activity of the mesothelium and a mismatch in the brinolytic balance in favor of the persistence of 
brin clots.13 Neighboring organs or the abdominal wall ma y adhere, generating a brin bridge 
between the attached tissues.14 Under the actions of various cytokines, these brin bands are 
transformed into granulation tissue by the ingrowth of capillaries and broblasts and subsequently 
converted into permanent, collagenous, and highly organized tissue containing nerve bers and 
vessels. 
Adhesions frequently cause long-term complications after abdominal and pelvic surgery.  After 
pediatric  abdominal  surgery, the incidence of adhesive small bowel obstruction can be as high as 
15.6%, for example, after treatment of gastroschisis and omphalocele in neonates.15,16 Other 
important clinical consequences of adhesions include infertility, chronic abdominal pain, 
malabsorption, and technical difculties at reoperation. Many pharmacological methods and barriers 
have been used for adhesion prevention but only few have been proven to be successful. Prevention 
of adherence of adjacent structures by keeping them apart seems most efcacious. In a recent 
systematic review, the efcacy and safety of the four adhesion barriers approved for use in Europe 
and the USA were evaluated, showing evidence that membranes of oxidized regenerated cellulose 
and hyaluronate carboxymethylcellulose reduce adhesion formation.17 Moreover, there is evidence 
that hyaluronate carboxymethylcellulose reduces the number of reoperations for adhesive small 
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bowel obstruction. Evidence for efcacy on other clinically critical outcomes is lacking. Of the liquid 
adhesion barriers that are available in the market, icodextrin 4% solution is the most widely used. 
There is, however, limited evidence for the benecial effect of icodextrin on the incidence of small 
bowel obstruction or other adhesion-related complications.17,18 
An understanding of the pathological processes enables the modulation of the peritoneal 
environment and brinolytic capacity, which seems to harbor a therapeutic opportunity to prevent 
postsurgical adhesion formation. Intraperitoneal treatment with recombinant human plasminogen 
activator (rPA) was effective in preventing postoperative adhesion formation in experimental 
studies.13 A pilot study in humans, however, showed no reduction of adhesions.19 Since there was no 
measurable elevation of plasma t-PA level in the treatment group, this negative result was ascribed 
to too small a dosage. 
An interesting option to potentially combine anti-inammatory, anti-coagulatory, and probrinolytic 
properties is the use of statins. Beside their cholesterol-lowering capacity, there is accumulating 
evidence that statins effectively lower plasma levels of CRP, have potent anti-inammatory 
properties, and are effective stimulators of brinolytic activity by increasing t-PA and lowering PAI-
1.20,21 Also, the use of an angiotensin-II receptor blocker has potential efcacy in adhesion prevention 
through decreasing TGF β. The intraperitoneal administration of these agents alone and combined 
effectively reduced postsurgical adhesions in mice.22 However, no data on efcacy in humans are 
available yet. Another potentially viable therapeutic target is substance P (a specic proinammatory 
neuropeptide).23 The effects associated with substance P are increasing inammatory cytokine mRNA 
expression, stimulating angiogenesis, and proliferation of broblasts. This is mainly mediated 
through binding to neurokinin-1 receptor. Binding to the neurokinin-1 receptor can be inhibited 
through intraperitoneal administration of a neurokinin-1 receptor antagonist. In rats, interference 
with the actions of substance P with this antagonist showed early effects on the mRNA expression of 
several key mediators of adhesiogenesis.24 
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induced by sterile stimuli.27 Chemoattractants, produced by mesothelial cells and local inammatory 
cells, induce the recruitment of phagocytes (neutrophils and later macrophages), transmigrating 
from peritoneal capillaries to the mesothelial surface. Dilation of peritoneal blood vessels results in 
enhanced permeability, peritoneal edema, and the formation of protein-rich peritoneal exudates.28 
The local defense mechanism is able to localize and control the bacterial invasion through the 
formation of brinous adhesions trapping microbes and promoting local effector mechanisms to 
phagocytose them.29 The omentum contributes to the overall localization process. The mesothelial 
cell layer of the omentum encloses two distinct types of tissue: an adipose-rich area and a thin 
translucent membranous area.30 The adipose-rich area contains omental milky spots, consisting 
mainly of inammatory cells. The translucent area has a net-like structure with multiple 
fenestrations, and its function is associated with regulating uid transport. The fenestrations also 
facilitate adhesion of the omentum to damaged or inamed organs, giving it motile properties. Once 
localized to the site of contamination, the omentum acts to absorb microbes and contaminants 
through its stomata and secretes phagocytes through the milky spots. The omentum promotes 
healing via the local expression of growth factors and the stimulation of angiogenic activity.31 An 
abscess forms when this localizing defense mechanism fails to completely clear the bacterial 
contamination. Such abscesses consist of bacteria, neutrophils, and necrotic debris walled off by a 
brinous or brous capsule termed pyogenic membrane. When viable bacteria are entrapped in the 
abscess wall or in the center, they cannot be reached by phagocytes and antibiotic therapy. This can 
result in bacterial proliferation32 and, if overwhelmed, can lead to a systemic inammatory response 
syndrome through the release of pro-inammatory mediators (e.g., TNF α and IL-1) into the systemic 
circulation.33 
The cornerstones of successful therapy in intra-abdominal infection are—source control, drainage of 
abscesses, and appropriate antibiotics. Very early antibiotic intervention is effective in reducing 
mortality in sepsis. Empirical use of antibiotics is often necessary when confronted by a sick patient 
and should be reevaluated by local resistance surveillance.34 The choice of the empirical antibiotic 
regimen should cover the intestinal ora, aerobes, and anaerobes. Examples of broad-spectrum 
antimicrobial regimens for pediatric patients with complicated intra-abdominal infection are an 
aminoglycoside-based regimen, a carbapenem (imipenem, meropenem, or ertapenem), a β-
lactam/β-lactamase inhibitor combination (piperacillin–tazobactam or ticarcillin–clavulanate), or an 
advanced-generation cephalosporin (cefotaxime, ceftriaxone, ceftazidime, or cefepime) with 
metronidazole.35 
After surgically eliminating the source of abdominal infection in patients with severe abdominal 
sepsis, open abdomen should be avoided, since it leads to higher mortality.36 An open abdomen is 
dened as a situation where the skin and fascia cannot be closed after laparotomy and the viscera 
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are exposed, needing temporary closure or coverage techniques.37 The only indication for open 
abdominal management is abdominal compartment syndrome, although even in this circumstance, 
temporary closure without tension is recommended. Planned re-laparotomy is not recommended 
and results in a higher mortality, a longer ICU and hospital stay, and higher costs34,36 when compared 
with an “on-demand” strategy of surgical re-exporation. 
 
Ascites 
Ascites is a pathological state where an excess of uid is accumulated within the peritoneal cavity. 
In approximately 80% of cases in adults, ascites is caused by hepatic cirrhosis. Other common 
causes include malignancy in 10% and heart failure in 3%.
38 Hepatic disorders are the most common 
cause of ascites in infants and children.
39
 
Three pathophysiologic processes contribute to the development of ascites in patients with 
cirrhotic liver disease: portal hypertension, vasodilation, and hyperaldosteronism. During the 
development of hepatic cirrhosis, the sinusoidal endothelial cells of the intra-hepatic 
microcirculation fail to function, resulting in aberrant paracrine signaling. This process causes 
inammation, brosis, and impaired vasomotor control, leading to increased intra-hepatic 
vascular resistance and portal hypertension.
40 Additionally, sinusoidal cells are highly permeable 
to albumin, making lymph formation dependent on hydrostatic forces alone, which are 
increased due to portal hypertension. A systemic effect of portal hypertension is vasodilation 
through increased nitric oxide production and hydrostatic pressure of the splanchnic circulation, 
leading to more uid extravasation into the peritoneum. Furthermore, systemic vasodilatation 
results in relative hypovolemia and stimulates the renin–angiotensin–aldosterone system.
41 
Increased antidiuretic hormone secretion induces water retention. While angiotensin normally 
promotes vasoconstriction, in the presence of hepatic cirrhosis, this effect is dampened.
42 If a 
patient develops hypoalbuminemia, a lower intra-vascular osmotic pressure exacerbates this 
process. 
An extensive summary of the different treatments for ascites due to cirrhotic liver disease 
goes beyond the scope of this review. In short, the intake of sodium should be restricted, and 
in most patients, addition of a diuretic is necessary. The most effective diuretic is 
spironolactone but a combination with furosemide might be required.
43,44 Paracentesis is a 
safe and effective treatment in the management of diuretic-resistant ascites.
45 If more than 
5 l of uid will be removed through paracentesis, intravenous albumin has been shown to 
improve survival.
46 A transjugular intra-hepatic portosystemic shunt has shown to improve 
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transplant-free survival in comparison to large-volume paracentesis.
47 Liver transplantation is 
a viable treatment in patients who develop diuretic-resistant ascites and early referral to a 
transplant center should be standard care. 
In the presence of peritoneal malignancy, ascites has a completely different etiology. Malignant 
ascites develops because of a mismatch between ltration and drainage in the peritoneal 
cavity. In patients with peritoneal carcinomatosis, the cross-sectional area of microvessels that 
line the peritoneal  cavity  is  increased.
48  Furthermore, due to the secretion of Vascular 
Endothelial Growth Factor (VEGF) by tumor cells, the permeability of microvessels is increased,
49 
leading to an increased accumulation of protein-rich uid in the peritoneal cavity. This shifts 
the oncotic pressure gradient further in the direction of the peritoneum. Impaired drainage 
from the peritoneum can also be caused by tumor cells blocking the peritoneal stomata, but 
this is a less important mechanism.
50
 
 
Due to the differences in etiology between malignant and cirrhotic ascites, diuretics are 
less effective in the treatment of malignant ascites. However, patients with extensive liver 
metastases might benet from a diuretic.
51 Intraperitoneal chemotherapeutics, 
corticosteroids, cytokines, and a VEGF inhibitor have been reported to improve the control 
of ascites.
52–55 A randomized clinical trial using intraperitoneal administration of a 
monoclonal antibody, Catumaxomab, showed longer paracentesis-free survival and 
improved palliation in comparison to paracentesis alone.
56 Aibercept, a VEGF inhibitor 
given intravenously, was evaluated in a phase 2, double-blinded, randomized, placebo-
controlled study also showed longer paracentesis-free survival, although this did not lead to 
an improved overall survival.
57
 
Complete resection of peritoneal metastasis is often not possible in patients with malignant 
ascites. Furthermore, the duration of postoperative recovery is comparable to the median 
overall survival time, making this patient category often considered ineligible for 
cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
58
 
Therefore, a laparoscopic approach with limited adhesiolysis and no cytoreductive surgery 
combined with HIPEC has been advocated. Due to its minimally invasive nature, this 
procedure has shown to be safe, and promising results with regard to palliation and overall 
survival have been reported.
59,60
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Peritoneal metastasis 
Peritoneal metastasis is a common route for gastrointestinal malignancies, including 
appendiceal, colorectal, gastric, and pancreatic cancers. It is the primary metastatic route 
for ovarian malignancies. Peritoneal carcinomatosis is associated with a poor prognosis, 
irrespective of the primary origin of the tumor.
8,27 The process of intraperitoneal tumor 
dissemination differs from hematologic metastasis where tumor cells need to enter and 
exit the circulation and penetrate tissues. Peritoneal dissemination occurs in 
gastrointestinal malignancies when tumor cells exfoliate from the primary tumor after it has 
invaded the visceral peritoneum or in the case of a perforation of the gastrointestinal 
tract.
11 After dissemination into the peritoneum, tumor cells must prevent apoptosis and 
evade peritoneal clearance through the lymphatic system. This requires tumor cells to 
attach to the disrupted mesothelial surface or the exposed extracellular matrix (ECM) or at 
the stomata of von Recklinghausen for further disease progression. Tumor cells may adhere 
to the surface of mesothelial cells through various receptors
61–63 but show a predilection of 
adhering to type 1 collagen of the ECM.
64,65 The ECM is, therefore, the initial site of 
metastasis.
66 Surgical injury of the peritoneum exposes the ECM and damages the 
mesothelial cell layer.
67 Additionally, interactions between immune, mesothelial, and tumor 
cells create an inammatory environment that causes the mesothelium to retract, 
exposing more of the ECM. Furthermore, inammatory cytokines up-regulate mesothelial 
cell surface receptors enabling the attachment of tumor cells
68,69 and therefore increase 
metastatic spread. Tumor cells have the ability to assemble into multicellular aggregates, 
named spheroids, through direct cell–cell attachments.
70 
When formed into spheroids, 
tumor cells have increased resistance against anoikis and chemotherapeutics.
71 
Additionally, spheroid formation is associated with more invasive tumors.
72 Targeting 
spheroid formation by attenuating the contractile abilities of tumor cells might be an 
important treatment modality and is an area of extensive research.
73 The presence of 
ascites in patients with advanced ovarian cancer decreases their life expectancy when 
compared with patients who present without ascites in similar advanced ovarian cancer.
74 
Malignant ascites contains multiple growth factors and cytokines,
75–77 which enhance 
resistance against chemotherapeutic agents
78 
and promote spheroid formation of tumor 
cells.
79 Increased amounts of brinogen and brin found in ascites may lead to the 
assemblage of tumor deposits that can become vascularized because of the presence of 
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angiogenic growth factors.
80 Notably, heparin-binding epidermal growth factor (HB-EGF) has 
been shown to contribute to disease progression in ovarian cancer patients.
81 A small study 
reported promising results with an inhibitor of HB-EGF.
82
 
The cornerstone in the treatment of peritoneal carcinomatosis, in the absence of other 
systemic metastasis, is complete cytoreductive surgery and HIPEC. Although associated with 
considerable morbidity and mortality, it has shown to improve overall survival. An important 
prognostic factor for survival is complete macroscopic tumor resection.
83,84
 
 
Conclusion 
The inammatory reaction of the peritoneum forms an essential part of the physiopathology 
of abscess  formation, adhesion formation, malignant ascites, and peritoneal metastasis. Specic 
pathways and interactions depend on the type of injury to the peritoneum. An increased 
understanding of these pathological processes has yielded potential targets for new 
therapies. 
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angiogenic growth factors.
80 Notably, heparin-binding epidermal growth factor (HB-EGF) has 
been shown to contribute to disease progression in ovarian cancer patients.
81 A small study 
reported promising results with an inhibitor of HB-EGF.
82
 
The cornerstone in the treatment of peritoneal carcinomatosis, in the absence of other 
systemic metastasis, is complete cytoreductive surgery and HIPEC. Although associated with 
considerable morbidity and mortality, it has shown to improve overall survival. An important 
prognostic factor for survival is complete macroscopic tumor resection.
83,84
 
 
Conclusion 
The inammatory reaction of the peritoneum forms an essential part of the physiopathology 
of abscess  formation, adhesion formation, malignant ascites, and peritoneal metastasis. Specic 
pathways and interactions depend on the type of injury to the peritoneum. An increased 
understanding of these pathological processes has yielded potential targets for new 
therapies. 
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Abstract 
Background/Aims: Adhesiolysis is a frequent part of colorectal surgery, potentially impeding the 
operation and causing inadvertent bowel injury. Such difficulties might compromise convalescence 
and oncological quality of resection. The aim of this prospective cohort study was to assess the 
impact of adhesiolysis on clinical outcomes and histopathological results in colorectal surgery.  
 
Methods: Colorectal procedures were selected from a prospective cohort study of adhesiolysis-
related problems. We compared the incidence of bowel injury, morbidity, costs, and the 
histopathology between patients undergoing elective colorectal surgery with or without adhesiolysis.  
 
Results: Two hundred and forty nine colorectal surgeries were analysed. Adhesiolysis was required 
in 59.0%. The mean adhesiolysis time was 28 min. In the adhesiolysis group, enterotomies occurred 
in 6.1% and seromuscular injuries in 27.2% compared to 0 and 6.9% respectively in the non-
adhesiolysis group (p = 0.012 and p < 0.001). In patients requiring adhesiolysis, 29.9% had major 
surgery-related complications (MSRC) compared to 15.7% without adhesiolysis (p = 0.007). There 
were no statistically significant differences regarding inpatient costs and resection margin or 
number of harvested lymph nodes.  
 
Conclusions: Adhesiolysis during colorectal surgery is related to an increased incidence of 
iatrogenic bowel injuries and MSRC. Despite the technical challenges associated with 
adhesiolysis, good histopathological results were obtained in oncological resections. 
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Introduction 
Adhesion formation is the most frequent cause of long-term complications following 
abdominal surgery. Complications of adhesions comprise small bowel obstruction and 
difficulties during reoperation.1,2 In a recent prospective series of major abdominal or pelvic 
surgeries, more than half of laparotomies required adhesiolysis, resulting in extension of 
operative time, 10% inadvertent bowel injury and more postoperative surgical complications.3 
The need for adhesiolysis was particularly high in colorectal and abdominal wall surgery, with 
colorectal surgery being most frequently performed in this series. 
Despite the fact that colorectal surgery has been the focus of adhesion formation and 
prevention research in the past decades4–7, the precise impact of adhesiolysis and related organ 
injury on the outcome of colorectal surgery has not been investigated. Knowledge of adhesion-
related morbidity is needed to inform patients properly and to take adhesiolysis-related risks 
into account in the operative decisionmaking. In addition, proper data on adhesiolysis time 
and the socioeconomic burden are helpful for operative room management and 
reimbursement policy. 
In colorectal cancer surgery, technical difficulties related to adhesiolysis might also interfere 
with the extent and quality of the resection. Adhesions may complicate appropriate 
mobilization of the colon and rectum8, thereby compromising resection margins and 
lymph node harvest. A lower number of lymph nodes harvested results in under-staging of 
tumours and subsequent under-treatment of patients.9 A more extensive nodal dissection is 
associated with improved survival.9,10 In addition to patient-related factors such as male 
gender and increasing age, narrow resection margins have been identified as risk factors for 
poor lymph node harvest.11 
The aim of this prospective study was to demonstrate the impact of adhesiolysis on bowel injury, 
major surgery related complications (MSRC), hospital costs, and oncological quality of resection 
in a cohort of elective colorectal operations. 
 
Methods and Materials 
Study Design 
This is a prospective observational study as part of the Laparotomy or Laparoscopy and 
Adhesions (LAPAD) study (ClinicalTrials.gov registration number NCT01236625). Detailed 
information on the LAPAD methods have been described previously.3,12 The LAPAD study was 
designed to assess the incidence and impact of adhesiolysis on per- and postoperative 
complications, quality of life and hospital costs. All adult competent patients undergoing elective 
laparotomy or laparoscopy admitted to the surgical ward between June 1, 2008 and June 2, 2010 
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at the department of surgery of the Radboud University Medical Center, Nijmegen, the 
Netherlands, were screened for participation in the LAPAD study. The study was approved by 
the local Institutional Review Board and conducted according to the revised version of the 
Declaration of Helsinki (October 2008, Seoul). 
 
Cohort Selection 
For each patient participating in the LAPAD study, the planned and actual operative procedures 
were noted using the hospitals operation coding system. The indications for the procedure 
were defined following the International Statistical Classification of Diseases and Related 
Health Problems, version 10 (ICD-10). The current study group was selected by operative 
procedure codes related to colorectal surgery. The datasheet, indications and operative notes 
of all patients within this cohort were reviewed. Patients undergoing multiple procedures in 
the same operative session were excluded if the colorectal procedure was only a minor part of 
the total surgery. 
Relevant patient, surgical and medical data were prospectively assessed before, during and 
after hospital stay and at the outpatient clinic until 6 months after discharge. At surgery, detailed 
information on adhesions, adhesiolysis and inadvertent organ damage was collected through 
direct observation by a trained researcher who did not take part in the operation. 
The presence of adhesions was assessed and the location, for example, ventral abdominal 
wall, operative area and other parts of the abdomen, was described. At these 3 locations, 
adhesions were graded according to the Zühlke classification 1 filmy adhesions: easy to 
separate by blunt dissection; no vascularization; 2 stronger adhesions: blunt dissection 
possible but partly sharp dissection possible (beginning of vascularization); 3 strong 
adhesions: lysis possible but sharp dissection only; clear vascularization; 4 very strong 
adhesions: lysis possible by sharp dissection only (organ strongly attached with severe 
adhesions and damage of organs hardly preventable).13 The duration of adhesiolysis was 
timed by stopwatch. Findings were recorded into the database real time by the researcher 
present in the operating theatre. 
 
Variables 
Primary outcomes were the incidence of adhesions, adhesiolysis time, the incidence of bowel 
defects, seromuscular injury, injuries to other organs and structures and the incidence of MSRC. 
Bowel defects were classified as inadvertent enterotomy or delayed diagnosed perforation 
(DDP). Inadvertent enterotomy was defined as any iatrogenic, unintended full thickness 
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bowel defect detected during operation. Pre-existing fistulas or defects created while 
dissecting the bowel loop that harboured the fistula were not scored as inadvertent 
enterotomy. DDP was defined as a bowel defect with spill of gastrointestinal content that was 
diagnosed postoperatively by imaging, at reoperation or at autopsy, and which could not 
be explained by anastomotic leakage, bowel ischemia or any other obvious cause of leakage 
unrelated to adhesiolysis. 
Seromuscular injury was defined as injury to the serosa and muscular layers of the bowel, 
without visualization of the bowel lumen or spillage of bowel content. As a rule, seromuscular 
injuries were repaired by suturing. Other intraoperative injuries comprised injury to the 
spleen, liver, pancreas, urogenital structures, lung, vascular structures, or nerves. 
Postoperative complications noted as MSRC were death, wound infection, anastomotic leak, 
fistula and abscess, pneumonia, sepsis, and haemorrhage. MSRCs were defined according to 
the criteria of the ICD-10, the National Nosocomial Infections Surveillance System, the 
Centre for Disease Control and prevention, or according to the decision of the senior surgical 
staff of the department. 
Secondary outcomes were other morbidity, oncological outcome and hospital costs including 
total operative time, blood loss, recovery unit stay, hospital stay, intensive care unit (ICU) 
admission, ICU stay, parenteral feeding, tube feeding, incidence of emergency reoperations, and 
incidence of readmission to the hospital within 30 days after discharge. 
Costs analysis included only the direct hospital costs: operation costs, ward stay, ICU stay, extra 
charges for parenteral and tube feeding, postoperative diagnostics, reoperation costs and 
blood products. Costs calculations were performed using the guidelines for cost analysis of the 
Dutch College of Health Insurance Companies using a top-down approach.14 Operation costs 
were calculated based on total anaesthesia time using operation room costs of $1,390 per 
hour including personnel, material and overhead costs. Total costs for the surgical ward and 
ICU were $661 and 2,289 per day respectively and included basic nutrition costs. Advanced 
methods of parenteral and tube feedings were considered extra nutritional costs. Diagnostics 
and reoperation costs were calculated using the 2004 price list for medical procedures by the 
Dutch College of Health Insurance Companies. Medication costs and blood products costs were 
calculated according to the standardized price list of the Dutch College of Health Insurance 
Companies updated for June 2008.15 
Oncological outcome was analysed in the subgroups of patients who had undergone surgery 
for colon or rectal cancer. The number of harvested lymph nodes, completeness of resection 
and distance from the bowel resection margin plain in colon resections and circumferential 
resection margin (CRM) in rectal resections, were extracted from the pathology reports. In 
Impact of adhesiolysis on outcome of colorectal surgery 
43
Ch
ap
te
r 3
Chapter 3 
42 
at the department of surgery of the Radboud University Medical Center, Nijmegen, the 
Netherlands, were screened for participation in the LAPAD study. The study was approved by 
the local Institutional Review Board and conducted according to the revised version of the 
Declaration of Helsinki (October 2008, Seoul). 
 
Cohort Selection 
For each patient participating in the LAPAD study, the planned and actual operative procedures 
were noted using the hospitals operation coding system. The indications for the procedure 
were defined following the International Statistical Classification of Diseases and Related 
Health Problems, version 10 (ICD-10). The current study group was selected by operative 
procedure codes related to colorectal surgery. The datasheet, indications and operative notes 
of all patients within this cohort were reviewed. Patients undergoing multiple procedures in 
the same operative session were excluded if the colorectal procedure was only a minor part of 
the total surgery. 
Relevant patient, surgical and medical data were prospectively assessed before, during and 
after hospital stay and at the outpatient clinic until 6 months after discharge. At surgery, detailed 
information on adhesions, adhesiolysis and inadvertent organ damage was collected through 
direct observation by a trained researcher who did not take part in the operation. 
The presence of adhesions was assessed and the location, for example, ventral abdominal 
wall, operative area and other parts of the abdomen, was described. At these 3 locations, 
adhesions were graded according to the Zühlke classification 1 filmy adhesions: easy to 
separate by blunt dissection; no vascularization; 2 stronger adhesions: blunt dissection 
possible but partly sharp dissection possible (beginning of vascularization); 3 strong 
adhesions: lysis possible but sharp dissection only; clear vascularization; 4 very strong 
adhesions: lysis possible by sharp dissection only (organ strongly attached with severe 
adhesions and damage of organs hardly preventable).13 The duration of adhesiolysis was 
timed by stopwatch. Findings were recorded into the database real time by the researcher 
present in the operating theatre. 
 
Variables 
Primary outcomes were the incidence of adhesions, adhesiolysis time, the incidence of bowel 
defects, seromuscular injury, injuries to other organs and structures and the incidence of MSRC. 
Bowel defects were classified as inadvertent enterotomy or delayed diagnosed perforation 
(DDP). Inadvertent enterotomy was defined as any iatrogenic, unintended full thickness 
Impact of adhesiolysis on outcome of colorectal surgery 
 
43 
bowel defect detected during operation. Pre-existing fistulas or defects created while 
dissecting the bowel loop that harboured the fistula were not scored as inadvertent 
enterotomy. DDP was defined as a bowel defect with spill of gastrointestinal content that was 
diagnosed postoperatively by imaging, at reoperation or at autopsy, and which could not 
be explained by anastomotic leakage, bowel ischemia or any other obvious cause of leakage 
unrelated to adhesiolysis. 
Seromuscular injury was defined as injury to the serosa and muscular layers of the bowel, 
without visualization of the bowel lumen or spillage of bowel content. As a rule, seromuscular 
injuries were repaired by suturing. Other intraoperative injuries comprised injury to the 
spleen, liver, pancreas, urogenital structures, lung, vascular structures, or nerves. 
Postoperative complications noted as MSRC were death, wound infection, anastomotic leak, 
fistula and abscess, pneumonia, sepsis, and haemorrhage. MSRCs were defined according to 
the criteria of the ICD-10, the National Nosocomial Infections Surveillance System, the 
Centre for Disease Control and prevention, or according to the decision of the senior surgical 
staff of the department. 
Secondary outcomes were other morbidity, oncological outcome and hospital costs including 
total operative time, blood loss, recovery unit stay, hospital stay, intensive care unit (ICU) 
admission, ICU stay, parenteral feeding, tube feeding, incidence of emergency reoperations, and 
incidence of readmission to the hospital within 30 days after discharge. 
Costs analysis included only the direct hospital costs: operation costs, ward stay, ICU stay, extra 
charges for parenteral and tube feeding, postoperative diagnostics, reoperation costs and 
blood products. Costs calculations were performed using the guidelines for cost analysis of the 
Dutch College of Health Insurance Companies using a top-down approach.14 Operation costs 
were calculated based on total anaesthesia time using operation room costs of $1,390 per 
hour including personnel, material and overhead costs. Total costs for the surgical ward and 
ICU were $661 and 2,289 per day respectively and included basic nutrition costs. Advanced 
methods of parenteral and tube feedings were considered extra nutritional costs. Diagnostics 
and reoperation costs were calculated using the 2004 price list for medical procedures by the 
Dutch College of Health Insurance Companies. Medication costs and blood products costs were 
calculated according to the standardized price list of the Dutch College of Health Insurance 
Companies updated for June 2008.15 
Oncological outcome was analysed in the subgroups of patients who had undergone surgery 
for colon or rectal cancer. The number of harvested lymph nodes, completeness of resection 
and distance from the bowel resection margin plain in colon resections and circumferential 
resection margin (CRM) in rectal resections, were extracted from the pathology reports. In 
Chapter 3
44
Chapter 3 
44 
our pathology department, a standardized report for colorectal cancer is used following 
the checklist recommended by the Dataset for colorectal cancer (2nd edition) of the Royal 
College of Pathologists and the Dutch National Guidelines for Colorectal Cancer Surgery.16,17 
Baseline demographics included gender, age, body mass index, smoking status, alcohol use 
disorders identification test alcohol abuse index18, abdominal operations in history, number of 
laparotomies in history, number of laparoscopies in history, generalized peritonitis in history, 
ASA classification, P-possum score, revised cardiac risk index, operative severity, surgical 
approach (open or laparoscopic) and level of surgical experience (consultant or resident). 
 
Statistical Methods 
Baseline characteristics, preoperative complications, postoperative morbidity and costs were 
compared between the patients that underwent adhesiolysis and the group that did not 
undergo adhesiolysis. In the subgroup of patients that underwent a resection of colorectal 
cancer, we compared the number of harvested lymph nodes, completeness of resection and 
distance from the bowel resection plain in colon resections and CRM in rectal resections, 
between patients with and without adhesiolysis. 
Adhesions form during the healing process of most often surgical, but also inflammatory, injury of 
the peritoneum.19 In order to achieve more homogeneity, the subgroup of patients that 
underwent adhesiolysis after prior abdominal surgery was analysed and preoperative 
complications and postoperative morbidity were compared with patients without adhesiolysis. 
Univariate comparisons were performed using linear regression for continuous and logistic 
regression  for  dichotomous data. Correlation between incidence of enterotomy and severity 
of adhesions (Zühlke classification) was assessed using Fisher’s exact test. Continuous data are 
expressed as mean with SD and dichotomous data as number with percentages. In 
composite outcomes, statistical results are presented for both the composite outcome and the 
individual components of the composite. Costs are presented as mean cost with 95% CI and 
expressed in US dollars. Dichotomous data were tested using univariate and multivariate 
regression. In multivariate regression, results were corrected for differences in baseline with p < 
0.10, except for a history of abdominal surgery and history of generalized peritonitis. Prior 
abdominal surgery and peritonitis were considered pathogenic for adhesion formation and 
were not expected to have further independent adverse effects on treatment outcomes. 
Statistical comparison of costs was performed by t test on the logistically transformed values 
of the costs to reduce the impact of outliers. All outcomes were assessed per operation and 
analysed according to intention-to-treat, unless otherwise stated. 
There was only minimal missing data; thus, we excluded cases with missing data per analysis. We 
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used SPSS® for Windows version 20.0 software (SPSS®, Chicago, Ill., USA) for statistical analysis. p < 
0.05 was considered significant. 
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Results 
Cohort and Baseline Comparison 
Eight hundred and forty four consecutive elective operations were screened for inclusion in the 
LAPAD study. Flow diagram of included operations is shown in figure 1. Two hundred and fifty 
five operations had one or more colorectal surgery codes. By reviewing the datasheets and 
operative notes, 6 operations were excluded because the colorectal procedure performed was 
only a minor part of the total surgery. Two hundred and forty nine patients who underwent a 
colorectal operation were included in this study. One hundred and twenty were oncological 
resections (fig. 1). Data on classification of adhesions were missing in 3/249 operations (1.2%). 
There were no further missing data. 
Adhesions were present in 151 of 249 patients (60.6%). One hundred and thirty eight patients 
had a history of intra-abdominal surgery of whom 115 (83.3%) had adhesions, 111 patients 
had no prior abdominal surgery of whom 36 (32.4%) had abdominal adhesions. Adhesions to 
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our pathology department, a standardized report for colorectal cancer is used following 
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abdominal surgery. In 120 of 151 (79.5%) patients, adhesions were present at the operative area 
and in 86 of 151 (57.0%), adhesions were found at other parts of the abdomen. 
Adhesiolysis was performed in 147 patients. Median Zühlke score of the adhesions was 3 
(range 1–4) at the incision scar and at the operative area of a previous operation, and 2.5 
(range 1–4) at other parts of the abdomen. Mean adhesiolysis time was 28.0 min (±32.3) and 
median 15 min (1–177). 
Table 1 shows the baseline data for the groups with and without adhesiolysis. Patients in the 
adhesiolysis group were younger (p = 0.002) and had more abdominal surgery (p < 0.001) and 
generalized peritonitis (p < 0.001). More patients in the adhesiolysis group were operated by a 
consultant and not a registrar (p = 0.003). Indications for surgery were equally divided, except 
for restoration of bowel continuity (p < 0.001). There were no other significant differences in 
baseline characteristics. 
 
Impact of Adhesiolysis on Peroperative Complications 
Twelve inadvertent enterotomies (median 1, range 1–3) occurred in 9 out of 147 (6.1%) 
patients in the adhesiolysis group and none in the non-adhesiolysis group (p = 0.012; table 2). 
In all, 12 enterotomies occurred only in patients with a history of a previous laparotomy, in 1 
out of 50 (2.0%) after one and in 8/63 (12.7%) after 2 or more prior open abdominal surgeries (p 
= 0.015). In operations complicated by an inadvertent enterotomy, the median highest Zühlke 
score was 4 (range 3–4). 
Inadvertent injury to the seromuscular layer occurred in 40 (27.2%) procedures with 
adhesiolysis compared to 7 (6.9%) without adhesiolysis (p < 0.001). 
DDP occurred in 3 patients in the adhesiolysis group and in none of the patients in the non-
adhesiolysis group. DDP occurred after an operation with 1 enterotomy and 5 seromuscular 
injuries, after an operation with 1 seromuscular injury and an operation without enterotomy 
or seromuscular injury. DDP occurred in 2 patients with no history of abdominal surgery and 1 
patient with a previous laparotomy.  
Other  organs  were  injured  in  9 (6.1%) patients (vascular structures n = 4, liver n = 2, spleen n 
= 1, ureter n = 1, bladder n = 1) in the adhesiolysis group compared to 2 (2.0%; spleen n = 1, 
vascular structures n = 1) in the nonadhesiolysis group (p = 0.23). 
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Table 1: Baseline comparison between operations with and without adhesiolysis 
Values are mean ± SD, median (range) or n (%). BMI = body mass index; ASA = American Society of Anesthesiologists; RCRI = revised 
cardiac risk index. 
 
 
 
 
 Adhesiolysis (n= 147) No adhesiolysis (n=102) p value 
Demographics   
    Male 68 (46.3) 59 (57.8) 0.072 
    Female 79 (53.7) 43 (42.2) 
Age* 56.4 ± 16.4 62.3 ± 13.8 0.002 
BMI* 24.9 ± 4.2 25.4 ± 4.2 0.28 
Smoking status    
    Non smoker 49 (33.3) 42 (41.2) 0.33 
    Previous-smoker 66 (44.9) 44 (43.1) 
    Smoker 32 (21.8) 16 (15.7) 
Alcohol abuse    
    Low risk 141 93 0.28 
    Moderate risk 4 5 
    High risk 2 4 
Surgical history    
Abdominal surgery in history    
    Yes 113 (76.9) 23 (22.5) < 0.001 
    No 34 (23.1) 79 (77.5) 
Laparotomies in history† 1 (0-11) 0 (0-2) < 0.001 
Laparoscopies in history† 0 (0-2) 0 (0-1) 0.011 
Generalized peritonitis in history    
    Yes 23 (15.6) 0  < 0.001 
    No 124 (84.4) 102 (100.0) 
Preoperative risk assessment    
ASA classification    
    I 28 (19.0) 12 (11.8) 0.37 
    II 87 (59.2) 67 (65.7) 
    III 31 (21.1) 23 (22.6) 
    IV 1 (0.7) 0 (0) 
P-possum Score* 6.4 ± 10.7 6.1 ± 6.7 0.80 
RCRI Index    
    2 123 (83.7) 78 (76.5) 0.35 
    3 18 (12.2) 17 (16.7) 
    4 6 (4.1) 7 (6.9) 
Operative severity    
    Moderate 1 (0.7) 2 (1.9) 0.41 
    Large 115 (78.2) 74 (72.5) 
    Major 31 (21.1) 26 (25.5) 
Operation technique    
    Laparoscopic surgery 15 (10.2) 18 (17.6) 0.088 
    Open surgery 132 (89.8) 84 (82.4) 
Operation type    
    Right colectomy 37 (25.2) 31 (30.4) 0.36 
    Sigmoid or rectal resection 52 (35.4) 47 (46.1) 0.090 
    Subtotal or proctocolectomy 21 (14.3) 11 (10.8) 0.42 
    Other colectomy 5(3.4) 7 (6.9) 0.21 
    Restoration of continuity 25 (17.0) 1 (1.0) <0.001 
    End colostomy 7 (4.8) 5 (4.9) 1.0 
Surgical experience    
    Surgeon 98 (66.7) 53 (52.0) 0.003 
    Resident 49 (33.3) 49 (48.0) 
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Table 1: Baseline comparison between operations with and without adhesiolysis 
Values are mean ± SD, median (range) or n (%). BMI = body mass index; ASA = American Society of Anesthesiologists; RCRI = revised 
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Table 2: Peroperative complications and MSRC compared between operations with and without 
adhesiolysis 
 Adhesiolysis 
(n=147) 
No adhesiolysis 
(n=102) 
Crude OR P value Adjusted OR* Adjusted 
P value* 
Peroperative complications       
    Enterotomy 9 (6.1) 0 NA 0.012 NA NA 
    Seromuscular injury 40 (27.2) 7 (6.9) 5.1 (2.2 – 11.9) < 0.001 5.3 (2.1 – 13.1) < 0.001 
    Other organ injury 9 (6.1) 2 (2.0) 3.3 (0.69 – 15.4) 0.14 2.7 (0.54 – 13.6) 0.23 
Delayed Diagnosed 
Perforation 
3 (2.0) 0 NA 0.27  NA NA 
MSRC’s       
    Death 6 (4.1) 2 (2.0) 2.1 (0.42 – 10.8) 0.36 2.7 (0.51 – 14.0) 0.25 
    Wound infection 10 (6.8)  4 (3.9) 1.8 (0.55 – 5.9) 0.34 2.0 (0.57 – 7.0) 0.28 
    Anastomotic leak 8 (5.4) 2 (2.0) 2.9 (0.60 – 13.8) 0.19 2.1 (0.40 – 11.0) 0.39 
    Fistula/abscess 7 (4.8) 2 (2.0) 2.5 (0.51 – 12.3) 0.26 1.7 (0.31 – 9.1) 0.56 
    Pneumonia  13 (8.8) 8 (7.8) 1.1 (0.46 – 2.9) 0.78 1.6 (0.59 – 4.4) 0.35 
    Sepsis 4 (2.7) 2 (2.0) 1.40 (0.25 – 7.8) 0.70 1.9 (0.31 – 11.2) 0.49 
    Hemorrhage 5 (3.4) 1 (1.0) 3. 6 (0.41 – 30.9) 0.25 4.1 (0.44 – 37.7) 0.22 
    Urinary tract infection 11 (7.5) 2 (2.0) 4.0 (0.88 – 18.7) 0.073 3.1 (0.63 – 15.3) 0.16 
Any MSRC 44 (29.9) 16 (15.7) 2.3 (1.2 – 4.4) 0.011 2.6 (1.3 – 5.3) 0.007 
Values are n (%). NA = Not applicable. * Adjustment for gender and age. 
 
 
Impact  of  Adhesiolysis  on Postoperative Morbidity and Costs 
The incidence of total MSRCs was 44 (29.9%) in the adhesiolysis group compared to 16 
(15.7%) in the nonadhesiolysis group (adjusted OR 2.6 (1.3–5.3); p = 0.007; table 2). Removing 
urinary tract infection as MRSC, the incidence was 36 (24.5%) and significantly higher in the 
adhesiolysis group compared to 15  (14.5%) in the nonadhesiolysis group (adjusted OR 2.5 (1.2–
5.0); p = 0.011). There were no significant differences in the incidences of a single MSRC, also 
after multivariate regression. 
The readmission rate within 30 days was significantly higher in the adhesiolysis group (adjusted 
OR 6.0 (1.7– 20.7); p = 0.005; table 3). The mean hospital stay was 11.6 ± 15.7 days in the 
adhesiolysis group and 9.0 ± 7.4 days in the non-adhesiolysis group (adjusted p = 0.10). There 
were no significant differences between the adhesiolysis and no adhesiolysis group with 
regard to operation time, blood loss, recovery unit stay, ICU admission and ICU stay, 
parenteral feeding, tube feeding and reoperations (table 3). 
The inpatient costs were on average $2,355 higher in the adhesiolysis group compared to the 
costs in the nonadhesiolysis group. The difference did not reach statistical significance due to 
large variations in costs between patients (log transformed p = 0.18; table 4). 
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Table 3: Crude and adjusted results for morbidity outcomes compared between operations with and 
without adhesiolysis 
  Adhesiolysis 
(n=147) 
No adhesiolysis 
(n=102) 
Crude OR  P value Adjusted OR* Adjusted 
P value* 
Operation time (min)  201 ± 84 189 ± 80 12.3 (-8.6 to 33.3) 0.25 2.3 (-18.3 to 22.9) 0.82 
Blood loss (ml)  876 ± 1044 806 ± 948 69.8 (-185.5 to 
325.0) 
0.60 - 104.5 (-351.9 to 
143.0) 
0.41 
Recovery unit stay, h  5.6 ± 10.4 5.3 ± 7.6 0.35 (-2.0 to 2.7) 0.78 0.17 (-2.4 to 2.7) 0.90 
Hospital stay, days  11.6 ± 15.7 9.0 ± 7.4 2.6 (-0.70 to 5.9) 0.12 2.9 (- 0.58 to 6.3) 0.10 
ICU admission  24 (16.3) 17 (16.7) 0.98 (0.49 to 1.9) 0.98 1.1 (0.52 to 2.3) 0.82 
ICU stay, days  1.5 ± 11.8 0.9 ± 3.6 0.89 (-0.93 to 2.7) 0.34 0.44 (-0.87 to 1.7) 0.51 
Parenteral feeding  25 (17.0) 12 (11.8) 1.5 (0.73 to 3.2) 0.26 1.7 (0.74 to 3.6) 0.22 
Parenteral feeding, days  10.6 ± 8.1 13.3 ± 10.6 -2.7 (-9.1 to 3.7) 0.40 -3.7 (-12.0 to 4.5) 0.36 
Tube feeding  22 (15.0) 18 (17.6) 0.82 (0.42 to 1.6) 0.57 0.78 (0.37 to 1.6) 0.51 
Tube feeding, days  15.5 ± 32.5 7.4 ± 6.1 7.4 (-4.3 to 19.1) 0.21 11.2 (-5.9 to 28.4) 0.19 
Reoperations        
    Any  28 (19.0) 12 (11.7) 1.6 (0.77 to 3.4) 0.20 1.7 (0.76 to 3.6) 0.21 
    Relaparotomy  22 (15.0) 10 (9.8) 1.6 (0.73 to 3.6) 0.23 1.7 (0.73 to 3.9) 0.22 
Readmission within 30 
days  
  
22 (15.0) 
 
3 (2.9) 
 
5.8 (1.7 to 20.0) 
 
0.005 
 
4.9 (1.4 to 17.5) 
 
0.015 
Valueas are mean  ± SD or n (%). * Adjusted for gender and age. 
 
 
Table 4: Socioeconomic cost analysis compared between operations with and without adhesiolysis 
and compared between with or without inadvertent bowel defect in the subgroup of operations with 
adhesiolysis 
 
 
Adhesiolysis (n=147) 
mean (95% CI) 
No adhesiolysis (n=102) 
mean (95% CI) 
P value P value 
(log transformed) 
 Operation cost 3830 (3590 to 4070) 3666 (3397 to 3954) 0.39 0.29 
Ward stay 4558 (3906 to 5210) 3773 (3229 to 4317) 0.071 1.0 
ICU stay 2451 (-761 to 5663) 1497 (307 to 2687) 0.59 0.83 
Extra charges for parenteral/tube feeding 418 (219 to 616) 346 (130 to 563) 0.63 0.74 
Medication  367 (190 to 544) 221 (151 to 291) 0.14 0.36 
Diagnostics (radiology, pathology and 
microbiology) 
269 (201 to 338) 235 (168 to 303) 0.50 0.53 
Reoperations 139 (79 to 200) 79 (27 to 131) 0.14 0.14 
Blood products 173 (99 to 246) 55 (20 to 91) 0.005 0.012 
Total costs 12,264 (8473 to 16,055) 9909 (7731 to 12,086) 0.27 0.18 
 
 
Impact  of  Adhesiolysis on Oncological  Outcomes 
One hundred and twenty patients underwent a resection for cancer, 49 for rectal and 71 for colon 
cancer. Twenty (41%) rectal cancer patients and 31 (44%) colon cancer patients required 
adhesiolysis. Baseline characteristics of these subgroups are shown in table 5. For the total group of 
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Table 2: Peroperative complications and MSRC compared between operations with and without 
adhesiolysis 
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P value* 
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OR 6.0 (1.7– 20.7); p = 0.005; table 3). The mean hospital stay was 11.6 ± 15.7 days in the 
adhesiolysis group and 9.0 ± 7.4 days in the non-adhesiolysis group (adjusted p = 0.10). There 
were no significant differences between the adhesiolysis and no adhesiolysis group with 
regard to operation time, blood loss, recovery unit stay, ICU admission and ICU stay, 
parenteral feeding, tube feeding and reoperations (table 3). 
The inpatient costs were on average $2,355 higher in the adhesiolysis group compared to the 
costs in the nonadhesiolysis group. The difference did not reach statistical significance due to 
large variations in costs between patients (log transformed p = 0.18; table 4). 
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Table 3: Crude and adjusted results for morbidity outcomes compared between operations with and 
without adhesiolysis 
  Adhesiolysis 
(n=147) 
No adhesiolysis 
(n=102) 
Crude OR  P value Adjusted OR* Adjusted 
P value* 
Operation time (min)  201 ± 84 189 ± 80 12.3 (-8.6 to 33.3) 0.25 2.3 (-18.3 to 22.9) 0.82 
Blood loss (ml)  876 ± 1044 806 ± 948 69.8 (-185.5 to 
325.0) 
0.60 - 104.5 (-351.9 to 
143.0) 
0.41 
Recovery unit stay, h  5.6 ± 10.4 5.3 ± 7.6 0.35 (-2.0 to 2.7) 0.78 0.17 (-2.4 to 2.7) 0.90 
Hospital stay, days  11.6 ± 15.7 9.0 ± 7.4 2.6 (-0.70 to 5.9) 0.12 2.9 (- 0.58 to 6.3) 0.10 
ICU admission  24 (16.3) 17 (16.7) 0.98 (0.49 to 1.9) 0.98 1.1 (0.52 to 2.3) 0.82 
ICU stay, days  1.5 ± 11.8 0.9 ± 3.6 0.89 (-0.93 to 2.7) 0.34 0.44 (-0.87 to 1.7) 0.51 
Parenteral feeding  25 (17.0) 12 (11.8) 1.5 (0.73 to 3.2) 0.26 1.7 (0.74 to 3.6) 0.22 
Parenteral feeding, days  10.6 ± 8.1 13.3 ± 10.6 -2.7 (-9.1 to 3.7) 0.40 -3.7 (-12.0 to 4.5) 0.36 
Tube feeding  22 (15.0) 18 (17.6) 0.82 (0.42 to 1.6) 0.57 0.78 (0.37 to 1.6) 0.51 
Tube feeding, days  15.5 ± 32.5 7.4 ± 6.1 7.4 (-4.3 to 19.1) 0.21 11.2 (-5.9 to 28.4) 0.19 
Reoperations        
    Any  28 (19.0) 12 (11.7) 1.6 (0.77 to 3.4) 0.20 1.7 (0.76 to 3.6) 0.21 
    Relaparotomy  22 (15.0) 10 (9.8) 1.6 (0.73 to 3.6) 0.23 1.7 (0.73 to 3.9) 0.22 
Readmission within 30 
days  
  
22 (15.0) 
 
3 (2.9) 
 
5.8 (1.7 to 20.0) 
 
0.005 
 
4.9 (1.4 to 17.5) 
 
0.015 
Valueas are mean  ± SD or n (%). * Adjusted for gender and age. 
 
 
Table 4: Socioeconomic cost analysis compared between operations with and without adhesiolysis 
and compared between with or without inadvertent bowel defect in the subgroup of operations with 
adhesiolysis 
 
 
Adhesiolysis (n=147) 
mean (95% CI) 
No adhesiolysis (n=102) 
mean (95% CI) 
P value P value 
(log transformed) 
 Operation cost 3830 (3590 to 4070) 3666 (3397 to 3954) 0.39 0.29 
Ward stay 4558 (3906 to 5210) 3773 (3229 to 4317) 0.071 1.0 
ICU stay 2451 (-761 to 5663) 1497 (307 to 2687) 0.59 0.83 
Extra charges for parenteral/tube feeding 418 (219 to 616) 346 (130 to 563) 0.63 0.74 
Medication  367 (190 to 544) 221 (151 to 291) 0.14 0.36 
Diagnostics (radiology, pathology and 
microbiology) 
269 (201 to 338) 235 (168 to 303) 0.50 0.53 
Reoperations 139 (79 to 200) 79 (27 to 131) 0.14 0.14 
Blood products 173 (99 to 246) 55 (20 to 91) 0.005 0.012 
Total costs 12,264 (8473 to 16,055) 9909 (7731 to 12,086) 0.27 0.18 
 
 
Impact  of  Adhesiolysis on Oncological  Outcomes 
One hundred and twenty patients underwent a resection for cancer, 49 for rectal and 71 for colon 
cancer. Twenty (41%) rectal cancer patients and 31 (44%) colon cancer patients required 
adhesiolysis. Baseline characteristics of these subgroups are shown in table 5. For the total group of 
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colorectal cancer resections, incidences of total MSRCs significantly differed between adhesiolysis and 
no adhesiolysis (17 (33.3%) compared to 11 (15.9%); p = 0.026; table 5). There were no significant 
differences in incomplete resection (circumferential), resection margin and number of 
harvested lymph nodes between patients with and without adhesiolysis during resection of 
colon or rectal cancer (table 6). 
 
 
Table 5: Baseline comparison including neoadjuvant therapy between operations with and 
without adhesiolysis of the subgroup of colorectal resection for colorectal cancer (n = 120) and 
of the subgroups of operations for rectal and colon cancer 
 Adhesiolysis 
(n=51) 
No 
adhesiolysis 
(n=69) 
P 
value 
Rectum 
adhesiolysis 
(n=20) 
Rectum no 
adhesiolysis 
(n=29) 
P 
value 
Colon 
adhesiolysis 
(n=31) 
Colon no 
adhesiolysis 
(n=40) 
P 
value 
Gender          
    Male 28 (54.9) 43 (62.3) 0.41 12 (60.0) 22 (75.9) 0.24 16 (51.6) 21 (52.5) 0.94 
    Female 23 (45.1) 26 (37.7) 8 (40.0) 7 (24.1) 15 (48.4) 19 (47.5) 
Age 68.8 ± 12.5 66.8 ± 9.7 0.35 63.1 ±14.4 65.9 ± 9.4 0.44 72.5 ± 9.6 67.5 ± 10.0 0.034 
BMI 25.7 ± 3.7 25.4 ± 4.1 0.73 25.6 ± 3.3 25.8 ± 4.4 0.83 25.7 ± 4.0 25.1 ± 3.9 0.53 
Abdominal surgery 32 (62.7) 13 (18.8) <0.001 10 (50.0) 5 (17.2) 0.026 22 (71.0) 8 (20.0) <0.001 
SCRT-TME < 2    6 (30.0) 10 (34.5) 0.95 - -  
SCRT-TME > 4    3 (15.0) 5 (17.2) - -  
CRT    8 (40.0) 11 (37.9) - -  
Chemotherapy    0  0  2 (6.5) 3 (7.5) 0.66 
MSRC 17 (33.3) 11 (15.9) 0.026 9 (45.0) 7 (24.1) 0.13 8 (25.8) 4 (10.0) 0.078 
Right 18 (35.3) 20 (29.0) 0.49 - -  18 (58.1) 20 (50.0) 0.41 
Extended right 3 (5.9) 2 (2.9) - -  3 (9.7) 2 (5.0) 
Left hemicolectomy 2 (3.9) 4 (5.8) - -  2 (6.5) 4 (10.0) 
Sigmoid resection 4 (7.8) 6 (8.7) - -  4 (12.9) 6 (15.0) 
Rectosigmoid 1 (2.0) 7 (10.1) - -  1 (3.2) 7 (17.5) 
Low anterior 13 (25.5) 12 (17.4) 12 (60.0) 12 (41.4) 0.35 1 (3.2) 0  
Abdominoperineal 8 (15.7) 16 (23.2) 8 (40.0) 16 (55.2) 0  0  
Subtotal colectomy 2 (3.9) 1 (1.4) - - 2 (6.5) 1 (2.5) 
Proctocolectomy 0 (0) 1 (1.4) 0 (0) 1 (3.4) 0  0  
Values are mean ± SD or n (%). 
BMI = Body mass index; SCRT = short course radiotherapy; TME = total mesorectal excision; CRT = chemoradiotherapy. 
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Table 6: Oncological results analysis of resections in rectal colon cancer compared between 
operations with and without adhesiolysis. 
 Rectal  
cancer 
adhesiolysis 
(n=20) 
Rectal  
cancer no 
adhesiolysis 
(n=29) 
Relative 
risk 
P value  Colon  
cancer 
adhesiolysis 
(n=31) 
Colon  
cancer no 
adhesiolysis 
(n=40) 
P value
Incomplete resection 1 (5.0) 1 (3.4) 0.073 1.0 Incomplete resection 1 (3.2) 0  0.44 
CRM (mm) 8.3 ± 6.0 
(n=17) 
7.6 ± 5.8 
(n=21) 
 0.70 Margin to nearest  
    resection plain, mm 
76.1 ± 56.2 
(n=26) 
64.7 ± 45.7 
(n=34) 
0.41 
Number harvested  
    of lymph nodes  
 
13 ± 7 
 
12 ± 6 
  
0.63 
Number harvested 
    of lymph nodes  
 
15 ± 8 
 
17 ± 10 
 
0.42 
Values are mean ± SD or n (%). 
 
 
Subgroup  Analysis  of  the  Adhesiolysis  Group  by  Cause of Adhesions 
The adhesiolysis group comprised 113 patients with and 34 without prior abdominal surgery. 
Patients with prior abdominal surgery in the adhesiolysis group had more severe adhesions 
(median Zühlke score 3, range 1–4). These adhesions were mostly located under the incision of a 
previous operation or at the operative area (78.7 and 83.5%, respectively). Median adhesiolysis 
time in these patients was 18 min (1–177). The 34 patients without prior abdominal surgery 
mainly had a few low-grade adhesions (median Zühlke score 1, range 1–3) with a median 
adhesiolysis time of 5 min (range 1–93). These adhesions were mostly located at the operative 
area (71.4%), adjacent to a local inflammatory process or tumour. 
Incidence of enterotomy due to adhesiolysis of postoperative adhesions was 9 (6.1%) and of 
seromuscular injury 36 (31.9%) compared to 0 and 7 (6.9%) respectively in the non-
adhesiolysis group (p = 0.004 and p < 0.001). The incidence of MSRC was 30 (26.5%) in the 
group with adhesiolysis of postoperative adhesions compared to 16 (15.7%) in the non-
adhesiolysis group (p = 0.055). The mean hospital stay was comparable between both groups 
(10.2 ± 8.4 and 9.0 ± 7.4 days [p = 0.28]). The readmission rate within 30 days was significantly 
higher in the adhesiolysis of postoperative adhesions group with 16 (14.2%) vs. 3 (2.9%) in the 
non-adhesiolysis group 
(p = 0.004). 
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colorectal cancer resections, incidences of total MSRCs significantly differed between adhesiolysis and 
no adhesiolysis (17 (33.3%) compared to 11 (15.9%); p = 0.026; table 5). There were no significant 
differences in incomplete resection (circumferential), resection margin and number of 
harvested lymph nodes between patients with and without adhesiolysis during resection of 
colon or rectal cancer (table 6). 
 
 
Table 5: Baseline comparison including neoadjuvant therapy between operations with and 
without adhesiolysis of the subgroup of colorectal resection for colorectal cancer (n = 120) and 
of the subgroups of operations for rectal and colon cancer 
 Adhesiolysis 
(n=51) 
No 
adhesiolysis 
(n=69) 
P 
value 
Rectum 
adhesiolysis 
(n=20) 
Rectum no 
adhesiolysis 
(n=29) 
P 
value 
Colon 
adhesiolysis 
(n=31) 
Colon no 
adhesiolysis 
(n=40) 
P 
value 
Gender          
    Male 28 (54.9) 43 (62.3) 0.41 12 (60.0) 22 (75.9) 0.24 16 (51.6) 21 (52.5) 0.94 
    Female 23 (45.1) 26 (37.7) 8 (40.0) 7 (24.1) 15 (48.4) 19 (47.5) 
Age 68.8 ± 12.5 66.8 ± 9.7 0.35 63.1 ±14.4 65.9 ± 9.4 0.44 72.5 ± 9.6 67.5 ± 10.0 0.034 
BMI 25.7 ± 3.7 25.4 ± 4.1 0.73 25.6 ± 3.3 25.8 ± 4.4 0.83 25.7 ± 4.0 25.1 ± 3.9 0.53 
Abdominal surgery 32 (62.7) 13 (18.8) <0.001 10 (50.0) 5 (17.2) 0.026 22 (71.0) 8 (20.0) <0.001 
SCRT-TME < 2    6 (30.0) 10 (34.5) 0.95 - -  
SCRT-TME > 4    3 (15.0) 5 (17.2) - -  
CRT    8 (40.0) 11 (37.9) - -  
Chemotherapy    0  0  2 (6.5) 3 (7.5) 0.66 
MSRC 17 (33.3) 11 (15.9) 0.026 9 (45.0) 7 (24.1) 0.13 8 (25.8) 4 (10.0) 0.078 
Right 18 (35.3) 20 (29.0) 0.49 - -  18 (58.1) 20 (50.0) 0.41 
Extended right 3 (5.9) 2 (2.9) - -  3 (9.7) 2 (5.0) 
Left hemicolectomy 2 (3.9) 4 (5.8) - -  2 (6.5) 4 (10.0) 
Sigmoid resection 4 (7.8) 6 (8.7) - -  4 (12.9) 6 (15.0) 
Rectosigmoid 1 (2.0) 7 (10.1) - -  1 (3.2) 7 (17.5) 
Low anterior 13 (25.5) 12 (17.4) 12 (60.0) 12 (41.4) 0.35 1 (3.2) 0  
Abdominoperineal 8 (15.7) 16 (23.2) 8 (40.0) 16 (55.2) 0  0  
Subtotal colectomy 2 (3.9) 1 (1.4) - - 2 (6.5) 1 (2.5) 
Proctocolectomy 0 (0) 1 (1.4) 0 (0) 1 (3.4) 0  0  
Values are mean ± SD or n (%). 
BMI = Body mass index; SCRT = short course radiotherapy; TME = total mesorectal excision; CRT = chemoradiotherapy. 
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Table 6: Oncological results analysis of resections in rectal colon cancer compared between 
operations with and without adhesiolysis. 
 Rectal  
cancer 
adhesiolysis 
(n=20) 
Rectal  
cancer no 
adhesiolysis 
(n=29) 
Relative 
risk 
P value  Colon  
cancer 
adhesiolysis 
(n=31) 
Colon  
cancer no 
adhesiolysis 
(n=40) 
P value
Incomplete resection 1 (5.0) 1 (3.4) 0.073 1.0 Incomplete resection 1 (3.2) 0  0.44 
CRM (mm) 8.3 ± 6.0 
(n=17) 
7.6 ± 5.8 
(n=21) 
 0.70 Margin to nearest  
    resection plain, mm 
76.1 ± 56.2 
(n=26) 
64.7 ± 45.7 
(n=34) 
0.41 
Number harvested  
    of lymph nodes  
 
13 ± 7 
 
12 ± 6 
  
0.63 
Number harvested 
    of lymph nodes  
 
15 ± 8 
 
17 ± 10 
 
0.42 
Values are mean ± SD or n (%). 
 
 
Subgroup  Analysis  of  the  Adhesiolysis  Group  by  Cause of Adhesions 
The adhesiolysis group comprised 113 patients with and 34 without prior abdominal surgery. 
Patients with prior abdominal surgery in the adhesiolysis group had more severe adhesions 
(median Zühlke score 3, range 1–4). These adhesions were mostly located under the incision of a 
previous operation or at the operative area (78.7 and 83.5%, respectively). Median adhesiolysis 
time in these patients was 18 min (1–177). The 34 patients without prior abdominal surgery 
mainly had a few low-grade adhesions (median Zühlke score 1, range 1–3) with a median 
adhesiolysis time of 5 min (range 1–93). These adhesions were mostly located at the operative 
area (71.4%), adjacent to a local inflammatory process or tumour. 
Incidence of enterotomy due to adhesiolysis of postoperative adhesions was 9 (6.1%) and of 
seromuscular injury 36 (31.9%) compared to 0 and 7 (6.9%) respectively in the non-
adhesiolysis group (p = 0.004 and p < 0.001). The incidence of MSRC was 30 (26.5%) in the 
group with adhesiolysis of postoperative adhesions compared to 16 (15.7%) in the non-
adhesiolysis group (p = 0.055). The mean hospital stay was comparable between both groups 
(10.2 ± 8.4 and 9.0 ± 7.4 days [p = 0.28]). The readmission rate within 30 days was significantly 
higher in the adhesiolysis of postoperative adhesions group with 16 (14.2%) vs. 3 (2.9%) in the 
non-adhesiolysis group 
(p = 0.004). 
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Discussion 
In this prospective single center study more than half of the patients undergoing colorectal 
surgery required some degree of adhesiolysis, predominantly in patients with previous 
abdominal surgery in history. Adhesiolysis led to enterotomy in 1 of 16 procedures; this ratio 
increased to 1 of 12 procedures in patients with postsurgical adhesions, and to 1 of 8 procedures 
in patients with 2 or more prior abdominal operations. Adhesiolysis doubled major surgical 
complications’ rate and led to a higher incidence of readmission. There was a trend towards 
prolonged hospital stay with almost 3 days, and higher costs when adhesiolysis were needed. 
This subgroup of elective colorectal operations from a prospective cohort study of 755 all 
types elective abdominal operations was chosen because colorectal surgery involves a large 
patient group and this type of surgery has been associated with adhesion-related 
complications.4,20–22 Almost two-third of patients had baseline adhesions, mostly originating 
from previous surgery, harboring the highest risk of surgical complications when lysed. The 
risk is related to more dense adhesions particularly to a midline scar. Lysis of mostly filmy 
adhesions at the operative area adjacent to the disease process did not increase preoperative 
complications risk. The 28 min adhesiolysis time, the 6–8% enterotomies, the 30% occurrence of 
major surgical complications and 14% readmission rate are indicators of the large disease 
burden of postoperative adhesion formation in unselected, elective, (non)malignant 
colorectal surgery. 2 The 8% enterotomy rate compares favorably with the 19% of patients 
who incurred an enterotomy when undergoing adhesiolysis at repeat colorectal surgery in a 
previous retrospective analysis from our institution. 21 This higher enterotomy rate may be 
explained by the predominant number of patients with inflammatory bowel disease and 
with multiple extended resections in the previous study, necessitating more elaborated lysis 
of dense adhesions. Another explanation might be the stricter definition of iatrogenic 
bowel defects in this study, which did not include enterotomies in the proximity of a 
preexisting bowel fistula. The most likely explanation, however, is the increased awareness in 
our hospital during the last decade for adhesiolysis related complications, by surgeons 
taking time to carefully lyse adhesions and meticulously repair all injuries. These study 
results can raise awareness of other colorectal surgeons similarly taking prudence and care 
in operations that require adhesiolysis. 
Our results are not in agreement with a large but retrospective analysis of 1,071 patients 
operated for colorectal cancer that, apart from delayed gastrointestinal motility, did not show a 
higher postoperative complication rate in patients with adhesions. 23 In that study, outcome 
data were based on operative and discharge reports introducing reporting bias. Operative and 
hospital discharge notes are inferior to concurrent tracking of adhesions and (post)operative 
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complications as performed in this study.24,25 Real-time gathering of data by means of 
predefined scoring lists during an operation is rather unique in surgical research. It is elaborative 
but necessary to accurately and objectively assess operative sequelae. New technology such as 
Google glass or a medical data recorder may help making observation less laboursome. 
This study is the first to investigate the impact of adhesiolysis on oncological quality of resection 
in colorectal cancer surgery. The oncological outcome parameters were not included in the 
study protocol but retrospectively extracted from the pathology reports. Through the use of 
standardized reports for colorectal cancer as recommended by the National Guidelines for 
Colorectal Cancer Surgery and following the Dataset for colorectal cancer (2nd edition) of the 
Royal College of Pathologists reliability of the pathology reports is high.16,17 We did not find 
smaller resection margins or a lower number of harvested lymph nodes in patients that 
required adhesiolysis. This finding corresponds with results of 2 retrospective studies 
reporting on the impact of prior abdominal surgery on curative resection for colorectal 
cancer. Since abdominal surgery results in intra-abdominal adhesions in up to 90% of patients 
7,26,27, prior abdominal surgery is considered a proxy of need for adhesiolysis. In patients 
undergoing resection of colon cancer via minilaparotomy, a similar number of harvested lymph 
nodes was found between patients with or without prior abdominal surgery.28 A study in 
laparoscopic colorectal resection showed no significant differences in resection margins or 
number of harvested lymph nodes.29 The generalizability of these 2 retrospective studies is 
limited since the reported numbers of lymph nodes harvested were approximately half the 
number we found. The number of lymph nodes retrieved from a resection specimen may be 
related to factors such as the extent of the resection undertaken or the use of neoadjuvant 
therapy, but it is likely that the accuracy of pathological examination of the specimen is most 
important. The quality of histopathological examination should be taken into account when 
reporting on differences in lymph node yield and resection margins. Unfortunately, we could 
only analyse oncological outcome parameters in small subgroups. Histopathological 
examination showed high lymph node yield, adequate margins, and low percentage 
incomplete resections  with only minimal differences between the adhesiolysis group and the 
no adhesiolysis group. Despite the absence of significant differences in histopathological 
outcome parameters in our study, the impact of adhesiolysis on oncological outcome deserves 
further attention. Whether adhesiolysis impacts number of harvested lymph nodes and 
resection margins should be assessed in a larger cohort of colorectal cancer patients. The 
effect of adhesiolysis on long-term oncological outcome should be investigated as well, since 
long-term oncological outcome might be affected by adhesiolysis due to a higher incidence of 
MSRCs, which potentially delays the start of adjuvant treatment.30 
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Discussion 
In this prospective single center study more than half of the patients undergoing colorectal 
surgery required some degree of adhesiolysis, predominantly in patients with previous 
abdominal surgery in history. Adhesiolysis led to enterotomy in 1 of 16 procedures; this ratio 
increased to 1 of 12 procedures in patients with postsurgical adhesions, and to 1 of 8 procedures 
in patients with 2 or more prior abdominal operations. Adhesiolysis doubled major surgical 
complications’ rate and led to a higher incidence of readmission. There was a trend towards 
prolonged hospital stay with almost 3 days, and higher costs when adhesiolysis were needed. 
This subgroup of elective colorectal operations from a prospective cohort study of 755 all 
types elective abdominal operations was chosen because colorectal surgery involves a large 
patient group and this type of surgery has been associated with adhesion-related 
complications.4,20–22 Almost two-third of patients had baseline adhesions, mostly originating 
from previous surgery, harboring the highest risk of surgical complications when lysed. The 
risk is related to more dense adhesions particularly to a midline scar. Lysis of mostly filmy 
adhesions at the operative area adjacent to the disease process did not increase preoperative 
complications risk. The 28 min adhesiolysis time, the 6–8% enterotomies, the 30% occurrence of 
major surgical complications and 14% readmission rate are indicators of the large disease 
burden of postoperative adhesion formation in unselected, elective, (non)malignant 
colorectal surgery. 2 The 8% enterotomy rate compares favorably with the 19% of patients 
who incurred an enterotomy when undergoing adhesiolysis at repeat colorectal surgery in a 
previous retrospective analysis from our institution. 21 This higher enterotomy rate may be 
explained by the predominant number of patients with inflammatory bowel disease and 
with multiple extended resections in the previous study, necessitating more elaborated lysis 
of dense adhesions. Another explanation might be the stricter definition of iatrogenic 
bowel defects in this study, which did not include enterotomies in the proximity of a 
preexisting bowel fistula. The most likely explanation, however, is the increased awareness in 
our hospital during the last decade for adhesiolysis related complications, by surgeons 
taking time to carefully lyse adhesions and meticulously repair all injuries. These study 
results can raise awareness of other colorectal surgeons similarly taking prudence and care 
in operations that require adhesiolysis. 
Our results are not in agreement with a large but retrospective analysis of 1,071 patients 
operated for colorectal cancer that, apart from delayed gastrointestinal motility, did not show a 
higher postoperative complication rate in patients with adhesions. 23 In that study, outcome 
data were based on operative and discharge reports introducing reporting bias. Operative and 
hospital discharge notes are inferior to concurrent tracking of adhesions and (post)operative 
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complications as performed in this study.24,25 Real-time gathering of data by means of 
predefined scoring lists during an operation is rather unique in surgical research. It is elaborative 
but necessary to accurately and objectively assess operative sequelae. New technology such as 
Google glass or a medical data recorder may help making observation less laboursome. 
This study is the first to investigate the impact of adhesiolysis on oncological quality of resection 
in colorectal cancer surgery. The oncological outcome parameters were not included in the 
study protocol but retrospectively extracted from the pathology reports. Through the use of 
standardized reports for colorectal cancer as recommended by the National Guidelines for 
Colorectal Cancer Surgery and following the Dataset for colorectal cancer (2nd edition) of the 
Royal College of Pathologists reliability of the pathology reports is high.16,17 We did not find 
smaller resection margins or a lower number of harvested lymph nodes in patients that 
required adhesiolysis. This finding corresponds with results of 2 retrospective studies 
reporting on the impact of prior abdominal surgery on curative resection for colorectal 
cancer. Since abdominal surgery results in intra-abdominal adhesions in up to 90% of patients 
7,26,27, prior abdominal surgery is considered a proxy of need for adhesiolysis. In patients 
undergoing resection of colon cancer via minilaparotomy, a similar number of harvested lymph 
nodes was found between patients with or without prior abdominal surgery.28 A study in 
laparoscopic colorectal resection showed no significant differences in resection margins or 
number of harvested lymph nodes.29 The generalizability of these 2 retrospective studies is 
limited since the reported numbers of lymph nodes harvested were approximately half the 
number we found. The number of lymph nodes retrieved from a resection specimen may be 
related to factors such as the extent of the resection undertaken or the use of neoadjuvant 
therapy, but it is likely that the accuracy of pathological examination of the specimen is most 
important. The quality of histopathological examination should be taken into account when 
reporting on differences in lymph node yield and resection margins. Unfortunately, we could 
only analyse oncological outcome parameters in small subgroups. Histopathological 
examination showed high lymph node yield, adequate margins, and low percentage 
incomplete resections  with only minimal differences between the adhesiolysis group and the 
no adhesiolysis group. Despite the absence of significant differences in histopathological 
outcome parameters in our study, the impact of adhesiolysis on oncological outcome deserves 
further attention. Whether adhesiolysis impacts number of harvested lymph nodes and 
resection margins should be assessed in a larger cohort of colorectal cancer patients. The 
effect of adhesiolysis on long-term oncological outcome should be investigated as well, since 
long-term oncological outcome might be affected by adhesiolysis due to a higher incidence of 
MSRCs, which potentially delays the start of adjuvant treatment.30 
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We found a 60% incidence of adhesions in patients undergoing colorectal surgery, of whom 
83% had prior abdominal, predominantly open, surgery. Since minimally invasive surgery 
has become the operative technique of choice for nearly all types of abdominal surgery, the 
incidence of adhesions and the burden might decrease in time compared to our results. A few 
large populationbased register studies showed a significantly lower incidence of small bowel 
obstruction after laparoscopic surgery compared to open abdominal surgery.31,32 A literature 
review of comparative, mainly experimental, studies on adhesion formation between 1966 
and 2002 showed less adhesions after laparoscopic surgery. However, laparoscopic surgery is 
not adhesion-free surgery.33,34 Therefore, adhesionand adhesiolysis-related morbidity will 
remain a problem in the minimally invasive era. Further knowledge on incidence and location of 
adhesions after open and laparoscopic procedures is necessary to make specific risk assessments 
and recommendations for anti-adhesive strategies in both operation techniques. 
Adhesiolysis increases the risk of major surgical complications in colorectal surgery. All 
physicians performing colorectal surgery should be aware of these findings and address the 
higher intraand postoperative complication rate in preoperative counseling of patients, 
particularly in those who had multiple previous abdominal operations. Less than 10% of 
surgeons and gynecologists routinely inform their patients of the risk of adhesions and the 
potential of adhesion prevention.35 Awareness of the burden of adhesions might increase the 
use of adhesion barriers in colorectal and general surgery. Efficacy and safety of barriers has 
recently been shown in a comprehensive systematic review 36; adhesion barriers decrease 
incidence and severity of adhesions as well as operative time at repeat surgery.37 Small bowel 
obstruction and female infertility have historically been the focus of adhesion (prevention) 
research. Future research should include the need for adhesiolysis and adhesiolysis-related 
complications during repeat abdominal surgery as endpoints. Furthermore, the incidence of 
postoperative complications and oncological outcome including time to start of adjuvant 
chemotherapy should be incorporated when including abdominal surgery for malignancies. 
 
Conclusion 
Adhesiolysis increases the incidence of iatrogenic bowel injuries and MSRC, prolongs hospital 
stay and is associated with a higher readmission rate following colorectal surgery. 
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We found a 60% incidence of adhesions in patients undergoing colorectal surgery, of whom 
83% had prior abdominal, predominantly open, surgery. Since minimally invasive surgery 
has become the operative technique of choice for nearly all types of abdominal surgery, the 
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potential of adhesion prevention.35 Awareness of the burden of adhesions might increase the 
use of adhesion barriers in colorectal and general surgery. Efficacy and safety of barriers has 
recently been shown in a comprehensive systematic review 36; adhesion barriers decrease 
incidence and severity of adhesions as well as operative time at repeat surgery.37 Small bowel 
obstruction and female infertility have historically been the focus of adhesion (prevention) 
research. Future research should include the need for adhesiolysis and adhesiolysis-related 
complications during repeat abdominal surgery as endpoints. Furthermore, the incidence of 
postoperative complications and oncological outcome including time to start of adjuvant 
chemotherapy should be incorporated when including abdominal surgery for malignancies. 
 
Conclusion 
Adhesiolysis increases the incidence of iatrogenic bowel injuries and MSRC, prolongs hospital 
stay and is associated with a higher readmission rate following colorectal surgery. 
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Abstract 
Background 
Prior abdominal surgery increases complexity of abdominal operations. Effort to prevent injury 
during adhesiolysis might result in less extensive bowel resection in colorectal cancer surgery. The 
aim of this study was to evaluate the effect of prior abdominal surgery on the outcome of colorectal 
cancer surgery.   
 
Methods 
A nationwide prospective database of patients with primary colorectal cancer resection in The 
Netherlands between 2010 and 2012 was reviewed for histopathology, morbidity and mortality in 
patients with compared to patients without prior abdominal surgery. 
 
Results 
9,042 patients with and 17,679 without prior abdominal surgery were analyzed. After prior 
abdominal surgery 20.7% had less than 10 lymph nodes in the histopathological specimen compared 
to 17.8% without prior abdominal surgery (adjusted OR 1.17, 95% CI 1.09 -1.26). Adjusted ORs for 
less than 10 and 12 lymph nodes were significant in colon cancer resection and not in rectal cancer 
resection. Subgroups of patients who had previous hepatobiliary surgery or other abdominal surgery 
had a higher incidence of inadequate number of harvested lymph nodes. Prior colorectal surgery 
increased the percentage of positive circumferential rectal resection margin by 64% (12.5% and 
7.6%; adjusted OR 1.70, 95% CI 1.21 – 2.39). For colon cancer morbidity was significantly higher in 
patients with prior surgery (33.2% and 29.7%; adjusted OR 1.18, 95% CI 1.10 – 1.26), 30-day mortality 
was comparable (4.7% prior surgery and 3.8% without prior surgery; adjusted OR 1.01, 95% CI 0.88-
1.17).   
 
Conclusions 
Prior abdominal surgery compromises the quality of resection and increases postoperative morbidity 
in patients with primary colorectal cancer.  
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Introduction 
Prior abdominal surgery increases the complexity and morbidity of abdominal operations, mainly due 
to the frequent presence of postoperative intra-abdominal adhesions.1 The incidence of 
postoperative intra-abdominal adhesions after previous surgery ranges between 67% and 95%.2-5 
Adhesions may necessitate adhesiolysis, which is time consuming and results in full-thickness or 
seromuscular bowel injury in one third of the patients.6 Adhesiolysis and associated bowel injury 
increase morbidity and mortality.6, 7 The cautious approach to the bowel during adhesiolysis to avoid 
injury, might compromise access to the operative field and extent of bowel resection, with possibly 
smaller or even incomplete resection margins. When access to the pelvic area for performing rectal 
resection is difficult due to a previous operation, care is taken not to injure ureters or main vessels 
and nerves, possibly limiting mesorectal excision.  A small resection margin, has been identified as a 
risk factor for poor lymph node harvest.8 Minimal information is available regarding the effect of 
previous surgery on quality of resection margin or number of lymph nodes. Two retrospective studies 
showed no difference in number of harvested lymph nodes and resection margin.9, 10 Both studies 
comprised low numbers of patients (n=86 and n=267), and both reported overall mean number of 
harvested lymph nodes less than 10. This low number possibly reflects inadequate surgical resection 
or inadequate quality of histopathological examination of the specimen.  
Since 2009 the Dutch Surgical Colorectal Audit (DSCA) database is in use to assess and benchmark 
outcomes of colorectal cancer treatments between hospitals. Prior surgery is one of the many 
variables recorded in this database. This gave us the opportunity to evaluate the effect of prior 
abdominal surgery on the outcome of colorectal cancer surgery in more than 25 000 Dutch patients 
with respect to histopathological quality of resection and postoperative morbidity and mortality. 
 
Patients and Methods 
DSCA 
Data were retrieved from the Dutch Surgical Colorectal Audit (DSCA), which was initiated by the 
Dutch Surgical Society to monitor and improve the quality of surgical care in colorectal cancer 
patients on a national level. The DSCA contains data on primary colorectal cancer resections 
registered by all 92 Dutch hospitals performing colorectal cancer surgery as from 2009.11 Recurrent 
colorectal cancer patients are not included in the database. The data set shows a high level of 
completeness on most items and a case ascertainment of approximately 95% when compared with 
the Netherlands Cancer Registry.12 Details of the dataset regarding data collection and methodology 
have been published elsewhere.11 Medical ethics committee approval was not required for this study 
as all patient and hospital information in the DSCA was anonymous.  
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Abstract 
Background 
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resection is difficult due to a previous operation, care is taken not to injure ureters or main vessels 
and nerves, possibly limiting mesorectal excision.  A small resection margin, has been identified as a 
risk factor for poor lymph node harvest.8 Minimal information is available regarding the effect of 
previous surgery on quality of resection margin or number of lymph nodes. Two retrospective studies 
showed no difference in number of harvested lymph nodes and resection margin.9, 10 Both studies 
comprised low numbers of patients (n=86 and n=267), and both reported overall mean number of 
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or inadequate quality of histopathological examination of the specimen.  
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Patients and Methods 
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registered by all 92 Dutch hospitals performing colorectal cancer surgery as from 2009.11 Recurrent 
colorectal cancer patients are not included in the database. The data set shows a high level of 
completeness on most items and a case ascertainment of approximately 95% when compared with 
the Netherlands Cancer Registry.12 Details of the dataset regarding data collection and methodology 
have been published elsewhere.11 Medical ethics committee approval was not required for this study 
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In-and exclusion criteria 
All patients aged 18 years and older who underwent colonic and rectal cancer resection in the 
Netherlands between January 2010 and December 2012 were included in this study. Patients who 
underwent a transanal procedure were excluded from analysis. 
 
Outcomes 
Primary outcome measures were number of harvested lymph nodes, circumferential rectal resection 
margin (CRM), CRM positivity, and completeness of resection in colon cancer.  The CRM was 
considered positive if tumor cells were within 1 mm of the resection margin. Completeness of 
resection was defined as complete resection (resection with margins free of disease at 
histopathology, R0) or incomplete resection (margins positive for disease at histopathology, R1 or 
R2). R1 and R2 were taken together because of relatively small patient numbers with incomplete 
resection. Besides absolute number of harvested lymph nodes we used cut-offs of 10 and 12 lymph 
nodes. These are the cut-offs of the Dutch and US guidelines.13, 14 Secondary outcome measures were 
postoperative complications and 30-day mortality. 
Potential risk factors for adverse oncological or clinical outcome, including patient factors (age, sex, 
body mass index (BMI), ASA fitness grade, previous abdominal surgery), tumor factors (stage, 
location, preoperative tumor complications) and treatment factors (neoadjuvant therapy, type of 
surgical resection, operation technique, urgency of surgery, extent of resection), were extracted from 
the database. There is no information regarding adhesions in the database (e.g. incidence or severity 
of adhesions or adhesiolysis time).  
 
Statistical analysis 
Univariable analyses were carried out to examine the association previous abdominal surgery and 
number of harvested lymph nodes, CRM, CRM positivity, completeness of resection, postoperative 
complications and 30-day mortality. Multivariable logistic regression analyses were performed to 
correct for possible confounders. A manual stepwise model was used, with inclusion of variables with 
P < 0·20. Clinically relevant variables, i.e. neoadjuvant therapy, were added to the statistical model. 
Conversion from laparoscopic to open technique and tumor localization were not included in the 
multivariate analysis because of the collinearity between prior operations and conversion, and 
between localization of the primary tumor and type of resection. Type of resection is highly 
influenced by the localization of the primary tumor, but the type of resection has a larger influence 
on clinical and histopathological outcome, especially in case of synchronous tumors.  
Subgroup analysis regarding number of lymph nodes and percentage of resections with less than 10 
and 12 lymph nodes was performed for colon and rectal cancer separately. Number of lymph nodes 
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after colon and rectal cancer resection, percentage of colon and rectal cancer resections with less 
than 10 and 12 lymph nodes, incomplete colon cancer resection and CRM and CRM positivity were 
analyzed in subgroups of different types of abdominal surgery in history as defined in the database: 
colorectal surgery (including appendectomy), urogenital surgery, hepatobiliary surgery (including 
cholecystectomy), upper gastrointestinal surgery (including pancreatic surgery), or other abdominal 
surgery not otherwise specified. These subgroups of previous surgery were analyzed because 
reported incidences of adhesion-related and adhesiolysis-related complications differ between 
different anatomical locations of prior surgery.2, 15 This subgroup analysis was performed in the 
cohort 2011-2012, because of a high level of missing data on location of prior surgery in patients 
operated in 2010. Subgroup analysis by magnitude of the previous operation was not possible 
because this item is not registered in the database.  
Results are reported as odds ratios with 95% confidence intervals. All data were analyzed using SPSS 
for Windows version 20.0 software (SPSS, Chicago, IL). We excluded per analysis those cases with 
missing data. 
 
Results 
27,341 Colorectal cancer patients were included in the database from 2010 to 2012. After excluding 
patients younger than 18 years (n=17), transanal procedures (n=344), and patients with missing data 
of prior abdominal surgery (n=259), 26,721 patients were eligible for inclusion. 9,042 Patients 
(33.8%) had undergone one or more previous abdominal operations,17,679 patients (66.2%) had no 
prior abdominal surgery. 
 
Baseline characteristics  
Baseline characteristics for the groups with and without prior abdominal surgery are presented in 
Table 1. All data significantly differed between groups due to large patient numbers. Clinically 
relevant differences were found for age and sex. Mean age was 71.3 in the prior abdominal surgery 
group compared to 68.4 in the no prior abdominal surgery group. The prior abdominal surgery group 
comprised 41.9% male patients compared to 61.3% in the no prior abdominal surgery group. 
 
Histopathological and clinical outcome 
Mean number of lymph nodes in the histopathology specimen was 15.2 in the group with and 15.6 in 
the group without prior abdominal surgery (Table 2). Number of lymph nodes was less than 10 and 
12 in 20.7% and 35.8% of patients with prior abdominal surgery compared to 17.8% and 32.8% in 
patients without prior abdominal surgery. For colonic resection the percentage of patients with less 
than 10 and 12 lymph nodes was higher in the prior surgery compared to the no prior surgery group. 
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Table 1: Baseline characteristics Cohort 2010-2012 
Prior Abdominal Operations Yes (N=9,042) No (N=17,679) P value 
Age 71.3 (±10.8) 68.4 (±11.3) <0.001 
Sex % 41.9% male 61.3% male <0.001 
ASA % 
    I 
    II 
    III 
    IV 
    V 
 
15.5 
58.2 
24.8 
1.5 
0.1 
 
23.0 
55.1 
20.0 
1.8 
0.1 
 
<0.001 
Urgency operation % 
    Elective 
    Elective after stent placement 
    Urgent 
    Emergency 
    Unknown 
 
85.9 
0.7 
7.4 
5.9 
0.2 
 
83.8 
0.6 
8.0 
7.5 
0.1 
 
 
<0.001 
Tumor localization % 
    Caecum 
    Appendix 
    Ascending colon 
    Hepatic flexure 
    Transverse colon 
    Splenic flexure 
    Descending colon 
    Sigmoid colon 
    Rectum 
 
15.9 
0.8 
14.6 
4.8 
6.6 
2.3 
4.7 
25.3 
24.9 
 
13.3 
0.4 
12.4 
4.4 
5.0 
2.4 
4.3 
28.8 
29.0 
 
<0.001 
Neoadjuvant Therapy % (rectal cancer, N=6457) 
    No 
    Short course 
    Long course 
    Chemoradiation 
N=1921 
3.4 
55.2 
5.9 
35.5 
N=4536  
2.7 
54.1 
5.8 
37.4 
 
0.26 
Operation Technique % 
    Open 
    Laparoscopic 
 
60.6 
39. 4 
 
54.2 
45.8 
 
<0.001 
Conversion in  laparoscopy (n=8589) % 
    No 
    Early (<30 minutes) 
    Late (>30 minutes) 
 
76.5 
12.5 
11.1 
 
82.6 
8.5 
9.0 
 
<0.001 
Reason for conversion % 
(N=1406) 
    Advanced tumor 
    Accessibility 
    Peroperative complication 
 
 
14.3 
79.1 
6.7 
 
 
26.9 
65.4 
7.7 
 
 
<0.001 
Type of Resection % 
    Ileocaecal resection/appendicectomy 
    Right hemicolectomy 
    Transverse colectomy 
    Left hemicolectomy 
    (Low)Anterior Resection/sigmoidectomy 
    Subtotal colectomy 
    Abdominoperineal Resection 
    Proctocolectomy 
    Other 
 
1.1 
36.1 
2.7 
7.8 
40.6 
1.7 
7.6 
0.8 
1.4 
 
0.9 
30.7 
1.9 
7.7 
47.3 
1.4 
8.5 
0.6 
1.0 
 
<0.001 
  
Prior Abdominal Surgery Jeopardizes Quality of Resection in Colorectal Cancer 
 
67 
Table 1 (continued): Baseline characteristics Cohort 2010-2012 
Prior Abdominal Operations Yes (N=9,042) No (N=17,679) P value 
T-stage (pathol) % 
    1 
    2 
    3 
    4 
    X 
    0 
 
7.1 
20.8 
55.7 
13.0 
2.1 
1.3 
 
6.1 
19.6 
57.6 
13.5 
1.8 
1.4 
 
0.001 
N-stage (pathol) % 
    0 
    1 
    2 
    X 
 
60.3 
24.3 
13.8 
1.6 
 
57.5 
25.4 
16.1 
1.0 
 
 
<0.001 
 
 
Table 2: Histopathological and clinical outcome, cohort 2010-2012 
 Prior abdominal 
operations N = 8949 b 
No prior abdominal 
operations N = 17534 b 
Crude OR/ mean 
difference (95% CI) 
Adjusted OR / mean 
difference (95% CI) a 
Number of lymph nodes  
     - colon cancer 
     - rectal cancer 
15.2 
16.1 
12.5 
15.6 
16.6 
13.0 
0.39 (0.11 – 0.66) * 
0.55 (0.20 – 0.90) * 
0.46 (0.11 – 0.81) * 
0.37 (0.14 to 0.60) * 
0.43 (0.15 – 0.71) * 
0.14 (-0.23 to 0.50) 
< 10 lymph nodes (% pts) 
     - colon cancer  
     - rectal cancer   
20.7 
16.5 
32.9 
17.8 
13.4 
28.7 
1.20 (1.13 – 1.28) * 
1.28 (1.18 – 1.39) * 
1.22 (1.10 – 1.36) * 
1.17 (1.09 – 1.26) * 
1.22 (1.11 – 1.33) * 
1.09 (0.96 – 1.23) 
< 12 lymph nodes (% pts) 
     - colon cancer  
     - rectal cancer   
35.8 
30.7 
50.8 
32.8 
27.6 
45.6 
1.14 (1.08 – 1.20) * 
1.16 (1.09 – 1.24) * 
1.23 (1.11 – 1.36) * 
1.10 (1.04 – 1.17) * 
1.10 (1.02 – 1.18) * 
1.11 (0.99 – 1.24) 
Incomplete resection colon 
cancer (% pts) 
3.3 3.8 0.87 (0.73 – 1.02) 0.92 (0.77 – 1.11) 
Circumferential rectal 
resection margin (mm) 
11.0 11.1 0.111 (-0.56 to 0.77) 0.10 (-0.82 to 1.02) 
CRM positivity (% pts) 10.2 9.1 1.14 (0.94 – 1.38) 1.12 (0.90 – 1.40) 
Complications (% pts) 
     - colon cancer  
     - rectal cancer   
34.5 
33.2 
38.0 
32.1 
29.7 
37.9 
1.11 (1.05 – 1.17) * 
1.17 (1.10 – 1.25) * 
1.01 (0.91 – 1.11) 
1.14 (1.07 – 1.21) * 
1.18 ( 1.10 – 1.26) * 
1.04 (0.92 -1.17) 
30-day mortality (% pts) 
     - colon cancer  
     - rectal cancer   
4.7 
5.3 
2.7 
3.8 
4.3 
2.6 
1.24 (1.09 – 1.40) * 
1.24 (1.08 – 1.42) * 
1.04 (0.76 – 1.41) 
1.01 (0.88 – 1.17)  
1.01 (0.86 – 1.18) 
1.02 (0.70 – 1.47) 
* p < 0.05 
a adjusted for male sex, age, ASA fitness grade, type of surgical resection, T stage at histopathology, N stage at histopathology, urgency 
of surgery, operation technique and neoadjuvant chemotherapy 
b missing data excluded per analysis 
 
 
For rectal resection differences were not significant after adjustment  for other variables (Table 2). 
No differences were found in completeness of colonic resection, mean circumferential rectal 
resection margin and CRM positivity.  
There was a small but significant increase in percentage of patients with postoperative complications 
Prior Abdominal Surgery Jeopardizes Quality of Resection in Colorectal Cancer 
67
Ch
ap
te
r 4
Chapter 4 
66 
Table 1: Baseline characteristics Cohort 2010-2012 
Prior Abdominal Operations Yes (N=9,042) No (N=17,679) P value 
Age 71.3 (±10.8) 68.4 (±11.3) <0.001 
Sex % 41.9% male 61.3% male <0.001 
ASA % 
    I 
    II 
    III 
    IV 
    V 
 
15.5 
58.2 
24.8 
1.5 
0.1 
 
23.0 
55.1 
20.0 
1.8 
0.1 
 
<0.001 
Urgency operation % 
    Elective 
    Elective after stent placement 
    Urgent 
    Emergency 
    Unknown 
 
85.9 
0.7 
7.4 
5.9 
0.2 
 
83.8 
0.6 
8.0 
7.5 
0.1 
 
 
<0.001 
Tumor localization % 
    Caecum 
    Appendix 
    Ascending colon 
    Hepatic flexure 
    Transverse colon 
    Splenic flexure 
    Descending colon 
    Sigmoid colon 
    Rectum 
 
15.9 
0.8 
14.6 
4.8 
6.6 
2.3 
4.7 
25.3 
24.9 
 
13.3 
0.4 
12.4 
4.4 
5.0 
2.4 
4.3 
28.8 
29.0 
 
<0.001 
Neoadjuvant Therapy % (rectal cancer, N=6457) 
    No 
    Short course 
    Long course 
    Chemoradiation 
N=1921 
3.4 
55.2 
5.9 
35.5 
N=4536  
2.7 
54.1 
5.8 
37.4 
 
0.26 
Operation Technique % 
    Open 
    Laparoscopic 
 
60.6 
39. 4 
 
54.2 
45.8 
 
<0.001 
Conversion in  laparoscopy (n=8589) % 
    No 
    Early (<30 minutes) 
    Late (>30 minutes) 
 
76.5 
12.5 
11.1 
 
82.6 
8.5 
9.0 
 
<0.001 
Reason for conversion % 
(N=1406) 
    Advanced tumor 
    Accessibility 
    Peroperative complication 
 
 
14.3 
79.1 
6.7 
 
 
26.9 
65.4 
7.7 
 
 
<0.001 
Type of Resection % 
    Ileocaecal resection/appendicectomy 
    Right hemicolectomy 
    Transverse colectomy 
    Left hemicolectomy 
    (Low)Anterior Resection/sigmoidectomy 
    Subtotal colectomy 
    Abdominoperineal Resection 
    Proctocolectomy 
    Other 
 
1.1 
36.1 
2.7 
7.8 
40.6 
1.7 
7.6 
0.8 
1.4 
 
0.9 
30.7 
1.9 
7.7 
47.3 
1.4 
8.5 
0.6 
1.0 
 
<0.001 
  
Prior Abdominal Surgery Jeopardizes Quality of Resection in Colorectal Cancer 
 
67 
Table 1 (continued): Baseline characteristics Cohort 2010-2012 
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For rectal resection differences were not significant after adjustment  for other variables (Table 2). 
No differences were found in completeness of colonic resection, mean circumferential rectal 
resection margin and CRM positivity.  
There was a small but significant increase in percentage of patients with postoperative complications 
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after prior surgery (34.5% and 32.1%; adjusted OR 1.14 (95% CI 1.07-1.21). For colonic resection the 
percentage of patients with complications was higher in the prior surgery compared to the no prior 
surgery group. For rectal resection no differences was found (Table 2). 30-day mortality was 0.9 
percent higher in patients with (4.7%) compared to those without prior abdominal surgery (3.8%). 
This difference was not significant after adjustment for other variables. 
 
Table 3: Histopathological outcome after colon cancer surgery according to type of prior abdominal 
surgery, cohort 2011-2012 
 Prior colorectal 
operations N= 1832 b 
No prior abdominal 
operations N= 10404 b  
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.3 17.1 0.80 (0.33 – 1.27) * 0.61 (0.14 – 1.08) * 
< 10 lymph nodes (% pts) 14.2 11.9 1.23 (1.06 – 1.42) * 1.11 (0.94 – 1.30) 
< 12 lymph nodes (% pts) 28.9 25.5 1.19 (1.06 – 1.33) * 1.12 (1.00 – 1.27)** 
Incomplete resection (% pts) 6.2 3.8 1.66 (1.14 – 2.42) * 1.30 (0.90 – 1.89) 
 Prior urogenital 
operations 
N= 1790 b 
No prior abdominal 
operations 
N= 10440 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.8 17.0 0.23 (-0.24 to 0.71) 0.25 (-0.25 to 0.74) 
< 10 lymph nodes (% pts) 13.0 12.1 1.08 (0.93 – 1.26) 1.09 (0.92 – 1.29) 
< 12 lymph nodes (% pts) 25.9 26.1 0.99 (0.88 – 1.11) 0.97 (0.86 – 1.10) 
Incomplete resection (% pts) 3.3 3.6 0.91 (0.68 – 1.20) 1.03 (0.76 – 1.39) 
 Prior hepatobiliary 
operations N= 922 b 
No prior abdominal 
operations N= 11317 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.2 17.0 0.77 (0.13 – 1.40) * 0.40 (-0.24 to 1.03) 
< 10 lymph nodes (% pts) 14.9 12.0 1.28 (1.06 – 1.54) * 1.28 (1.04 – 1.58) * 
< 12 lymph nodes (% pts) 28.2 25.9 1.12 (0.97 – 1.30) 1.09 (0.92 – 1.28) 
Incomplete resection (% pts) 3.7 3.5 1.04 (0.73 – 1.49) 1.15 (0.78 – 1.71) 
 Prior upper 
gastrointestinal 
operations N= 200 b 
No prior abdominal 
operations 
N= 10928 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 21.7 17.0 -4.68 (-6.58 to -2.78) -0.25 (-1.60 to 1.11) 
< 10 lymph nodes (% pts)  16.0 12.0 1.40 (0.95 – 2.05) 1.13 (0.74 – 1.73) 
< 12 lymph nodes (% pts) 28.0 25.9 1.11 (0.82 – 1.52) 0.91 (0.65 – 1.27) 
Incomplete resection (% pts) 3.3 3.6 0.94 (0.44 – 2.00) 1.08 (0.45 – 2.58) 
 Prior other abdominal 
operations N= 815 b 
No prior abdominal 
operations N= 11296 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.7 17.0 0.28 (-0.39 to 0.95) 0.12 (-0.55 to 0.79) 
< 10 lymph nodes (% pts) 15.1 12.0 1.30 (1.06 – 1.59) * 1.28 (1.02 – 1.59) * 
< 12 lymph nodes (% pts) 29.2 25.8 1.18 (1.01 – 1.38) * 1.16 (0.98 – 1.37) 
Incomplete resection (% pts) 3.7 3.6 1.04 (0.71 - 1.53) 1.06 (0.71 – 1.60) 
a adjusted for male sex, age, ASA fitness grade, type of surgical resection, T stage at histopathology, N stage at histopathology, urgency 
of surgery, operation technique and neoadjuvant chemotherapy 
b missing data excluded per analysis 
* P < 0.05 
** P = 0.058 
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Table 4: Histopathological outcome after rectal cancer surgery according to type of prior abdominal 
surgery, cohort 2011-2012 
 Prior colorectal 
operations 
N= 588 b 
No prior abdominal 
operations 
N= 3654 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.8 13.3 0.42 (-0.19 to 1.03) 0.22 (-0.41 to 0.85) 
< 10 lymph nodes (% pts) 30.4 26.2 1.23 (1.02 – 1.49) * 1.11 (0.89 – 1.38) 
< 12 lymph nodes (% pts) 47.4 43.9 1.15 (0.97 – 1.37) 1.03 (0.84 – 1.25) 
Circumferential margin (mm) 10.0 10.8 0.83 (-0.12 to 1.77) 0.64 (-0.37 to 1.65) 
CRM positivity (% pts) 12.5 7.6 1.74 (1.29 – 2.33) * 1.70 (1.21 – 2.39) * 
 Prior urogenital 
operations 
N= 531 b 
No prior abdominal 
operations 
N= 3711 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.7 13.3 0.56 (-0.08 to 1.21) 0.22 (-0.49 to 0.93) 
< 10 lymph nodes (% pts) 29.2 26.5 1.14 (0.94 – 1.40) 1.00 (0.78 – 1.28) 
< 12 lymph nodes (% pts) 48.2 43.8 1.19 (1.00 – 1.43) 1.13 (0.91 – 1.41) 
Circumferential margin (mm) 12.1 10.5 -1.59 (-2.60 to -0.59) * -1.80 (-2.95 to -0.65) * 
CRM positivity (% pts) 5.2 8.7 0.58 (0.37 – 0.90) 0.71 (0.44 – 1.16) 
 Prior hepatobiliary 
operations 
N= 271 b 
No prior abdominal 
operations 
N= 3965 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.5 13.3 0.76 (-0.11 to 1.63) 0.59 (-0.29 to 1.47) 
< 10 lymph nodes (% pts) 32.1 26.5 1.31 (1.01 – 1.71) * 1.21 (0.90 – 1.63) 
< 12 lymph nodes (% pts) 53.1 43.8 1.45 (1.14 – 1.86) * 1.32 (1.01 – 1.74) * 
Circumferential margin (mm) 9.9 10.8 0.83 (-0.47 to 2.14) 0.60 (-0.78 to 1.98) 
CRM positivity (% pts) 6.1 8.4 0.71 (0.42 – 1.21) 0.53 (0.28 – 1.01) 
 Prior upper 
gastrointestinal 
operations N=81 b 
No prior abdominal 
operations 
N= 3785 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 14.2 13.3 -0.91 (-2.46 to 0.65) -1.13 (-2.70 to 0.44) 
< 10 lymph nodes (% pts) 21.0 26.2 0.75 (0.44 – 1.28) 0.63 (0.34 – 1.18) 
< 12 lymph nodes (%) 35.8 43.8 0.72 (0.45 – 1.13) 0.67 (0.40 – 1.12) 
Circumferential margin (mm) 12.2 10.9 -1.36 (-3.88 to 1.15) -1.55 (-4.21 to 1.11) 
CRM positivity (% pts) 10.6 7.7 1.43 (0.64 – 3.15) 1.62 (0.70 – 3.77) 
 Prior other 
abdominal 
operations 
N= 316 b 
No priorabdominal 
operations 
N= 3885 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 13.0 13.2 0.25 (-0.56 to 1.06) 0.28 (-0.57 to 1.13) 
< 10 lymph nodes (% pts) 27.5 26.7 1.04 (0.81 – 1.35) 1.09 (0.81 – 1.48) 
< 12 lymph nodes (% pts) 44.9 44.2 1.03 (0.82 – 1.30) 0.98 (0.75 – 1.28) 
Circumferential margin (mm) 11.3 10.7 -0.68 (-1.93 to 0.57) -0.68 (-2.06 to 0.69) 
CRM positivity (%) 9.4 8.2 1.73 (1.29 – 2.31) * 1.44 (0.89 – 2.36) 
a adjusted for male sex, age, ASA fitness grade, type of surgical resection, T stage at histopathology, N stage at histopathology, 
urgency of surgery, operation technique and neoadjuvant chemotherapy 
b missing data excluded per analysis 
* P < 0.05 
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after prior surgery (34.5% and 32.1%; adjusted OR 1.14 (95% CI 1.07-1.21). For colonic resection the 
percentage of patients with complications was higher in the prior surgery compared to the no prior 
surgery group. For rectal resection no differences was found (Table 2). 30-day mortality was 0.9 
percent higher in patients with (4.7%) compared to those without prior abdominal surgery (3.8%). 
This difference was not significant after adjustment for other variables. 
 
Table 3: Histopathological outcome after colon cancer surgery according to type of prior abdominal 
surgery, cohort 2011-2012 
 Prior colorectal 
operations N= 1832 b 
No prior abdominal 
operations N= 10404 b  
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.3 17.1 0.80 (0.33 – 1.27) * 0.61 (0.14 – 1.08) * 
< 10 lymph nodes (% pts) 14.2 11.9 1.23 (1.06 – 1.42) * 1.11 (0.94 – 1.30) 
< 12 lymph nodes (% pts) 28.9 25.5 1.19 (1.06 – 1.33) * 1.12 (1.00 – 1.27)** 
Incomplete resection (% pts) 6.2 3.8 1.66 (1.14 – 2.42) * 1.30 (0.90 – 1.89) 
 Prior urogenital 
operations 
N= 1790 b 
No prior abdominal 
operations 
N= 10440 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.8 17.0 0.23 (-0.24 to 0.71) 0.25 (-0.25 to 0.74) 
< 10 lymph nodes (% pts) 13.0 12.1 1.08 (0.93 – 1.26) 1.09 (0.92 – 1.29) 
< 12 lymph nodes (% pts) 25.9 26.1 0.99 (0.88 – 1.11) 0.97 (0.86 – 1.10) 
Incomplete resection (% pts) 3.3 3.6 0.91 (0.68 – 1.20) 1.03 (0.76 – 1.39) 
 Prior hepatobiliary 
operations N= 922 b 
No prior abdominal 
operations N= 11317 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.2 17.0 0.77 (0.13 – 1.40) * 0.40 (-0.24 to 1.03) 
< 10 lymph nodes (% pts) 14.9 12.0 1.28 (1.06 – 1.54) * 1.28 (1.04 – 1.58) * 
< 12 lymph nodes (% pts) 28.2 25.9 1.12 (0.97 – 1.30) 1.09 (0.92 – 1.28) 
Incomplete resection (% pts) 3.7 3.5 1.04 (0.73 – 1.49) 1.15 (0.78 – 1.71) 
 Prior upper 
gastrointestinal 
operations N= 200 b 
No prior abdominal 
operations 
N= 10928 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 21.7 17.0 -4.68 (-6.58 to -2.78) -0.25 (-1.60 to 1.11) 
< 10 lymph nodes (% pts)  16.0 12.0 1.40 (0.95 – 2.05) 1.13 (0.74 – 1.73) 
< 12 lymph nodes (% pts) 28.0 25.9 1.11 (0.82 – 1.52) 0.91 (0.65 – 1.27) 
Incomplete resection (% pts) 3.3 3.6 0.94 (0.44 – 2.00) 1.08 (0.45 – 2.58) 
 Prior other abdominal 
operations N= 815 b 
No prior abdominal 
operations N= 11296 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 16.7 17.0 0.28 (-0.39 to 0.95) 0.12 (-0.55 to 0.79) 
< 10 lymph nodes (% pts) 15.1 12.0 1.30 (1.06 – 1.59) * 1.28 (1.02 – 1.59) * 
< 12 lymph nodes (% pts) 29.2 25.8 1.18 (1.01 – 1.38) * 1.16 (0.98 – 1.37) 
Incomplete resection (% pts) 3.7 3.6 1.04 (0.71 - 1.53) 1.06 (0.71 – 1.60) 
a adjusted for male sex, age, ASA fitness grade, type of surgical resection, T stage at histopathology, N stage at histopathology, urgency 
of surgery, operation technique and neoadjuvant chemotherapy 
b missing data excluded per analysis 
* P < 0.05 
** P = 0.058 
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Table 4: Histopathological outcome after rectal cancer surgery according to type of prior abdominal 
surgery, cohort 2011-2012 
 Prior colorectal 
operations 
N= 588 b 
No prior abdominal 
operations 
N= 3654 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.8 13.3 0.42 (-0.19 to 1.03) 0.22 (-0.41 to 0.85) 
< 10 lymph nodes (% pts) 30.4 26.2 1.23 (1.02 – 1.49) * 1.11 (0.89 – 1.38) 
< 12 lymph nodes (% pts) 47.4 43.9 1.15 (0.97 – 1.37) 1.03 (0.84 – 1.25) 
Circumferential margin (mm) 10.0 10.8 0.83 (-0.12 to 1.77) 0.64 (-0.37 to 1.65) 
CRM positivity (% pts) 12.5 7.6 1.74 (1.29 – 2.33) * 1.70 (1.21 – 2.39) * 
 Prior urogenital 
operations 
N= 531 b 
No prior abdominal 
operations 
N= 3711 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.7 13.3 0.56 (-0.08 to 1.21) 0.22 (-0.49 to 0.93) 
< 10 lymph nodes (% pts) 29.2 26.5 1.14 (0.94 – 1.40) 1.00 (0.78 – 1.28) 
< 12 lymph nodes (% pts) 48.2 43.8 1.19 (1.00 – 1.43) 1.13 (0.91 – 1.41) 
Circumferential margin (mm) 12.1 10.5 -1.59 (-2.60 to -0.59) * -1.80 (-2.95 to -0.65) * 
CRM positivity (% pts) 5.2 8.7 0.58 (0.37 – 0.90) 0.71 (0.44 – 1.16) 
 Prior hepatobiliary 
operations 
N= 271 b 
No prior abdominal 
operations 
N= 3965 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 12.5 13.3 0.76 (-0.11 to 1.63) 0.59 (-0.29 to 1.47) 
< 10 lymph nodes (% pts) 32.1 26.5 1.31 (1.01 – 1.71) * 1.21 (0.90 – 1.63) 
< 12 lymph nodes (% pts) 53.1 43.8 1.45 (1.14 – 1.86) * 1.32 (1.01 – 1.74) * 
Circumferential margin (mm) 9.9 10.8 0.83 (-0.47 to 2.14) 0.60 (-0.78 to 1.98) 
CRM positivity (% pts) 6.1 8.4 0.71 (0.42 – 1.21) 0.53 (0.28 – 1.01) 
 Prior upper 
gastrointestinal 
operations N=81 b 
No prior abdominal 
operations 
N= 3785 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 14.2 13.3 -0.91 (-2.46 to 0.65) -1.13 (-2.70 to 0.44) 
< 10 lymph nodes (% pts) 21.0 26.2 0.75 (0.44 – 1.28) 0.63 (0.34 – 1.18) 
< 12 lymph nodes (%) 35.8 43.8 0.72 (0.45 – 1.13) 0.67 (0.40 – 1.12) 
Circumferential margin (mm) 12.2 10.9 -1.36 (-3.88 to 1.15) -1.55 (-4.21 to 1.11) 
CRM positivity (% pts) 10.6 7.7 1.43 (0.64 – 3.15) 1.62 (0.70 – 3.77) 
 Prior other 
abdominal 
operations 
N= 316 b 
No priorabdominal 
operations 
N= 3885 b 
Crude OR / mean 
difference (95% CI) 
Adjusted OR /mean 
difference (95% CI) a 
Number of lymph nodes 13.0 13.2 0.25 (-0.56 to 1.06) 0.28 (-0.57 to 1.13) 
< 10 lymph nodes (% pts) 27.5 26.7 1.04 (0.81 – 1.35) 1.09 (0.81 – 1.48) 
< 12 lymph nodes (% pts) 44.9 44.2 1.03 (0.82 – 1.30) 0.98 (0.75 – 1.28) 
Circumferential margin (mm) 11.3 10.7 -0.68 (-1.93 to 0.57) -0.68 (-2.06 to 0.69) 
CRM positivity (%) 9.4 8.2 1.73 (1.29 – 2.31) * 1.44 (0.89 – 2.36) 
a adjusted for male sex, age, ASA fitness grade, type of surgical resection, T stage at histopathology, N stage at histopathology, 
urgency of surgery, operation technique and neoadjuvant chemotherapy 
b missing data excluded per analysis 
* P < 0.05 
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Histopathological outcome by type of prior operation 
Histopathological results divided by type of prior abdominal surgery, i.e. colorectal surgery, 
urogenital surgery, hepatobiliary surgery, upper gastrointestinal surgery and other abdominal 
operations are shown in Table 3 and 4 for colonic and rectal resection, respectively. Prior upper  
gastrointestinal and urogenital operations did not compromise the quality of oncological resection as  
reflected by number of lymph nodes, resection margins and completeness of resection, for both 
colonic and rectal resections. Prior colorectal resection significantly decreased the number of lymph 
nodes in colon specimens. There was a trend towards a higher percentage of patients with less than 
12 lymph nodes in the specimen (28.9% vs 25.5%, P = 0.058). An almost two-third increase in 
patients with CRM positivity of rectal specimens was found (12.5% prior colorectal resection and 7.6 
no prior colorectal resection). Prior hepatobiliary surgery and prior other abdominal surgery were 
associated with increased percentages of patients with less than 10 lymph nodes by 24 and 26, 
respectively, for colonic resection. For rectal resection, prior hepatobiliary surgery increased the 
percentage of patients with less than 12 lymph nodes by 21. No significant effects of other 
abdominal surgery were found for rectal resections. 
 
Discussion 
Prior abdominal surgery jeopardizes subsequent abdominal surgical procedures. In the large Dutch 
Surgical Colorectal Cancer Audit (DSCA) prospective database of colorectal cancer patients increased 
postoperative complications were demonstrated after prior abdominal surgery. More importantly, 
prior abdominal surgery had negative effects on histopathological outcome parameters. A higher risk 
of inadequate numbers of harvested lymph nodes was demonstrated for colonic resections. Prior 
colorectal surgery was associated with an almost two-third increase of positive circumferential 
resection margins in rectal cancer patients. 
Results of the present study are in agreement with an earlier report of a higher morbidity rate after 
repeat surgery.6 In a case-matched study of laparoscopic intestinal resection even a doubling of the 
incidence of postoperative complications was found after previous midline laparotomy.1 The DSCA 
database does not contain information on the extent of prior operations, but only a gross 
differentiation of anatomical locations where patients had their previous abdominal surgery. It is 
likely that the prior abdominal surgery group partly consists of laparoscopic or minor surgical 
procedures such as appendectomy and cholecystectomy, which may account for the relatively small 
effect on postoperative morbidity found in the present study.   
Two small retrospective series demonstrated no impact of prior abdominal surgery on 
histopathological outcome parameters in colorectal cancer. The number of lymph nodes in colon 
specimens resected via minilaparotomy was similar between 76 patients with prior abdominal 
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surgery and 187 patients without prior surgery.10 Comparison of lymph node numbers and resection 
margins after laparoscopic colorectal resection in 16 patients with and 44 patients without previous 
abdominal surgery also revealed no differences.9 These different results can be explained by the 
small number of patients included in both studies. The low mean number of lymph nodes, in both 
studies less than 10, raises doubts about the quality of surgery or histopathological examination. 
Multiple studies have been published evaluating risk factors for circumferential margin positivity in 
rectal cancer surgery. Well recognized risk factors for increased CRM positivity are higher T and N 
stage, male sex and absence of preoperative chemoradiation.16-19 Prior abdominal surgery has never 
been taken into account in previous studies. Since the mesorectal fascia is a retroperitoneal plane, 
CRM will not be directly affected by intraperitoneal adhesions. However, when the lower abdomen 
has been explored before surgeons can experience difficulty gaining access to the pelvis. The 
association of prior colorectal surgery with increase in positive CRM is therefore most likely explained 
by more challenging surgery and compromised access to the pelvic area due to intraperitoneal 
adhesions. 
The major strength of this study is the use of a very large prospective, complete and validated 
dataset. However, there are limitations, because the database does not contain descriptions of the 
presence or severity of adhesions, nor whether adhesiolysis was performed during surgery. 
Adhesiolysis has demonstrated to increase morbidity and mortality in previous studies 6, 7 and 
adhesions as a factor for a lower quality of colorectal resection specimens is suggested given the 
significant findings for prior surgery. The effect of postoperative adhesions on histopathological 
outcome might even have been underestimated, because a small portion of patients with prior 
abdominal surgery do not have adhesions.2-5 On the other hand, intra-abdominal adhesions also 
occur in patients without prior abdominal surgery. However, the incidence of these adhesions is less 
than 30% 5 and they are mostly low-grade, easy to separate and do not require a lengthy 
adhesiolysis.6 
Some known risk factors for adverse histopathological outcome, such as distance to the nearest 
bowel resection plane and failure to use a pathology template were not available in the DSCA 
database.8 The pathology template for colorectal cancer was introduced in the Netherlands in 2009 
and is generally used. 
Prior abdominal surgery was not specified in the database except for the ‘anatomical location’. 
Particularly, magnitude (i.e. laparoscopic or minimal invasive approach) of the previous operations 
and intra-abdominal complications, e.g. postoperative peritonitis could not be assessed. Differences 
in results between open and minimal invasive prior surgery is expected as there is increasing 
evidence for a lower risk of adhesion-related complications after laparoscopic surgery.20 
Postoperative peritonitis may render a minimal invasive operation into a very adhesiogenic surgical 
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Histopathological outcome by type of prior operation 
Histopathological results divided by type of prior abdominal surgery, i.e. colorectal surgery, 
urogenital surgery, hepatobiliary surgery, upper gastrointestinal surgery and other abdominal 
operations are shown in Table 3 and 4 for colonic and rectal resection, respectively. Prior upper  
gastrointestinal and urogenital operations did not compromise the quality of oncological resection as  
reflected by number of lymph nodes, resection margins and completeness of resection, for both 
colonic and rectal resections. Prior colorectal resection significantly decreased the number of lymph 
nodes in colon specimens. There was a trend towards a higher percentage of patients with less than 
12 lymph nodes in the specimen (28.9% vs 25.5%, P = 0.058). An almost two-third increase in 
patients with CRM positivity of rectal specimens was found (12.5% prior colorectal resection and 7.6 
no prior colorectal resection). Prior hepatobiliary surgery and prior other abdominal surgery were 
associated with increased percentages of patients with less than 10 lymph nodes by 24 and 26, 
respectively, for colonic resection. For rectal resection, prior hepatobiliary surgery increased the 
percentage of patients with less than 12 lymph nodes by 21. No significant effects of other 
abdominal surgery were found for rectal resections. 
 
Discussion 
Prior abdominal surgery jeopardizes subsequent abdominal surgical procedures. In the large Dutch 
Surgical Colorectal Cancer Audit (DSCA) prospective database of colorectal cancer patients increased 
postoperative complications were demonstrated after prior abdominal surgery. More importantly, 
prior abdominal surgery had negative effects on histopathological outcome parameters. A higher risk 
of inadequate numbers of harvested lymph nodes was demonstrated for colonic resections. Prior 
colorectal surgery was associated with an almost two-third increase of positive circumferential 
resection margins in rectal cancer patients. 
Results of the present study are in agreement with an earlier report of a higher morbidity rate after 
repeat surgery.6 In a case-matched study of laparoscopic intestinal resection even a doubling of the 
incidence of postoperative complications was found after previous midline laparotomy.1 The DSCA 
database does not contain information on the extent of prior operations, but only a gross 
differentiation of anatomical locations where patients had their previous abdominal surgery. It is 
likely that the prior abdominal surgery group partly consists of laparoscopic or minor surgical 
procedures such as appendectomy and cholecystectomy, which may account for the relatively small 
effect on postoperative morbidity found in the present study.   
Two small retrospective series demonstrated no impact of prior abdominal surgery on 
histopathological outcome parameters in colorectal cancer. The number of lymph nodes in colon 
specimens resected via minilaparotomy was similar between 76 patients with prior abdominal 
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surgery and 187 patients without prior surgery.10 Comparison of lymph node numbers and resection 
margins after laparoscopic colorectal resection in 16 patients with and 44 patients without previous 
abdominal surgery also revealed no differences.9 These different results can be explained by the 
small number of patients included in both studies. The low mean number of lymph nodes, in both 
studies less than 10, raises doubts about the quality of surgery or histopathological examination. 
Multiple studies have been published evaluating risk factors for circumferential margin positivity in 
rectal cancer surgery. Well recognized risk factors for increased CRM positivity are higher T and N 
stage, male sex and absence of preoperative chemoradiation.16-19 Prior abdominal surgery has never 
been taken into account in previous studies. Since the mesorectal fascia is a retroperitoneal plane, 
CRM will not be directly affected by intraperitoneal adhesions. However, when the lower abdomen 
has been explored before surgeons can experience difficulty gaining access to the pelvis. The 
association of prior colorectal surgery with increase in positive CRM is therefore most likely explained 
by more challenging surgery and compromised access to the pelvic area due to intraperitoneal 
adhesions. 
The major strength of this study is the use of a very large prospective, complete and validated 
dataset. However, there are limitations, because the database does not contain descriptions of the 
presence or severity of adhesions, nor whether adhesiolysis was performed during surgery. 
Adhesiolysis has demonstrated to increase morbidity and mortality in previous studies 6, 7 and 
adhesions as a factor for a lower quality of colorectal resection specimens is suggested given the 
significant findings for prior surgery. The effect of postoperative adhesions on histopathological 
outcome might even have been underestimated, because a small portion of patients with prior 
abdominal surgery do not have adhesions.2-5 On the other hand, intra-abdominal adhesions also 
occur in patients without prior abdominal surgery. However, the incidence of these adhesions is less 
than 30% 5 and they are mostly low-grade, easy to separate and do not require a lengthy 
adhesiolysis.6 
Some known risk factors for adverse histopathological outcome, such as distance to the nearest 
bowel resection plane and failure to use a pathology template were not available in the DSCA 
database.8 The pathology template for colorectal cancer was introduced in the Netherlands in 2009 
and is generally used. 
Prior abdominal surgery was not specified in the database except for the ‘anatomical location’. 
Particularly, magnitude (i.e. laparoscopic or minimal invasive approach) of the previous operations 
and intra-abdominal complications, e.g. postoperative peritonitis could not be assessed. Differences 
in results between open and minimal invasive prior surgery is expected as there is increasing 
evidence for a lower risk of adhesion-related complications after laparoscopic surgery.20 
Postoperative peritonitis may render a minimal invasive operation into a very adhesiogenic surgical 
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procedure. In our own series of consecutive elective colorectal operations 15% of patients who 
needed adhesiolysis had suffered from previous intra-abdominal infection.6 The lack of specific 
information on prior surgery does not make the negative effect of prior abdominal surgery on 
outcome of colorectal cancer surgery less plausible. At most, we can assume that the negative 
impact is greater when prior abdominal operations are major. Eight-two percent of patients with 
prior urogenital operations were women and diagnostic laparoscopy and laparoscopic tubal ligation 
were probably the most common procedures. Female gender and a minimally adhesiogenic 
procedure in history may explain the association of prior urogenital procedures with a larger 
circumferential margin in rectal resection.     
Long-term oncological outcome, overall and disease-free survival, are not available in the DSCA 
database. However, previous studies have shown that an inadequate number of lymph nodes 
evaluated is associated with an impaired outcome 21, 22, and CRM positivity increases local recurrence 
risk.23 Additionally, the higher incidence of postoperative complications might worsen long-term 
oncological outcome.24 
With higher life-expectancy and advances in surgical technique the incidence of repeat abdominal 
surgery has increased. Since adhesion formation is a possible reason for our findings, routine use of 
anti-adhesive barriers particularly in initial colorectal and hepatobiliary surgery could potentially 
benefit outcome of reoperations in the same anatomical areas. In a recent systematic review we 
showed that hyaluronate carboxymethylcellulose has the potential to alleviate the incidence of 
adhesion related complications in colorectal surgery.25 Also in two-stage liver surgery hyaluronate 
carboxymethylcellulose was shown to reduce operation time.26 The potentially beneficial effect of 
anti-adhesives on histopathological results of oncological resections should be taken into account in 
future studies on adhesion prevention.  
This present study addresses the negative effect of prior abdominal surgery on the outcome of 
colorectal cancer surgery. Surgeons should be aware of this effect when performing an oncological 
resection in patients with abdominal surgery in history to dissect the right planes and obtain 
sufficient amounts of lymph nodes not compromising the extent of resection. The completeness and 
quality of preoperative patient informed consent may benefit from the results of this study. 
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procedure. In our own series of consecutive elective colorectal operations 15% of patients who 
needed adhesiolysis had suffered from previous intra-abdominal infection.6 The lack of specific 
information on prior surgery does not make the negative effect of prior abdominal surgery on 
outcome of colorectal cancer surgery less plausible. At most, we can assume that the negative 
impact is greater when prior abdominal operations are major. Eight-two percent of patients with 
prior urogenital operations were women and diagnostic laparoscopy and laparoscopic tubal ligation 
were probably the most common procedures. Female gender and a minimally adhesiogenic 
procedure in history may explain the association of prior urogenital procedures with a larger 
circumferential margin in rectal resection.     
Long-term oncological outcome, overall and disease-free survival, are not available in the DSCA 
database. However, previous studies have shown that an inadequate number of lymph nodes 
evaluated is associated with an impaired outcome 21, 22, and CRM positivity increases local recurrence 
risk.23 Additionally, the higher incidence of postoperative complications might worsen long-term 
oncological outcome.24 
With higher life-expectancy and advances in surgical technique the incidence of repeat abdominal 
surgery has increased. Since adhesion formation is a possible reason for our findings, routine use of 
anti-adhesive barriers particularly in initial colorectal and hepatobiliary surgery could potentially 
benefit outcome of reoperations in the same anatomical areas. In a recent systematic review we 
showed that hyaluronate carboxymethylcellulose has the potential to alleviate the incidence of 
adhesion related complications in colorectal surgery.25 Also in two-stage liver surgery hyaluronate 
carboxymethylcellulose was shown to reduce operation time.26 The potentially beneficial effect of 
anti-adhesives on histopathological results of oncological resections should be taken into account in 
future studies on adhesion prevention.  
This present study addresses the negative effect of prior abdominal surgery on the outcome of 
colorectal cancer surgery. Surgeons should be aware of this effect when performing an oncological 
resection in patients with abdominal surgery in history to dissect the right planes and obtain 
sufficient amounts of lymph nodes not compromising the extent of resection. The completeness and 
quality of preoperative patient informed consent may benefit from the results of this study. 
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Abstract 
Background 
After colorectal surgery, most patients develop adhesions, with a high burden of associated 
complications. Laparoscopy seems to reduce adhesion formation, but evidence to prove this is poor. 
Trials comparing open- and laparoscopic colorectal surgery have never assessed adhesion formation. 
Adhesion formation after laparoscopic and open colorectal cancer resection was compared in a 
prospective observational study of patients, who received liver surgery for colorectal metastases. 
 
Methods  
In six liver centers in The Netherlands, data on intra-abdominal adhesions were gathered during liver 
surgery. Incidence of adhesions to the ventral abdominal wall adjacent to the original incision was 
compared between patients with prior laparoscopic- and open colorectal resection. Secondary 
outcomes were incidence of any adhesions, extent and severity of adhesions, and morbidity related 
to adhesions or adhesiolysis. 
 
Findings 
Between March 2013 and December 2015, 151 patients were included. Ninety patients (59·6%) 
underwent open colorectal resection and 61 patients (40·4%) received laparoscopic colorectal 
resection. The incidence of adhesions to the previous incision was 78·9% after open colorectal 
resection compared to 37·7% after laparoscopic colorectal resection (p<0·001). The incidence of 
abdominal wall adhesions and of any adhesion was significantly higher after open resection; the 
incidence of visceral adhesions did not significantly differ. The extent of abdominal wall and visceral 
adhesions was significantly higher after open- compared to laparoscopic resection. The median 
highest Zühlke score at the original incision was significantly higher after open resection. There were 
no differences in incidence of small bowel obstruction during the interval between the colorectal and 
liver operations, the incidence of serious adverse events and length of stay after liver surgery. 
 
Interpretation 
Laparoscopic colorectal cancer resection is associated with a lower incidence, extent and severity of 
adhesions to parietal surfaces. Laparoscopy does not reduce the incidence of visceral adhesions.  
 
Funding 
No funding. 
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Research in Context 
Evidence Before this Study 
A search within the PubMed database was carried out for reports on randomized controlled trials 
and observational studies on incidence of postoperative adhesions after open- and laparoscopic 
colorectal surgery, published between January 1990 and December 2012. The search string “Tissue 
adhesions OR Adhesi* AND Colorectal surgery OR Colorectal surgery OR Colectomy OR 
Proctocolectomy OR Hartmann OR Pouch surgery OR Ileal pouch-anal anastomosis OR Rectal 
resection OR Colon resection OR Low anterior resection OR Hemicolectomy” was used, limited to 
human studies. Reference lists of retrieved articles were searched for relevant additional studies. 
The search retrieved no randomized controlled trials on incidence of adhesions after open- versus 
laparoscopic colorectal surgery. Two observational studies on incidence of adhesions after open- 
versus laparoscopic colorectal surgery were found. One observational study reported the incidence 
of adhesions after laparoscopic colorectal surgery only. The reported adhesion incidence was lower 
after laparoscopic surgery (32%) compared to open surgery (77%). However, the numbers of patients 
in all studies were small, and none of the studies assessed total incidence of any visceral- and 
abdominal wall adhesions. Assessment of adhesions was limited to abdominal wall plus adnexal 
adhesions in the laparoscopic study, and abdominal wall in one comparative study and peristomal 
adhesions in the other. Additional data on the incidence of adhesions after open colorectal surgery 
from the control arms (no treatment) of five randomized controlled trials on the efficacy of an 
adhesion barrier, showed a mean adhesion incidence of 95%. In these trials, the anatomical sites 
evaluated for adhesions also varied, and none of the trials evaluated total incidence of adhesions. 
The reported adhesion incidence appears to be lower after laparoscopic- compared to open surgery. 
The 60% to 100% adhesion incidence reported after open colorectal surgery and the 21% to 50% 
adhesion incidence reported after laparoscopic colorectal surgery are most likely an underestimation 
of the actual adhesion rate. 
 
Added Value of this Study 
This study was designed to assess the incidence of postoperative adhesions after laparoscopic- 
compared to open colorectal cancer resection. Assessment of adhesions included both abdominal 
wall and visceral sites. The most important ndings of this study are the significantly lower incidence 
of adhesions to the abdominal wall after laparoscopic colorectal cancer surgery compared to open 
colorectal cancer surgery, however, there was no reduction of adhesions between viscera, and yet, a 
62% total incidence of adhesions. 
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Implications of all Available Evidence 
This study provides the first high-quality data on the incidence of adhesions after laparoscopic- 
compared to open colorectal cancer surgery, in which the data enhances knowledge and could 
contribute to daily practice of many doctors. Lower incidence of adhesions reduces the number of 
patients with a lifetime risk of adhesion-related complications, adding long-term benefit to the 
already known short-term benefits of laparoscopic colorectal cancer surgery. The findings of this 
study are of particular importance for future repeat surgery. Lower incidence of abdominal wall 
adhesions after laparoscopy facilitates entry, and lowers the risk of bowel injury, at repeat abdominal 
surgery. The findings of this study reject the common assumption that in the laparoscopic era, 
adhesions would no longer be an issue. This is consistent with a recent meta-analysis that has 
reported only small advantages of laparoscopy on the incidence of small bowel obstruction after 
colorectal surgery. The best method for further prevention of postoperative adhesions in the 
laparoscopic era should be investigated in future studies. The incidence of adhesions must be 
quantified for the design of these studies and to guide use of adhesion barriers. 
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Introduction 
Most patients develop adhesions after abdominal surgery. Adhesions can remain asymptomatic, or 
cause serious complications, such as small bowel obstruction (SBO), secondary female infertility and 
chronic abdomino-pelvic pain.1 Adhesiolysis at repeat surgery, particularly complicated by 
inadvertent bowel defects, can lead to increased mortality, postoperative sepsis, intra-abdominal 
complications, longer hospital stay, more readmissions, and increased costs.2 The clinical burden of 
adhesions and socioeconomic costs are huge, involving millions of patients treated by a great variety 
of doctors.  
Laparoscopy could potentially reduce adhesion formation by decreasing injury to serosal and 
peritoneal surfaces.3 Patients who undergo laparoscopy have smaller incisions and there is less tissue 
manipulation and retraction with instruments, gloved hands and swabs. In laparoscopic surgery, 
blood loss is usually minimal, and desiccation in the closed peritoneal cavity is less than in open 
surgery.4 In contrast, pneumoperitoneum in laparoscopic surgery has been associated with increased 
propensity of adhesion formation throughout the abdomen, due to the dry gas flow and relative 
ischemic condition by increased abdominal pressure.5 
The incidence of adhesions is reported to be 67-93% after open abdominal surgery.6,7 Data on 
adhesion formation after laparoscopic surgery is scarce. In experimental studies and small clinical 
series, laparoscopy demonstrated a lower incidence compared to open surgery.8-11 Two large 
population-based register studies showed a lower risk for adhesion-related readmissions and small 
bowel obstruction after laparoscopic- compared to open colorectal surgery.12,13 A systematic review 
of nonrandomized studies showed that all types of laparoscopic procedures slightly lowered the 
incidence of small bowel obstruction.1 Altogether, it seems that laparoscopy is beneficial regarding 
adhesion formation and related complications, however, evidence is lacking from prospective 
comparative studies with adhesion formation as the primary endpoint. 
Demonstrating evidence for reduction of adhesions and related early and late complications by 
laparoscopy is of scientific-, clinical- and societal interest. Colorectal surgery for cancer is common, 
and has a high likelihood of adhesion formation and associated complications.15,16 During the last 
decade, the laparoscopic approach for colorectal cancer resection has been broadly implemented in 
surgical practice and has become the standard in some countries.17,18 In multicenter randomized 
trials, only minor improvements have been demonstrated on length of stay and blood loss without 
an impact on survival.19,20 The broad acceptation of laparoscopic colorectal cancer resection hampers 
the answer to the question of whether laparoscopy reduces adhesions or not, by reducing the 
likelihood of a trial with adhesion formation as the primary endpoint. Such a trial would also demand 
a large number of patients and a second surgery to assess adhesions. It is unlikely that a sufficiently 
large trial will ever be performed. 
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large trial will ever be performed. 
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An alternative study design was conducted that chose liver surgery for colorectal metastases as an 
opportunity to assess adhesions after laparoscopic- compared to open colorectal cancer resection. 
An advantage of this study design is that adhesiolysis related complications of the liver operation 
could also be investigated. 
 
Methods and Materials 
Study Design and Patients 
This was a multicenter prospective observational study (clinicaltrials.gov registration number: 
NCT01720966) designed to compare the incidence and impact of adhesions between open- and 
laparoscopic colorectal resections. All adult patients undergoing liver surgery between March 2013 
and December 2015 in six liver centers in the Netherlands were screened for inclusion. Inclusion 
criteria were colorectal liver metastases that could be resected or treated with radiofrequency 
ablation (RFA) after prior colorectal cancer surgery. Treatment of liver metastases was performed by 
laparotomy or laparoscopy. Exclusion criteria were age under 18 years, mental disorder, prior 
percutaneous drainage for postoperative abscess, and a history of liver, colorectal (including surgical 
reintervention for anastomotic leakage), ovarian, or abdominal wall surgery, either before resection 
of the primary tumor or during the interval between resection of the primary tumor and liver 
resection. The main logistical reasons to exclude eligible patients were participation in concurrent 
studies or operating surgeon not trained in adhesion assessment. 
Relevant patient, surgical and medical data were prospectively recorded. During treatment of liver 
metastases, detailed information of adhesions was collected by the surgeon. In the participating 
centers, one or two surgeons were instructed in adhesion assessment, and adhesion assessment in 
the first cases was supervised by one investigator (MS). Evaluation of adhesions comprised the 
location, extent and grading according to the Zühlke classification.21 Peroperative complications were 
scored by the operating surgeon directly after surgery. Postoperative complications related to 
adhesions and adhesiolysis were scored by the ward doctors. Case record forms were checked with 
the medical records and input of data in the database was independently verified by a second 
investigator. The local institutional review board waived the need for ethical review (registration 
number: 2012/502). The study was conducted according to the revised version of the Declaration of 
Helsinki (October 2008, Seoul). 
 
Variables 
The primary outcome was the incidence of adhesions to the ventral abdominal wall around the 
incision(s) made for the previous colorectal cancer resection. 
Secondary outcomes were: total incidence of adhesions; extent of adhesions; Zühlke classification of 
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adhesions; performance of adhesiolysis; duration of adhesiolysis; surgical complications; serious 
adverse events; length of stay in hospital; and episodes of bowel obstruction in the interval between 
colorectal and liver surgery. 
The extent of adhesions to the abdominal wall around the site of the primary incision was 
determined as estimated percentage of the length of the incision: after laparoscopic colorectal 
resection, the primary incision was the specimen extraction incision, not the separate trocar 
incisions.  For assessment of the extent of adhesions to the entire ventral abdominal wall, a 
schematic diagram of the abdominal wall with nine segments was used (figure 1a); extent of 
adhesions was expressed as the number of segments, in which adhesions were present: visceral 
adhesions were defined as adhesions between organs, but not to the abdominal wall. As an 
indication of the extent of visceral adhesions, a schematic diagram was provided, with the addition of 
a tenth segment for the pelvis (figure 1b). The extent of adhesions was expressed as the number of 
segments, in which adhesions were present. The severity of adhesions to the ventral abdominal wall 
around the site of the primary incision and to the ventral abdominal wall was graded according to the 
Zühlke classification.21 The gradation is based on the most severe adhesion at the area of the primary 
incision and to the abdominal wall. 
 
Figure 1: Schematic diagram to assess extent of adhesions as number of segments, in which 
adhesions are present: a) Schematic diagram of the abdominal wall divided into 9 segments. b) 
Schematic diagram of the abdominal cavity divided into 10 segments.  
 
    a)     b)  
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Adhesiolysis time was divided into five categories (1-15 min; 16-30 min; 31-45 min; 46-60 min; >60 
min). 
Surgical complications included: inadvertent enterotomy; serosal bowel injury; other inadvertent 
organ injury during adhesiolysis; and delayed diagnosed perforation. Inadvertent enterotomy was 
defined as any iatrogenic, unintended, full-thickness bowel defect detected during operation. Serosal 
bowel injury was defined as injury to the serosa, with or without muscular layers of the bowel, 
without visualization of the bowel lumen or spillage of bowel content. Delayed diagnosed perforation 
was defined as a bowel defect with spill of gastrointestinal content that was diagnosed 
postoperatively by imaging at reoperation or at autopsy, and that could not be explained by 
anastomotic leakage, bowel ischemia, or any other obvious cause of leakage unrelated to 
adhesiolysis. 
Postoperative morbidity noted as serious adverse events included: wound infection (categorized as 
superficial or deep); intra-abdominal abscess; pneumonia; sepsis; hemorrhage; urinary tract 
infection; and death. Any episode of bowel obstruction in the interval between colorectal and liver 
surgery was recorded according to conservative or surgical treatment. Any episode of bowel 
obstruction within the first two weeks after colorectal resection was considered (prolonged) 
postoperative ileus. 
Baseline demographics included: sex; age; number and type of laparotomies and laparoscopies in 
history; incision type in previous laparotomies; incision type for specimen retrieval in previous 
laparoscopies; history of radiotherapy on the abdomen or pelvis; and history of chemotherapy. 
Operation technique, type of incision, type of liver resection, RFA, and other procedures were 
recorded during liver surgery. Operation technique was categorized as either open, laparoscopic or 
conversion to open. Type of liver surgery was categorized as minor or major (≥ three adjacent 
segments) hepatectomy, RFA without resection or refrain from resection because of unexpected 
findings. For RFA, the segment(s) within which ablation was performed were registered. 
 
Statistical Methods 
The sample size calculation was based on an expected 27% difference in incidence of adhesions to 
the ventral abdominal wall adjacent to the primary incision, derived from non-published data from a 
recent observational cohort study 2. To show this effect with 80% power, and a two-sided α level of 
5%, 147 patients were needed. 
All variables were compared between patients with an open- or laparoscopic colorectal resection. 
Continuous data were assessed for normality of distribution. In case of normally distributed data, 
univariate comparisons were performed using independent T-Test and linear regression. With 
abnormal distribution, continuous data were compared with the Mann-Whitney U Test. For 
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dichotomous data, Pearson’s Chi-Square Test and Logistic Regression testing were performed. 
Correlations of dichotomous variables with a count less than five per cell were assessed using 
Fisher’s Exact Test. All tests were performed as two-sided. Continuous data are expressed as mean 
with standard deviation in case of normal distribution, or median with interquartile range (IQR), in 
case of abnormal distribution, and dichotomous data, as number with percentages. 
Alongside raw analyses, corrections for the following potential confounders at the primary endpoint 
were made: type of colorectal resection; time from colorectal resection; historical laparotomies; 
historical laparoscopies; pelvic radiotherapy; and chemotherapy. 
Cases with missing data per analysis were excluded. SPSS® for Windows version 20·0 Software (SPSS®, 
Chicago, Illinois, USA) was used for statistical analysis. P<0·05 was considered significant. 
 
Figure 2: Inclusion flow chart 
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Results 
Patients and Baseline Comparisons 
Between March, 2013, and December, 2015, 696 patients who underwent a resection for colorectal 
liver metastases were assessed for eligibility, 540 patients were excluded and 156 patients entered 
the study (figure 2). After data verification, another five patients were excluded; four patients, 
because they met predefined exclusion criteria, and one patient, because data on presence of 
adhesions was missing. 
A total of 151 patients were analyzed: 90 patients (59·6%) underwent previous open colorectal 
cancer surgery and 61 patients (40·4%) laparoscopic colorectal cancer surgery. Baseline 
characteristics and details of liver surgery are given in Table 1. Median time interval between 
colorectal resection and liver surgery was 12·5 (IQR 6-25·5) months after open- compared to six (IQR 
2-14) months after laparoscopic colorectal resection (p<0·001). There were no other significant 
differences in baseline characteristics. There were no significant differences in technique or type of 
liver surgery between the groups.  
 
Adhesions 
The incidence of adhesions to the ventral abdominal wall around the site of the primary incision was 
significantly higher after open- compared to laparoscopic colorectal resection (table 2). 
The incidence of adhesions to the entire ventral abdominal wall and of any adhesions (adhesions to 
the abdominal wall and/or visceral adhesions) were also significantly higher after open- compared to 
laparoscopic colorectal resection. The incidence of visceral adhesions was not significantly different 
after open- compared to laparoscopic resection. The median percentage of the scar covered with 
adhesions was not significantly different, 70 (IQR 25-90) and 40 (IQR 10-92·5) after open- and 
laparoscopic surgery, respectively (p=0·10). The extent of adhesions was significantly higher after 
open- compared to laparoscopic colorectal surgery for both abdominal wall and visceral adhesions 
(Table 2). The mean highest Zühlke score of adhesions at the site of the primary incision was 2·7 ± 
0·70 after open- and 1·8 ± 0·66 after laparoscopic colorectal resection (p<0·001). The mean highest 
Zühlke score of adhesions to the ventral abdominal wall was 2·7 ± 1·1 after open- and 2·0 ± 1·2 after 
laparoscopic colorectal resection (p=0·077). 
 
Small Bowel Obstruction, Adhesiolysis and Complications 
The incidence of small bowel obstruction in the time between colorectal resection and liver surgery 
was four (4·4%) in the open group compared to zero in the laparoscopic group (p=0·15). Small bowel 
obstruction occurred after one, six and 16 months, with time missing in one case. 
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Table 1: Baseline Characteristics and Details of Liver Surgery. 
 
 
  
 Open (n= 90) Laparoscopic (n=61) P 
Sex    
    Male 61 (67·8) 37 (60·7) 0·37 
    Female 29 (32·2) 24 (39·3) 
Age* 68 (59-73) 65 (59-72·5) 0·36 
    
Colorectal resection (n=150) (n=90) (n=60)  
    Right colectomy 21 (23·3) 15 (25·0) 0·44 
    Left colectomy 44 (48·9) 23 (38·3) 
    Rectal resection 22 (24·4) 21 (35·0) 
    Subtotal colectomy 3 (3·3) 1 (1·7) 
    
(Extraction) Incision colorectal resection (n=90) (n=57)  
    Midline 88 (97·8) 22 (38·6)  
    Transverse 2 (2·2) 5 (8·8) 
    Right iliac fossa 0 9 (15·8) 
    Pfannenstiehl 0 19 (33·3) 
    Perineal 0 2 (3·5) 
    
Median time from colorectal resection (months)*  12·5  (6-25·5) 
(n=90) 
6 (2-14) 
(n=59) 
<0·001 
    
Abdominal surgery in history    
    0 laparotomy 69 (76·7) 51 (83·6) 0·50 
    1 laparotomy 17 (18·9) 7 (11·5) 
    2 laparotomies 3 (3·3) 3 (4·9) 
    3 laparotomies 1 (1·1) 0 
    
    0 laparoscopies 83 (92·2) 57 (93·4) 0·78 
    1 laparoscopy 7 (7·8) 4 (6·6) 
    
Pelvic radiotherapy 24 (26·7) 9 (14·8) 0·082 
Chemotherapy 47 (52·2) 29 (47·5) 0·57 
    
Liver surgery    
Operation technique    
    Open   80 (88·9) 54 (88·5) 0·20 
    Laparoscopy 10 (11·1) 5 (8·2) 
    Laparoscopy converted to open 0 2 (3·3) 
    
Operation type    
    Minor hepatectomy 56 (62·2) 38 (62·3) 0·98 
     Major hepatectomy 29 (32·2) 19 (31·1) 
    Explorative laparotomy 3 (3·3) 2 (3·3) 
    RFA without resection 2 (2·2) 2 (3·3) 
    
RFA 14 (15·6) 16 (26·2) 0·11 
    RFA 1 segments     7 (50·0)     6 (37·5) 0·73 
    RFA 2 segments     5 (35·7)     7 (43·8) 
    RFA 3 segments     2 (14·3)     2 (12·5) 
    RFA 4 segments     0     1 (6·3) 
Data are n (%) or median (IQR); RFA = radiofrequency ablation 
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Results 
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    Laparoscopy 10 (11·1) 5 (8·2) 
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Data are n (%) or median (IQR); RFA = radiofrequency ablation 
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Table 2: Primary- and Secondary Endpoints. 
 
 
Adhesiolysis performed during liver surgery was 1·6 times more frequent in the open colorectal 
resection patient group (table 2). No adhesiolysis-associated complications occurred during liver 
surgery in the laparoscopic group, two enterotomies occurred in the open group during 1-15 and 46-
60 minutes adhesiolysis. Five patients had serosal injury (adhesiolysis time 1-15 minutes in three 
patients, 31-45 minutes in one patient  
and 46-60 minutes in one patient). Other structures inadvertently injured were the common bile duct 
in one patient and the gallbladder in one patient (46-60 and 1-15 minutes adhesiolysis time). 
There were no significant differences in serious adverse events or length of stay after liver surgery 
between the laparoscopic and open groups. 
 
 Open (n=90) Laparoscopic (n=61) P value 
Primary Endpoint    
Adhesions at site of previous incision 71 (78·9) 23 (37·7) <0·001 
    
Secondary Endpoints    
Adhesions at abdominal wall 73 (81·1) 24 (39·3) <0·001 
    Number of segments 3 (2-4) 1 (1-2) <0·001 
Visceral adhesions 53 (58·9) 27 (44·3) 0·077 
    Number of segments 3 (1-4·5) 2 (1-2) 0·010 
Patients with any adhesions 80 (88·9) 38 (62·3) <0·001 
    
Adhesiolysis 51 (56·7) 21 (34·4) 0·007 
Duration of adhesiolysis    
    1-15 minutes 42 (82·4) 21 (100) 0·24 
    16-30 minutes 4 (7·8) 0 
    31-45 minutes 1 (2·0) 0 
    46-60 minutes 4 (7·8) 0 
    >60 minutes 0 0 
    
Enterotomy 2 (2·2) 0 0·52 
Serosal injury 5 (5·6) 0 0·082 
Other organ injury 2 (2·2) 0 0·52 
Delayed diagnosed perforation 1 (1·1) 0 1·00 
    
Death 1 (1·1) 0 1·00 
Wound infection superficial 3 (3·4) 2 (3·3) 1·00 
Wound infection deep 2 (2·2) 1 (1·6) 1·00 
Intra-abdominal abscess 5 (5·6) 4 (6·6) 1·00 
Pneumonia 7 (7·9) 4 (6·6) 1·00 
Sepsis 3 (3·4) 0 0·27 
Hemorrhage 1 (1·1) 0  1·00 
Urinary tract infection 1 (1·1) 4 (6·6) 0·16 
Any serious adverse event 15 (16·9) 12 (19·7) 0·66 
Length of stay (days) 6·7 (± 4·3) 7·1 (± 4·0) 0·57 
Data are n (%), median (IQR), or mean ± SD 
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Discussion 
This study has shown that laparoscopic colorectal cancer surgery is associated with reduced adhesion 
formation compared to the open procedure, particularly to the ventral abdominal wall. However, 
more than three in five patients still developed adhesions after laparoscopic colorectal cancer 
resection.  
Knowledge of the incidence of adhesions was mainly derived from old data of open abdominal 
surgery.6,7 In the last two decades, a shift towards laparoscopic surgery took place, but open surgery 
also evolved in this period. Incisions are now generally smaller, which reduces surgical trauma to the 
abdominal wall and parietal peritoneum. Gloves used in surgical procedures no longer contain 
powder, and new energy devices cause less peritoneal injury.4 Despite these developments, the 
incidence of adhesions after open colorectal resections was almost 90%, and was comparable with 
old data, versus 62% in laparoscopic resections. 
This incidence of adhesions in the laparoscopic group challenges the broad opinion that laparoscopy 
minimizes adhesion formation. The benefit was mainly regarding adhesions to the abdominal wall 
and was most likely due to small incisions, no retractors and only instrument manipulation. 
Laparoscopy did not reduce incidence of adhesions between viscera. The similar tissue dissection and 
remaining peritoneal wound surfaces in both approaches seem to outweigh the differences in 
invasiveness. The number of patients without any adhesion (38%) has important clinical 
consequences, because without further abdominal surgery, their lifetime risk of adhesion-related 
complications is zero. The decrease in extent and severity of adhesions after laparoscopic colorectal 
cancer surgery benefit repeated surgery by reducing time and difficulty of adhesiolysis, but might not 
decrease adhesive small bowel obstruction rate. 
Studies of adhesion formation after open versus laparoscopic colorectal surgery are limited to three 
small comparative series. In two studies, patients underwent a diagnostic laparoscopy during loop 
ileostomy closure, after prior proctocolectomy or low anterior resection.10,11 In another study, 
patients with prior colorectal resection underwent laparoscopy for various reasons.9 The primary 
endpoint was a video-assessed adhesion extent and severity score of adhesions to the abdominal 
wall, which was lower after laparoscopy in all studies. The incidence in the largest series was 30·8 % 
(four patients out of 13) in the laparoscopic surgery group, compared to 97·0% (32 patients out of 
33) in the open surgery group.9 The main drawback of these studies was the incomplete assessment 
of adhesions, and in particular, that information on clinically relevant visceral adhesions was lacking. 
The use of video-laparoscopy to map adhesions at ileostomy takedown is questionable because intra-
abdominal view can be hindered by dense adhesions in the proximity of the stoma, and without 
additional trocars, visceral adhesions are difficult to assess. In the present study, the majority of 
patients had their adhesions assessed by open surgery with an excellent view of the abdominal 
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Table 2: Primary- and Secondary Endpoints. 
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Data are n (%), median (IQR), or mean ± SD 
Adhesion formation after open- and laparoscopic surgery for colorectal cancer 
 
89 
Discussion 
This study has shown that laparoscopic colorectal cancer surgery is associated with reduced adhesion 
formation compared to the open procedure, particularly to the ventral abdominal wall. However, 
more than three in five patients still developed adhesions after laparoscopic colorectal cancer 
resection.  
Knowledge of the incidence of adhesions was mainly derived from old data of open abdominal 
surgery.6,7 In the last two decades, a shift towards laparoscopic surgery took place, but open surgery 
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Laparoscopy did not reduce incidence of adhesions between viscera. The similar tissue dissection and 
remaining peritoneal wound surfaces in both approaches seem to outweigh the differences in 
invasiveness. The number of patients without any adhesion (38%) has important clinical 
consequences, because without further abdominal surgery, their lifetime risk of adhesion-related 
complications is zero. The decrease in extent and severity of adhesions after laparoscopic colorectal 
cancer surgery benefit repeated surgery by reducing time and difficulty of adhesiolysis, but might not 
decrease adhesive small bowel obstruction rate. 
Studies of adhesion formation after open versus laparoscopic colorectal surgery are limited to three 
small comparative series. In two studies, patients underwent a diagnostic laparoscopy during loop 
ileostomy closure, after prior proctocolectomy or low anterior resection.10,11 In another study, 
patients with prior colorectal resection underwent laparoscopy for various reasons.9 The primary 
endpoint was a video-assessed adhesion extent and severity score of adhesions to the abdominal 
wall, which was lower after laparoscopy in all studies. The incidence in the largest series was 30·8 % 
(four patients out of 13) in the laparoscopic surgery group, compared to 97·0% (32 patients out of 
33) in the open surgery group.9 The main drawback of these studies was the incomplete assessment 
of adhesions, and in particular, that information on clinically relevant visceral adhesions was lacking. 
The use of video-laparoscopy to map adhesions at ileostomy takedown is questionable because intra-
abdominal view can be hindered by dense adhesions in the proximity of the stoma, and without 
additional trocars, visceral adhesions are difficult to assess. In the present study, the majority of 
patients had their adhesions assessed by open surgery with an excellent view of the abdominal 
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cavity.  
The difference between the open and laparoscopic group (median 12·5 versus six months) regarding 
time interval between liver surgery and colorectal surgery, might be attributed to the recent shift 
from open towards laparoscopic colorectal surgery in the Netherlands.17 Recently performed 
colorectal resections, were more often performed by laparoscopy. Faster recovery of colorectal 
resection after laparoscopy might also have contributed. Most likely, adhesion rate is not affected by 
this interval difference, since experimental studies demonstrate that fibrous adhesions form in the 
first weeks after peritoneal injury, do not disappear, and only can become more filmy in time.22 The 
shorter time between laparoscopic colorectal and liver surgery could explain the absence of small 
bowel obstruction, because a first episode of adhesive small bowel obstruction can occur many years 
after abdominal surgery.23 Although a recent meta-analysis demonstrated a lower incidence of small 
bowel obstruction after laparoscopic compared to open colorectal surgery, the relative difference 
was small.24 
The present large prospective study is the first to provide complete information on adhesion 
formation after laparoscopic colorectal cancer surgery, potentially improving patient counseling, risk 
assessment in repeated surgery, and selecting adhesion barriers.  
A limitation of the present study was the lack of details on initial colorectal surgery. Perforated- or 
locally advanced colorectal tumors increase adhesion formation, and presumably these tumors were 
removed by open surgery.3,4 However, based on national registry data the number of patients with 
these indications is small.15 
The high number of excluded patients was a potential threat to the external validity of this study. 
Many patients at risk for more extensive and severe adhesions after colorectal surgery due to prior 
other abdominal surgery were excluded. This probably also contributed to the low number of 
adhesiolysis related surgical complications in the open surgery group.2 
With the increasing number of reoperations in oncological surgery, the burden of adhesiolysis is 
expected to rise further. Oncological treatment can be seriously impaired due to diminished 
accessibility of the abdomen in case of (recurrent) liver metastases, local recurrence, or peritoneal 
metastases.25,26 Taking into account the increase of reoperations in future patients with colorectal 
cancer and the better prevention of de novo adhesions rather than adhesion reformation after 
adhesiolysis, maximal reduction of adhesions through a combination of minimally invasive surgery 
and anti-adhesives should be the aim at initial colorectal surgery.27 Such an approach also decreases 
operation time, prevents complications and may lead to better oncological outcome and survival.28-30 
In conclusion, adhesion formation is reduced after laparoscopic- compared to open colorectal cancer 
surgery. However, the majority of patients still develop adhesions after laparoscopic colorectal 
cancer resection. Laparoscopy does not seem to have an effect on visceral adhesion formation 
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incidence. Thus, patients remain at risk for developing small bowel obstruction, and reoperations 
near the same surgical site can still involve adhesiolysis with associated complications. 
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Abstract 
Background  
Formation of adhesions after peritoneal surgery results in high morbidity. Barriers to prevent 
adhesion are seldom applied, despite their ability to reduce the severity of adhesion formation. We 
evaluated the benefits and harms of four adhesion barriers that have been approved for clinical use. 
 
Methods  
In this systematic review and meta-analysis, we searched PubMed, CENTRAL, and Embase for 
randomised clinical trials assessing use of oxidised regenerated cellulose, hyaluronate carboxy 
methylcellulose, icodextrin, or polyethylene glycol in abdominal surgery. Two researchers 
independently identified reports and extracted data. We compared use of a barrier with no barrier 
for nine predefined outcomes, graded for clinical relevance. The primary 
outcome was reoperation for adhesive small bowel obstruction. We assessed systematic error, 
random error, and design error with the error matrix approach. This study is registered with 
PROSPERO, number CRD42012003321. 
 
Findings  
Our search returned 1840 results, from which 28 trials (5191 patients) were included in our meta-
analysis. The risks of systematic and random errors were low. No trials reported data for the effect of 
oxidised regenerated cellulose or polyethylene glycol on reoperations for adhesive small bowel 
obstruction. Oxidised regenerated cellulose reduced the incidence of adhesions (relative risk [RR] 
0.51, 95% CI 0.31–0.86). Some evidence suggests that hyaluronate carboxymethylcellulose reduces 
the incidence of reoperations for adhesive small bowel obstruction (RR 0.49, 95% CI 0.28–0.88). For 
icodextrin, reoperation for adhesive small bowel obstruction did not differ significantly between 
groups (RR 0.33, 95% CI 0.03–3.11). No barriers were associated with an increase in serious adverse 
events. 
 
Interpretation  
Oxidised regenerated cellulose and hyaluronate carboxymethylcellulose can safely reduce clinically 
relevant consequences of adhesions. 
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Introduction 
Adhesions are the most common cause of long-term complications from abdominal surgery. They 
can cause small bowel obstruction, injury at reoperations, female infertility, and chronic pain.1-5 
Adhesions can affect the quality of life of millions of patients, jeopardise life expectancy, and result in 
more than US$2 billion dollars of health-care costs in the USA yearly.2,6,7 
Steps are rarely taken to prevent adhesion despite evidence that adhesion barriers reduce their 
formation.1,8-11 Underestimating the burden of adhesions seems to be an important explanation for 
the lack of use of adhesion barriers.12 Unlike other postsurgery complications, the consequences of 
adhesion formation include various clinical entities that are often dealt with by specialists other than 
the surgeon who did the initial operation.4, 5,7 Additionally, many questions exist about the 
indications for adhesion barriers, cost-effectiveness, and which barrier to use.12,13 
Cochrane reviews have not answered the questions of efficacy and safety of barriers.14-16 More than 
20 different membranes and liquids have been investigated in clinical studies for use as adhesion 
barriers. Many were either unsuccessful in reducing the formation of adhesions or were only 
assessed using outcomes of little clinical importance.17,18 Some were even associated with 
detrimental effects.19 Results were dispersed over three reviews and only trials in gynaecological or 
colorectal surgery were included. Thus, appraising the available evidence about the use of adhesion 
barriers remains difficult. 
The error matrix approach has been specifically developed for such situations, in which the possible 
benefits and harms of an intervention are difficult to summarise.20 This approach consists of 
assessment of the three dimensions of systematic error, random error, and design error. The three 
dimensions of error can be presented in a three dimensional plot so that the relevance and strength 
of evidence for different benefits and harms can be judged at a single glance. 
We assessed the benefits and harms of use of adhesion barriers for all types of abdominal surgery by 
such an approach. 
 
Methods 
Study design and systematic review 
We assessed the results of our systematic review and meta-analyses by the error matrix approach. 
The error matrix approach has been validated in systematic reviews of cholecystectomy and inguinal 
hernia repair.21,22 We included randomised trials evaluating the four adhesion barriers that have been 
approved for clinical use by legislative authorities in Europe and the USA: hyaluronate 
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Abstract 
Background  
Formation of adhesions after peritoneal surgery results in high morbidity. Barriers to prevent 
adhesion are seldom applied, despite their ability to reduce the severity of adhesion formation. We 
evaluated the benefits and harms of four adhesion barriers that have been approved for clinical use. 
 
Methods  
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methylcellulose, icodextrin, or polyethylene glycol in abdominal surgery. Two researchers 
independently identified reports and extracted data. We compared use of a barrier with no barrier 
for nine predefined outcomes, graded for clinical relevance. The primary 
outcome was reoperation for adhesive small bowel obstruction. We assessed systematic error, 
random error, and design error with the error matrix approach. This study is registered with 
PROSPERO, number CRD42012003321. 
 
Findings  
Our search returned 1840 results, from which 28 trials (5191 patients) were included in our meta-
analysis. The risks of systematic and random errors were low. No trials reported data for the effect of 
oxidised regenerated cellulose or polyethylene glycol on reoperations for adhesive small bowel 
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icodextrin, reoperation for adhesive small bowel obstruction did not differ significantly between 
groups (RR 0.33, 95% CI 0.03–3.11). No barriers were associated with an increase in serious adverse 
events. 
 
Interpretation  
Oxidised regenerated cellulose and hyaluronate carboxymethylcellulose can safely reduce clinically 
relevant consequences of adhesions. 
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Introduction 
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Deerfield, IL, USA), and polyethylene glycol (Spraygel®, Sprayshield®, Confluent Surgical, Waltham, 
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MA, USA). 
We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials with Mesh 
descriptors including: “carboxymethylcellulose”, “hyaluronic acid”, “icodextrin”, “polyethylene 
glycols”, “tissue adhesions”, “intestinal obstruction”, “infertility, female”, “abdominal pain”, “pelvic 
pain”, and “intestinal disease/surgery”. The appendix shows the full search strategy. We did not 
apply any language restrictions and included all relevant articles up to Feb 2, 2013. Only randomised 
trials were included. We also searched the reference lists of identified trials, for further references, 
including those published in grey literature. We did additional searches to find relevant grey 
literature and unpublished trials (appendix). 
RPGtB and MWJS identified eligible reports; discrepancies were resolved through discussion. We 
applied the following inclusion criteria to the titles and abstracts of the search results: patients 
undergoing intraperitoneal surgery, application of one of the four adhesion barriers, and report of 
adhesion-related outcomes. Results of some trials were reported in more than one report. 
Information from the different reports was linked and analysed as a single trial. 
We assessed all trials for the risk of bias (measured by the level of evidence), the risk of random 
error, and the design error.20 We present data in a three-dimensional Manhattan plot. We assessed 
the risk of systematic error with the Cochrane Collaboration's instrument for bias risk assessment.23 
Six components associated with the risk of bias were assessed: generation of the allocation 
sequence, allocation concealment, masking of outcome assessors, selective outcome reporting, 
incomplete follow-up, and other potential sources of bias. Trials with a low risk for all six components 
were defined as having an overall low risk of bias. Trials in which one or more of the six bias 
components were unclear or had high risk of bias were defined to be at high risk of bias. Because 
masking the surgeon to allocation is impossible, trials in which patients and outcome assessors were 
masked were deemed to have a low risk of bias for masking. Additionally, we recorded data about 
funding sources. 
The risk of random error is the risk of drawing a false conclusion based on sparse data. This risk is 
quantified as the p value. However, because random low (and random high) p values might occur 
during accumulation of data and sequential testing, they do not sufficiently represent the risk of 
random error between different studies.24 The standard error (SE) measures the amount of variability 
in the sample mean; it indicates how closely the population mean is likely to be estimated by the 
sample mean. We therefore used SE to evaluate the risk of random error, using the algorithms 
suggested by the Cochrane collaboration.23 We defined small risk of random error as an SE of less 
than 0.20 and moderate risk as an SE of less than 1.00. Studies with higher risk of random error 
(≥1.00) fell outside the range of the plot. 
We assessed design error (external validity) by classifying the clinically relevant outcome measures 
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according to the Grading of Recommendations Assessment, Development and Evaluation approach.25 
We assessed publication bias with funnel plots. Raw data from unpublished studies and studies using 
adhesion-related outcomes other than those predefined were reported separately. 
We compared use of a barrier with no barrier for nine predefined outcomes. The primary outcome 
was reoperation for adhesive small bowel obstruction. We also assessed serious adverse events, 
total incidence of adhesions, reoperation time, small bowel obstruction from any cause, site-specific 
incidence of adhesions, and adhesion score. 
 
Statistical analysis 
We used the Mantel-Haenszel method for dichotomous data, presented as relative risks (RR) with 
95% CIs. We used the inverse variance method to pool continuous data; results are presented as 
standardised mean difference with 95% CIs. We assessed statistical heterogeneity with Cochran's 
test and I2. In the absence of statistical heterogeneity we used a fixed-effect model, otherwise we 
used a random-effects model. We did the analyses with Review Manager (version 5.1) and R (version 
2.12.0). 26 
We did three subgroup analyses. First, we compared the pooled results of trials with a low overall 
risk of bias with the pooled results from trials with a high overall risk of bias. Second, we compared 
the pooled results of trials with a low risk of funding bias with trials with an unclear or high risk for 
funding bias (trials sponsored by industry). Third, trials with clinical heterogeneity were not pooled 
into one overall effect estimate. Clinical heterogeneity was assessed by subgroup according to the 
type of operation (upper alimentary tract, lower alimentary tract or colorectal, abdominal wall, 
gynaecological, or urological surgery). All subgroup analyses were tested for interactions. 
The full review protocol is registered with PROSPERO (number CRD42012003321) and shown in the 
appendix. 
Role of the funding source 
There was no funding source for this study. RPGtB and HvG had full access to all data in the study and 
had final responsibility for the decision to submit for publication. 
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Figure 1: Study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Our search returned 1840 results, from which we included 33 trials assessing 5381 patients in our 
systematic review (Fig 1, table 1). Five trials either reported on outcomes not included in the 
predefined outcomes or had incomplete outcome data. Thus, 28 trials assessing 5191 patients were 
included in the meta-analyses. 20 trials were of gynaecological surgery, nine of colorectal surgery, 
and one each of gastric, hepatic, general paediatric, and small bowel obstruction surgery. 
Outcome measures were reoperation for adhesive small bowel obstruction (six trials), serious 
adverse events (14 trials), overall incidence of adhesions (six trials), operation time (three trials),
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small bowel obstruction by any cause (five trials), site-specific incidence of adhesions (ten trials), and 
adhesion score (13 trials). These outcome measures were ranked according to their clinical relevance 
for the patient according to Grading of Recommendations Assessment, Development and Evaluation 
with reoperation for adhesive small bowel obstruction as the highest relevance and adhesion score 
as the lowest (table 2). 
 
Table 2: Predefined outcomes ranked according to Grading of Recommendations Assessment, 
Development and Evaluation by relevance according to the patients' perspective 
Crucial for decision making 9 Reoperation for adhesive small bowel obstruction 
8 Serious Adverse Events 
Important for decision 
making 
6 Total incidence of adhesions 
5 Operation time of reoperation 
4 Small bowel obstruction(any cause)* 
Limited importance 2 Site specific incidence of adhesions 
1 Adhesion score 
* Includes small bowel obstructions not caused by adhesions 
 
Roughly two-thirds of trials adequately generated an allocation sequence (Fig 2). Most studies had 
adequate allocation concealment and masking of the outcome assessors. Follow-up methods and 
description of reasons for loss to follow-up were adequate in the majority of trials. The risk of 
outcome bias through selective reporting was low for some studies. The primary endpoint was 
changed during one trial.53 The timing of second look procedures varied widely in the study by Tinelli 
and colleagues.11 One trial was stopped prematurely because of organisational difficulties.57 
Overall, four trialshad a low risk of bias based on all six domains (figure 2).1,8,9,55 
Industry sponsored 16 trials (57%) and sponsoring was not reported for seven trials (25%). Two trials 
assessing hyaluronate carboxymethylcellulose were initiated and sponsored by independent 
parties.39,42 Another three trials were investigator driven, but the manufacturer supplied the 
adhesion barrier.38,48,57 The results from investigator-driven trials were similar to the results from 
industry-sponsored trials (appendix). 
The risk of random error (SE) was small for adhesion score in eight trials, and overall incidence of 
small bowel obstruction by any cause in one trial. Funnel plots appeared to be symmetrical: trials did 
not report extreme values (outside 95% CI) by most analyses (appendix). Three additional trials from 
grey literature and trial registries had limited available outcome data. Their findings accorded with 
the results of published studies (appendix).  
Oxidised regenerated cellulose is a solid barrier in the form of a knitted fabric. After application on 
the injured peritoneum it swells and becomes a gel. The gel breaks down to monosaccharides and is 
metabolised by glycosidases of peritoneal macrophages within 4 days to 2 weeks.58,59 Oxidised 
regenerated cellulose was compared with no adhesion barrier in 11 trials (1184 patients).8,9,11,27-29,31-35 
All trials were of gynaecological patients. Two trials had low risk of bias.8,9 Eight trials were explicitly 
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industry-sponsored and sponsorship was unclear for three trials. In eight studies (408 patients), each 
patient served as their own control by having one side of the pelvis randomly assigned to receive an 
adhesions barrier. The remaining three trials included 776 patients in a parallel group design. 
 
Figure 2: Methodological quality of trials included in meta-analysis. 
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the injured peritoneum it swells and becomes a gel. The gel breaks down to monosaccharides and is 
metabolised by glycosidases of peritoneal macrophages within 4 days to 2 weeks.58,59 Oxidised 
regenerated cellulose was compared with no adhesion barrier in 11 trials (1184 patients).8,9,11,27-29,31-35 
All trials were of gynaecological patients. Two trials had low risk of bias.8,9 Eight trials were explicitly 
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industry-sponsored and sponsorship was unclear for three trials. In eight studies (408 patients), each 
patient served as their own control by having one side of the pelvis randomly assigned to receive an 
adhesions barrier. The remaining three trials included 776 patients in a parallel group design. 
 
Figure 2: Methodological quality of trials included in meta-analysis. 
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Figure 3 shows the results of our meta-analysis. Figure 4 shows overall results from the included 
trials of oxidised regenerated cellulose. No trials reported data for the effect of oxidised regenerated 
cellulose on reoperations for adhesive small bowel obstruction. Evidence shows the beneficial effects 
of oxidised regenerated cellulose on the incidence of adhesions and adhesion scores from trials with 
low risks of both systematic and random error. No evidence exists for a beneficial effect on the 
incidence of serious adverse events (appendix). 
No trials reported data for pregnancy rate with oxidised regenerated cellulose. Incidence of serious 
adverse events after myomectomy was much the same between the two groups in one trial (RR 0.80, 
95% CI 0.46–1.39).11 Postoperative fever was the only serious adverse event recorded in both groups. 
 
Figure 3: Results of key comparisons of four adhesion barriers 
Random effect applied for the incidence of adhesions after application of oxidised regenerated cellulose and the incidence of serious 
adverse events after application of hyaluronate carboxymethylcellulose; fixed effects applied for the incidence of serious adverse events 
after application of icodextrin and the incidence of adhesions after application of polyethylene glycol. Only subtotals were pooled for 
hyaluronate carboxymethylcellulose and icodextrin because of heterogeneity in types of operations. The appendix shows forest plots for 
other comparisons. 
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Figure 4: Outcomes of oxidised regenerated cellulose versus no adhesion barrier 
Benefit (A) and no effect or harm (B). Systematic error: 1a is meta-analysis of low-bias risk randomised controlled trial, 1b a low-risk bias 
randomised controlled trial, 1c is meta-analysis of all randomised controlled trials, and 1d a high-risk bias randomised controlled trial. 
Standard error less than 0.20 is low risk for random error, 0.20–1.00 is moderate risk, and greater than 1.00 is high risk. Studies with a high 
risk for random error are outside the range and are considered irrelevant for decision making. Results most important for clinical decision 
making are the highest bars in the upper-left part of the plot. 
 
 
 
 
With regard to outcomes important for decision making, the overall incidence of adhesions reported 
by three trials (578 patients) was significantly reduced in the treatment group (RR 0.51, 95% CI 0.31–
0.86; Fig 3) with a number needed to treat of 6 (95% CI 3.37–21.00). The intervention effect 
increased when only trials with low risk of bias were assessed. No data were available for operation 
time and small bowel obstruction for any cause. Use of oxidised regenerated cellulose significantly 
reduced the site-specific incidence of adhesions (RR 0.66, 95% CI 0.59 to 0.74) and adhesion scores 
(standardised mean difference [SMD] −3.74, 95% CI −5.71 to −1.77). 
Hyaluronate carboxymethylcellulose is a solid adhesion barrier in the form of a thin translucent 
membrane. The membrane adheres well to moist tissue surfaces and forms a viscous gel in 1–2 days. 
The barrier is absorbed from the abdominal cavity within 7 days, and is metabolised and cleared via 
the kidney in a maximum of 28 days.60 
Nine trials (3052 patients) assessed hyaluronate carboxymethylcellulose (1517 patients) compared 
with no adhesion barrier (1535 patients).1,36-39,41-44 One trial had risk of low bias.1 Three trials were 
investigator driven, four were sponsored by industry, and in two trials the sponsor was not specified. 
Six trials were of colorectal surgery and one each was of gynaecological, hepatic, and gastric surgery. 
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Figure 5 shows overall results for hyaluronate carboxymethylcellulose. Some evidence suggests that 
hyaluronate carboxymethylcellulose reduces the incidence of reoperations for adhesive small bowel 
obstruction. Five trials evaluated this outcome, three in colorectal surgery, and one each in hepatic 
and gastric surgery. Hyaluronate carboxymethylcellulose significantly reduced the incidence of 
reoperations for adhesive small bowel obstruction in colorectal surgery (RR 0.49, 95% CI 0.28–0.88). 
The difference in the incidence of reoperation related to adhesive small bowel obstruction was not 
significant in hepatic surgery (RR 0.13, 95% CI 0.01–2.95) and gastric surgery (RR 0.35, 95% CI 0.01–
8.50). Operation time also seems to be reduced by use of hyaluronate carboxymethylcellulose. 
 
Figure 5: Outcomes of hyaluronate carboxymethylcellulose versus no adhesion barrier 
Benefit (A) and no effect or harm (B) 
 
 
 
 
 
Seven trials studied the incidence of serious adverse events, five for colorectal surgery and one each 
for hepatic and gastric surgery. Differences between groups for the incidences of serious adverse 
events were all non-significant (figure 3). 
A post-hoc analysis of one trial with low risk of bias showed that hyaluronate carboxymethylcellulose 
wrapped around a new bowel anastomosis seemed to result in a higher incidence of serious adverse 
events: abscesses, fistulas, and anastomotic leakages.1 In more recent trials, the practice of wrapping 
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hyaluronate carboxymethylcellulose around anastomoses has been abandoned.39,42 There were no 
data for pregnancy rate. 
In one trial of hyaluronate carboxymethylcellulose investigating two-stage hepatic surgery, operation 
time was significantly shorter in the hyaluronate carboxymethylcellulose group at reoperation (SMD 
−2.30, 95% CI −3.16 to −1.43). We report no significant difference for the outcome of small bowel 
obstruction from any cause in either gastric or colorectal surgery. 
Our meta-analysis showed that hyaluronate carboxymethylcellulose significantly reduced the 
incidence of site-specific adhesions (RR 0.71, 95% CI 0.54–0.95). Adhesion score was significantly 
reduced in one trial of gynaecological surgery (SMD −1.41, 95% CI −1.80 to −1.02), but not for 
colorectal surgery (−0.86, −1.96 to 0.24). 
Icodextrin is a water-soluble glucose polymer derived from cornstarch. It is a liquid adhesion barrier 
in a 4% solution. Before the icodextrin breaks down into oligosaccharides and is metabolised, the 
colloidal osmotic activity causes the fluid to reside in the abdominal cavity for 3–5 days.61,62 
Four trials (764 patients) randomly assigned patients to icodextrin (386 patients), no adhesion barrier 
(90 patients), or placebo (282 patients).46-49 The study of Kössi and colleagues was unclear about 
whether six patients were allocated to treatment or control.48 No trials had a low risk of bias. 
Most outcome data were not included in the Manhattan plot because of the high risk of random 
errors (appendix). Reoperation for adhesive small bowel obstruction did not differ significantly 
between groups (RR 0.33, 95% CI 0.03–3.11). Icodextrin has no beneficial effects on the number of 
serious adverse events (Fig 3). There is evidence of a moderate risk for random error that icodextrin 
reduces the incidence of small bowel obstruction. There is insufficient evidence to assess whether 
icodextrin has a beneficial effect on the incidence of adhesions or operation time (SMD −0.48, 95% CI 
−1.44 to 0.49). 
Incidence of serious adverse events was similar among the groups in gynaecological surgery (RR 1.00, 
95% CI 0.76–1.30) and lower alimentary tract surgery (0.98, 0.63–1.52).46,48,49 There were no data for 
pregnancy rate. 
Overall incidence of adhesions and operation time did not differ significantly for icodextrin. 
Icodextrin significantly reduced the incidence of small bowel obstruction by any cause (RR 0.20, 95% 
CI 0.04–0.88). There were no data for incidences of site-specific adhesions and we report no 
significant difference for adhesion score (SMD −0.29, 95% CI −2.97 to 2.39). 
The polyethylene glycol adhesion barrier consists of two liquid precursor solutions that quickly react 
after being sprayed in the abdomen, forming a hydrogel. One of the precursors contains a small 
amount of methylene blue, enabling the area covered and the thickness of the hydrogel layer to be 
seen during laparoscopy. The gel is degraded through hydrolysation and cleared via the kidneys in 
around 7–8 days.63 
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Four trials (191 patients) assessed polyethylene glycol in 111 patients and placebo in 80 
patients.53,54,55 One trial had a low risks of bias for all six bias risk domains.55 No data were available 
for reoperation for adhesive small bowel obstruction. No data were available about the effect of 
polyethylene glycol on pregnancy rate. The incidence of serious adverse events did not differ in three 
trials of gynaecological surgery (RR 0.55, 95% CI 0.16–1.87) and colorectal surgery (1.11, 0.43–2.85).   
Groups did not differ significantly for incidence of adhesions (RR 0.78, 95% CI 0.60 to 1.01). 
Polyethylene glycol had a beneficial effect on operation time in one trial with a low risk of systematic 
error (SMD −0.84, 95% CI −1.49 to −0.19). No data were available for small bowel obstruction by any 
cause and incidence of site-specific adhesions. 
Polyethylene glycol significantly reduced adhesion scores both in gynaecological surgery (SMD −0.71, 
95% CI −1.21 to −0.22) and in one trial of colorectal surgery with low risk of bias (SMD −1.71, 95% CI 
−2.45 to −0.97); however, the studies assessing these outcomes had high risk of random error. 
 
Discussion 
Sufficient evidence exists to suggest that oxidised regenerated cellulose and hyaluronate 
carboxymethylcellulose reduce adhesion formation. There is evidence that hyaluronate 
carboxymethylcellulose reduces the number of reoperations for adhesive bowel obstruction and 
operative time. Oxidised regenerated cellulose reduces the incidence of adhesions in gynaecological 
surgery, but no data were available about the effect on reoperations for adhesive bowel obstruction. 
Icodextrin had no effect on the incidence of reoperation for adhesive small bowel obstruction in one 
small trial, and no data for the primary outcome were available for polyethylene glycol. None of the 
four barriers investigated increased serious adverse events. 
28 trials had been done, which is high for surgical research. Detailed assessment of the risk of bias 
showed that these trials had a low risk of both systematic and random errors compared with other 
surgical research—eg, robotic surgery, laparoscopic cholecystectomy, and fast-track surgery.22,64 
Despite the large number of trials, outcome comparisons included only a few trials and results per 
comparison can easily be dominated by a single large trial. The different types of barrier used, the 
large clinical heterogeneity, and the different outcome parameters reported, hinder the pooling of 
results from multiple trials and made subgroup analyses necessary. Therefore, we assessed the 
potential benefits and harm of adhesion barriers by the error-matrix approach with visualisation in a 
Manhattan plot. This approach has the advantage over standard forest plots that several outcomes 
can be integrated and shown in one figure. 
Only 14 trials reported outcomes that are critical or important when considering whether to apply 
adhesion barriers—reoperation for adhesive small bowel obstruction, total incidence of adhesions, 
operation time of reoperation, and small bowel obstruction (any cause). Implementation of these 
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outcome measures is one of the biggest challenges in the design of trials of new adhesion barriers.65 
Completion of future trials will be challenging because of the need for many patients to assess 
clinically critical outcomes, multicausality of some outcomes (eg, pregnancy rate), and to provide 
long-term follow-up data (eg, for adhesive small bowel obstruction). The risk of publication bias 
cannot be fully excluded—we identified some trials that have not been published yet. However, we 
do not believe that results of these trials will alter conclusions: the results of unpublished studies 
matched those of published reports and funnel plots showed no publication bias. Most of the trials 
were sponsored by industry, which might have resulted in publication bias of positive results and 
overestimation of intervention effects. However, this effect seems unlikely because data of 
investigator-driven trials compare favourably with industry-sponsored trials and risk of publication 
bias was low. 
Although serious adverse events were reported for half the trials, safety data for some barriers are 
scarce. Few adverse events were reported for oxidised regenerated cellulose, probably because the 
barrier was only studied in gynaecological surgery, in which little bleeding occurs. Previous studies 
showed that oxidised regenerated cellulose barriers cause an inflammatory response when in 
contact with blood.66,67 Additional safety information for icodextrin comes from a large registry 
including over 4000 patients who had general and gynaecological surgery.68,69 The data support the 
good safety profile of icodextrin. 
Three Cochrane reviews have addressed adhesion prevention for gynaecological and open colorectal 
surgery.14-16 The present study aggregates the evidence from these three reviews and includes 
additional evidence from trials of gastric and hepatic surgery as well as two trials of colorectal 
surgery that were missed by previous reviews.43,55 Additionally, previous reviews did not rank 
different outcomes, despite the variety of consequences from a patient's perspective, and thus—for 
example—hiding the specific effect on adhesion incidence and type of small bowel obstruction.14 An 
adhesion barrier cannot reduce the incidence of bowel obstruction secondary to tumour or hernia. In 
addition, we deemed operation time to be an important clinical outcome because evidence suggests 
that prolonged adhesiolysis increases the risk of inadvertent organ injury.5,56 Compared with previous 
reviews, we did a more comprehensive and clinically meaningful analysis, which included risk of bias, 
risk of random error, a grey literature search, and an analysis of the role of sponsorship. The error 
matrix approach provides more detailed and clearer evidence of benefit and harm of an intervention. 
As more studies are done, clinical evidence increases and becomes more difficult to overview. The 
Manhattan plot helps to judge the relevance and strength of the evidence available for each specific 
adhesion-related outcome for a single intervention. 
Oxidised regenerated cellulose reduces adhesion formation in fertility surgery. The implications for 
clinical practice remain unclear because none of the trials assessed pregnancy rate. With regard to 
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the robustness of data for prevention of adhesion formation and safety, future studies should assess 
whether oxidised regenerated cellulose reduces reoperation-associated complications. 
Hyaluronate carboxymethylcellulose reduces operation time in two-stage liver surgery and has a 
modest reduction effect on adhesive small bowel obstruction. The number needed to treat to 
prevent one case of adhesive small bowel obstruction is high for this rare but potentially life-
threatening complication of general and gynaecological surgery. However, routine use in high-risk 
surgeries for bowel obstruction is warranted on the basis of our efficacy and safety results. We 
expect that with increasing evidence on clinical and socioeconomic effect of adhesiolysis, the use of 
hyaluronate carboxymethylcellulose to prevent organ injury during repeated open surgery will 
spread.5,56 
Indications for the use of an adhesion barrier also depend on its formulation. Both oxidised 
regenerated cellulose and hyaluronate carboxymethylcellulose are solid barrier films and difficult to 
apply during laparoscopic surgery. Icodextrin and polyethylene glycol are easier to apply at 
laparoscopy. Formulation could also affect efficacy and adverse events. The solid and viscous gel 
barriers are thought to be more effective at preventing adhesion at sites of severe peritoneal injury 
and adhesiolysis, whereas liquid barriers provide better protection for injured surfaces—eg, by 
retractors or desiccation—distant from the region of surgical dissection. However, no clear evidence 
supports this hypothesis. Two adhesion barrier gels based on hyaluronic acid were associated with 
serious adverse events.19 We doubt whether the gel formulation contributed to these adverse events 
because the hyaluronate carboxymethylcellulose film also becomes gelatinous after application. 
More likely, chemical adjuvants—the ferric ions—increase adverse tissue reactions.70 
Results from our study could be used to develop guidelines for the use of barriers to prevent 
adhesion-related complications. Thus far, guidelines are only available for gynaecological surgery.71 
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the robustness of data for prevention of adhesion formation and safety, future studies should assess 
whether oxidised regenerated cellulose reduces reoperation-associated complications. 
Hyaluronate carboxymethylcellulose reduces operation time in two-stage liver surgery and has a 
modest reduction effect on adhesive small bowel obstruction. The number needed to treat to 
prevent one case of adhesive small bowel obstruction is high for this rare but potentially life-
threatening complication of general and gynaecological surgery. However, routine use in high-risk 
surgeries for bowel obstruction is warranted on the basis of our efficacy and safety results. We 
expect that with increasing evidence on clinical and socioeconomic effect of adhesiolysis, the use of 
hyaluronate carboxymethylcellulose to prevent organ injury during repeated open surgery will 
spread.5,56 
Indications for the use of an adhesion barrier also depend on its formulation. Both oxidised 
regenerated cellulose and hyaluronate carboxymethylcellulose are solid barrier films and difficult to 
apply during laparoscopic surgery. Icodextrin and polyethylene glycol are easier to apply at 
laparoscopy. Formulation could also affect efficacy and adverse events. The solid and viscous gel 
barriers are thought to be more effective at preventing adhesion at sites of severe peritoneal injury 
and adhesiolysis, whereas liquid barriers provide better protection for injured surfaces—eg, by 
retractors or desiccation—distant from the region of surgical dissection. However, no clear evidence 
supports this hypothesis. Two adhesion barrier gels based on hyaluronic acid were associated with 
serious adverse events.19 We doubt whether the gel formulation contributed to these adverse events 
because the hyaluronate carboxymethylcellulose film also becomes gelatinous after application. 
More likely, chemical adjuvants—the ferric ions—increase adverse tissue reactions.70 
Results from our study could be used to develop guidelines for the use of barriers to prevent 
adhesion-related complications. Thus far, guidelines are only available for gynaecological surgery.71 
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Abstract 
Background 
Adhesion barriers are proven effective reducing adhesion-related complications after colorectal 
surgery. However, mostly for financial reasons, barriers are seldom applied. Aim of this study was to 
determine the cost-effectiveness of an adhesion barrier in colorectal surgery. 
 
Methods 
A decision tree model was developed to determine the cost-effectiveness using an adhesion barrier 
in colorectal surgery based on the best available evidence. Current practice (no adhesion barrier) was 
compared with using an adhesion barrier in open and laparoscopic colorectal surgery. Outcomes of 
the model were incidence of clinical consequences of adhesions, direct healthcare costs, and the 
incremental cost effectiveness ratio (ICER) representing the costs per patient with adhesions 
prevented. Uncertainty was addressed in deterministic and probabilistic sensitivity analyses. 
 
Results 
An adhesion barrier reduces the incidence of adhesions from 88.9% to 45.3% in open and 62.3% to 
31.8% in laparoscopic colorectal surgery, and the incidence of ASBO from 8.6% to 5.8% and 6.6% to 
4.5%. The adhesion barrier slightly reduces costs in open colorectal surgery when compared with no 
adhesion barrier ($4372 versus $4474). Using an adhesion barrier in laparoscopic procedures led to 
an increase in costs of $41 ($4220 versus $4179). The ICER for one patient was $135 for the 
laparoscopic cohort. Probabilistic sensitivity analysis showed a 65% and 37% probability of an 
adhesion barrier being cost-reducing for open and laparoscopic surgery, respectively. 
 
Conclusion 
The use of adhesion barriers in open colorectal surgery is cost-effective preventing adhesion related 
problems. In laparoscopic colorectal surgery, an adhesion barrier is effective at low costs. 
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Introduction 
Colorectal surgery commonly induces postoperative adhesion formation, causing a lifelong risk for 
small bowel obstruction, female infertility, and chronic visceral pain.1-4 Lysis of adhesions at 
reoperative surgery is associated with inadvertent organ injury, prolonged operative time and an 
increased risk of postoperative complications and therefore higher costs.5-7 Several adhesion barriers 
are developed to prevent postoperative adhesion formation after abdominal surgery. In a recent 
systematic review and meta-analysis on efficacy and safety of adhesion barriers, hyaluronate 
carboxymethylcellulose (HA/CMC) was proven to safely reduce the incidence of site specific 
adhesions, and the incidence of reoperations for adhesive small bowel obstruction after open 
colorectal surgery.8 Despite the burden of postoperative adhesions and the proven benefit of 
adhesion barriers, these are seldom applied. In a nationwide survey in 2009 in The Netherlands only 
13.4% of surgeons indicated to have used any adhesion barrier in the previous year, and a recent 
follow-up survey did not show much change (unpublished data).9 Doubts about cost-effectiveness 
and the need for adhesion prevention in minimally invasive surgery may explain the reluctance using 
barriers. Previous cost effectiveness analyses of adhesion barriers are based on costs of adhesion-
related readmission, and only concern open surgery.10,11 The efficacy data used were derived from 
second-look surgery studies, suggesting an approximate 25-50% reduction in the number or density 
of adhesions with the use of a barrier. In the absence of data on reduction of adhesion-related 
readmissions with the use of a barrier, costs were extrapolated from the reduction of adhesions. 
Since publication of these analyses evidence on both the burden of adhesions and the effectiveness 
of adhesion barriers has increased substantially. Earlier, readmission for postoperative small bowel 
obstruction was considered the most important complication.12 New evidence makes clear that 
difficulty due to dissecting adhesions at repeat abdominal surgery is an even bigger problem.13 
Moreover, evidence on efficacy of adhesion barriers is no longer limited to adhesion incidence, but 
comprises clinically relevant endpoints.8  
We developed a decision model for the use of an adhesion barrier in open and laparoscopic 
colorectal surgery, based on the best available evidence considering cost and effect. With this model 
we aim making an important step to an evidence based decision on the use of adhesion barriers in 
colorectal surgery. 
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Figure 1: Decision tree model for evaluation of the use of an adhesion barrier in colorectal surgery. 
 
Methods 
Decision model 
We designed a decision tree model using Microsoft Office Excel 2007, evaluating the strategy of 
adhesion prevention with an adhesion barrier in open and laparoscopic colorectal surgery. A decision 
model is a simplified framework of complex real-life processes, using a mathematical method to 
weigh risks, benefits, and costs of clinical strategies.14 In the model two strategies are compared: (1) 
current clinical practice; colorectal surgery without the use of an adhesion barrier; (2) colorectal 
surgery with the use of an adhesion barrier (figure 1). Hypothetical cohorts of patients undergoing 
colorectal surgery, open or laparoscopic, are distributed over the different pathways in the decision 
tree, based on a set of probabilities that were derived from recently published systematic reviews, 
and observational and intervention studies. This allowed us to synthesize evidence and thereby to 
evaluate effects and adhesion related health care costs determined by treatment decision. 
Adhesive small bowel obstruction (ASBO) and difficulties at reoperation were included in the model 
Adhesion barrier in colorectal surgery 
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as potential consequences of adhesions. Female infertility and chronic visceral pain were not 
considered. Risk for infertility will only be an additional reason for the use of an adhesion barrier in a 
very small and specific subgroup. Regarding chronic visceral pain no consistent evidence is available 
on etiology, incidence and costs after colorectal surgery.4 
Population 
The two target populations consist of patients undergoing a colorectal resection, either by open or 
laparoscopic approach. Colorectal resection is commonly performed and for various indications; the 
main indication being colorectal cancer.15 Colorectal surgery has a relatively high incidence of 
postoperative adhesion formation.13,16 In 2014 over 65% of colorectal cancer resections in the 
Netherlands were performed by laparoscopic technique.17 There is recent evidence that laparoscopy 
is associated with a lower incidence of adhesions, particularly to the abdominal wall (unpublished 
data).18 
Probabilities  
In the model hypothetical cohorts of patients undergoing a colorectal resection, with or without the 
use of an adhesion barrier, have different probabilities for the development of adhesions, and 
subsequent development of ASBO, operative or conservative treatment for ASBO, and adhesiolysis at 
future repeat surgery. Probability estimates were derived from recent literature (see table 1).8,19-30 
Risk ratios for adhesions, ASBO and operative treatment of ASBO with the use of an adhesion barrier 
are based on efficacy data for HA/CMC, since this is the only adhesion barrier with consistent 
evidence available on adhesion prevention in visceral surgery. Although HA/CMC is not easily 
applicable in laparoscopic surgery and evidence for laparoscopy is lacking, we extrapolated the 
efficacy data of HA/CMC in open colorectal resection to the laparoscopic model. The data on 
incidence of adhesions after open and laparoscopic colorectal surgery were derived from a 
multicentre study that has been submitted for publication, (clinicaltrials.gov registration number: 
NCT01720966). In this study adhesions after open and laparoscopic colorectal cancer surgery are 
compared at surgery for liver metastases. In the recent systematic review on the value of adhesion 
barriers there were no data on total incidence of adhesions with the use of HA/CMC.8 A new search 
yielded no additional data on total incidence of adhesions with the use of HA/CMC. Thus, adhesion 
incidence with HA/CMC was derived from the incidence of site-specific adhesions reported, i.e. 
midline, pelvic adhesions, only including the anatomical site with the highest incidence of adhesions 
from each study.19-21 The peristomal site was considered not relevant for total adhesion formation 
after colorectal surgery. The efficacy is expressed as a risk ratio of adhesions with the use of HA/CMC 
versus no barrier (RR 0.51 [95% CI 0.43-0.61]). 
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Table 1: Input probabilities in decision tree model. 
 
Open Laparoscopic  Adhesion barrier strategy 
Variable Probability α β Probability α β Source RR  95%CI Source 
Patients with 
adhesions  
0.889 80 10 0.623 38 23 Unpublished 
data 
0.51 0.43-
0.61 
19-21 
Patients with 
ASBO 4 years 
0.0856 199 2127 0.0663 77 1085 22-29 0.68 0.35-
1.32 
13 
Patients with 
ASBO treated 
surgically 
0.032 74 2252 0.031 36 1126 22-29 0.49 0.28-
0.88 
13 
Patients with 
repeat surgery 
4 years 
0.208 64 200 0.209 64 200 22-30    
α = patients with event; β = patients without event; RR = relative risk; CI = confidence interval; ASBO = adhesive small bowel obstruction 
 
The probability of ASBO and the probability of surgery for ASBO after colorectal surgery, were 
derived from an update (1990 - June 2016) of the systematic review on the burden of adhesions after 
abdominal surgery.22-29 Weighted mean follow-up of the studies was 55.3 months. The probability of 
future repeat abdominal  
surgery was derived from a recently published, prospective cohort of patients who underwent 
elective abdominal surgery.30 In four years after initial lower gastrointestinal tract surgery, 24% of 
patients underwent repeat abdominal surgery, including reoperations for ASBO. In the model 
reoperations for ASBO were subtracted from the probability for repeat surgery avoiding that these 
reoperations are two times included in the model. 
 
Costs 
An analysis of adhesion related costs was performed with a healthcare perspective, including only 
direct healthcare costs for treatment (table 2). All monetary values are presented in US dollars (USD). 
Euro was converted to US dollars using the exchange rate 1 Euro:1.1264 USD. 
The mean numbers of films per patient reported in two of the three studies on adhesion prevention 
with HA/CMC in colorectal surgery was 3.3 films. The total costs for HA/CMC were based on the use 
of 3.3 films and the price of a HA/CMC film in the Netherlands, adding up to a total cost of $629.68.19-
31 
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There was no recent literature available on costs of ASBO. To evaluate the healthcare costs of ASBO, 
all patients admitted from November 2013 to October 2015 to Radboud University Medical Center 
with the diagnosis ASBO were retrospectively analyzed to assess the costs of these admissions 
(n=39). Mean costs of an admission for ASBO with operative treatment (n=19) was $18.124,77 (SD 
$2.822,22). For non-operative treatment (n=20) mean costs were $2.565,12 (SD $298,88). 
The costs for repeat surgery were derived from a recent large cohort study on adhesiolysis-related 
morbidity in abdominal surgery.5 
 
Table 2: Costs used in the model. 
 Value SD Source 
Costs HA/CMC $ 630  19,21 
ASBO with operative treatment $ 18,125 $2,822 Radboud University Medical Centre 
ASBO with non-operative treatment $ 2,565 $ 299 Radboud University Medical Centre 
Repeat surgery no adhesions $ 14,063 $ 812 5 
Repeat surgery adhesions $ 18,579 $ 1,722 5 
SD = standard deviation 
 
Data analysis 
Data were analyzed using mean values for a base case analysis, to obtain percentage of ASBO, 
reoperation for ASBO, and patients with adhesions, and direct healthcare costs for the two strategies 
in four years following colorectal surgery. The time frame was based on the mean four years’ follow-
up periods of the studies underlying the probabilities for ASBO and repeat surgery. If the use of an 
adhesion barrier was more effective and more expensive, incremental cost-effectiveness ratios (ICER) 
were calculated to determine the additional costs for one patient with adhesions prevented. In case 
the adhesion barrier strategy was more effective and cost-reducing, this was considered dominant 
and ICERs were not calculated. A base case analysis was conducted for the two strategies in open and 
laparoscopic surgery separately. 
Probabilistic sensitivity analysis was performed, using Monte Carlo simulation, to explore the impact 
of uncertainties in the model parameters, shown in table 1 and 2. In the Monte Carlo simulation 
5,000 samples were drawn from the parameter distributions. For each sample, the hypothetical 
cohort runs through the model based on these sampled parameters, representing the uncertainty in 
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the cost-effectiveness estimation. Lognormal distributions were used for all risk ratios, beta 
distributions for probabilities, and costs were described by normal distributions.  
In addition, threshold analyses were conducted for the costs of the adhesion barrier and the 
probability of repeat surgery. Deterministic sensitivity analysis was conducted to explore influence of 
deviation in the efficacy of the adhesion barrier on the cost-effectiveness, assuming all other 
variables to be fixed. The efficacy of the adhesion barrier was changed to a best- and worst case 
scenario. For the worst case scenario the risk ratios for adhesions, ASBO, and operative treatment of 
ASBO were all set to the upper limit of their confidence interval (table 1). For the best case scenario 
all risk ratios were raised to the lower limit of their confidence interval. 
 
Results 
Base case analysis 
Taking the parameters at their base case values, for the open cohort the adhesion barrier strategy 
was both more effective and less expensive than the no adhesion barrier strategy, while in the 
laparoscopic cohort the adhesion barrier strategy was more effective, but more expensive (table 3). 
In open colorectal surgery the percentage of patients with adhesions reduced from 88.9% to 45.3%, 
and ASBO incidence from 8.6% to 5.8% with an adhesion barrier. The expected mean direct 
healthcare costs in four years after initial open colorectal surgery were reduced in the adhesion 
barrier group with $102, from $4474 in the group without an adhesion barrier to $4372. After 
laparoscopic colorectal surgery the rate of patients with any adhesions was reduced from 62.3% to 
31.8%, and ASBO incidence from 6.6% to 4.5% with an adhesion barrier. Costs increased with $41 
when an adhesion barrier was used. Direct health care costs over four years after laparoscopic 
surgery for the adhesion barrier group were $4220 versus $4179 for the no adhesion barrier group. 
In open colorectal surgery the adhesion barrier strategy dominated the current no-adhesion barrier 
practice.  For laparoscopic colorectal surgery the ICER for one patient with adhesions prevented was 
$135. 
 
Sensitivity analysis 
The results of the probabilistic sensitivity analysis are shown in figure 2a and b. Monte Carlo 
Simulation showed that the use of an adhesion barrier is always more effective for preventing 
adhesions or ASBO, for both open en laparoscopic surgery. The use of an adhesion barrier had a 62% 
probability of being cost-reducing in the open cohort. In the laparoscopic cohort the probability was  
35%.  
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Table 3: Results of base case and deterministic sensitivity analyses. 
Strategy Costs Percentage adhesions Percentage ASBO Costs per patient with 
adhesions prevented 
Open cohort 
Baseline     
   No barrier $4474 88.9% 8.6%  
   Barrier $4372 45.3% 5.8% Dominant 
     
Best case scenario     
   No barrier $4474 88.9% 8.6%  
   Barrier $4129 38.2% 3.0% Dominant 
     
Worst case scenario     
   No barrier $4474 88.9% 8.6%  
   Barrier $4789 54.2% 11.3% $908 
 
Laparoscopic cohort 
Baseline     
   No barrier $4179 62.3% 6.6%  
   Barrier $4220 31.8% 4.5% $135 
     
Best case scenario     
   No barrier $4179 62.3% 6.6%  
   Barrier $4016 26.8% 2.3% Dominant 
     
Worst case scenario     
   No barrier $4179 62.3% 6.6%  
   Barrier $4576 38.0% 8.7% $1,663 
     
 
Threshold analysis in the open cohort showed that using a barrier priced at $732 or more does no 
longer reduce costs. The same effect was seen with the reoperation rate set to 15% or less. In the 
laparoscopic cohort the thresholds for cost-reduction with an adhesion barrier were a price of $589 
and a reoperation rate of 25%. 
Results of the deterministic sensitivity analysis are shown in table 3. In the best case scenario, 
applying an adhesion barrier in both open and laparoscopic colorectal surgery reduces costs.  In the 
worst case scenario the ICER for one patient with adhesions prevented is $908 in the open and 
$1,664 in the laparoscopic cohort. 
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probability of being cost-reducing in the open cohort. In the laparoscopic cohort the probability was  
35%.  
Adhesion barrier in colorectal surgery 
131 
Table 3: Results of base case and deterministic sensitivity analyses. 
Strategy Costs Percentage adhesions Percentage ASBO Costs per patient with 
adhesions prevented 
Open cohort 
Baseline     
   No barrier $4474 88.9% 8.6%  
   Barrier $4372 45.3% 5.8% Dominant 
     
Best case scenario     
   No barrier $4474 88.9% 8.6%  
   Barrier $4129 38.2% 3.0% Dominant 
     
Worst case scenario     
   No barrier $4474 88.9% 8.6%  
   Barrier $4789 54.2% 11.3% $908 
 
Laparoscopic cohort 
Baseline     
   No barrier $4179 62.3% 6.6%  
   Barrier $4220 31.8% 4.5% $135 
     
Best case scenario     
   No barrier $4179 62.3% 6.6%  
   Barrier $4016 26.8% 2.3% Dominant 
     
Worst case scenario     
   No barrier $4179 62.3% 6.6%  
   Barrier $4576 38.0% 8.7% $1,663 
     
 
Threshold analysis in the open cohort showed that using a barrier priced at $732 or more does no 
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Figure 2a: Scatterplot of Monte Carlo simulation for open colorectal surgery displaying cost (y-axis) 
and effect (x-axis) of adhesion barrier strategy. 
 
 
Figure 2b: Scatterplot of Monte Carlo simulation for laparoscopic colorectal surgery displaying cost 
(y-axis) and effect (x-axis) of adhesion barrier strategy. 
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Discussion 
An adhesion barrier in open and laparoscopic colorectal surgery can effectively reduce adhesions, 
adhesive small bowel obstruction and adhesion-related problems at repeat abdominal surgery. 
Considering a four-year time frame, using an adhesion barrier reduces costs in open colorectal 
surgery, while in laparoscopic colorectal surgery the expenses are a little over $40 per patient and 
the additional costs for one patient with adhesions prevented are $135. 
The findings in the present study are in agreement with a comparable study, that demonstrated cost 
savings in open, all types, abdominal surgery, and potential cost-effectiveness in major laparoscopy.32 
Our study has the advantage that it concerns a homogenous group of patients with a high risk of 
postoperative adhesion formation. This well-defined population enhances the clinical applicability of 
the results. Also, more recent cost data are used in the present model of which the majority was 
specific for colorectal surgery. Costs are twice as much for operative treatment of ASBO and for the 
adhesion barrier compared to costs reported previously. A comparable underestimation of costs for 
the adhesion barrier and ASBO treatment was found in other cost-effectiveness reports early this 
century.10,11 The most important limitation of previous studies is the lack of evidence on efficacy of 
the adhesion barrier reducing adhesion-related complications. 
The major strength of the present study is that recently generated evidence for the burden of 
adhesions and the efficacy of adhesion barriers in colorectal surgery could be synthesized.  Limitation 
is the necessity of extrapolating data from open to laparoscopic colorectal surgery due to scarce and 
inconsistent evidence with other formulas of HA/CMC (e.g. slurry made of film and spray) in 
laparoscopy.33-35 A deviating efficacy in laparoscopy would be highly relevant especially because the 
majority of colorectal resections are being performed by laparoscopy.17 In the deterministic 
sensitivity analysis assumed worse effectiveness of the adhesion barrier (RR 0.61) resulted in an ICER 
of $908 in the open and $1,663 in the laparoscopic cohort, which for laparoscopy is more than a ten-
fold increase compared to base case analysis. 
The time frame to which the model applies was limited to four years, while adhesion related 
complications or repeat surgery may occur many years later.12 However, approximately 70% of ASBO 
occurs within the first 4 years after lower abdominal surgery; regarding repeat surgery there is no 
data available. Using a longer time frame would increase ASBO and repeat surgery rate, thereby 
potentially increasing the clinical benefit and cost-effectiveness of the adhesion barrier strategy. 
Female infertility and chronic visceral pain, which are known consequences of adhesions, were not 
included in the model. Risk for infertility is only applicable to a small and specific group of patients 
undergoing colorectal surgeries at young age. Regarding chronic visceral pain no consistent evidence 
is available, and most costs are generated outside the hospital.4 The incompleteness of the model for 
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Figure 2a: Scatterplot of Monte Carlo simulation for open colorectal surgery displaying cost (y-axis) 
and effect (x-axis) of adhesion barrier strategy. 
 
 
Figure 2b: Scatterplot of Monte Carlo simulation for laparoscopic colorectal surgery displaying cost 
(y-axis) and effect (x-axis) of adhesion barrier strategy. 
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Discussion 
An adhesion barrier in open and laparoscopic colorectal surgery can effectively reduce adhesions, 
adhesive small bowel obstruction and adhesion-related problems at repeat abdominal surgery. 
Considering a four-year time frame, using an adhesion barrier reduces costs in open colorectal 
surgery, while in laparoscopic colorectal surgery the expenses are a little over $40 per patient and 
the additional costs for one patient with adhesions prevented are $135. 
The findings in the present study are in agreement with a comparable study, that demonstrated cost 
savings in open, all types, abdominal surgery, and potential cost-effectiveness in major laparoscopy.32 
Our study has the advantage that it concerns a homogenous group of patients with a high risk of 
postoperative adhesion formation. This well-defined population enhances the clinical applicability of 
the results. Also, more recent cost data are used in the present model of which the majority was 
specific for colorectal surgery. Costs are twice as much for operative treatment of ASBO and for the 
adhesion barrier compared to costs reported previously. A comparable underestimation of costs for 
the adhesion barrier and ASBO treatment was found in other cost-effectiveness reports early this 
century.10,11 The most important limitation of previous studies is the lack of evidence on efficacy of 
the adhesion barrier reducing adhesion-related complications. 
The major strength of the present study is that recently generated evidence for the burden of 
adhesions and the efficacy of adhesion barriers in colorectal surgery could be synthesized.  Limitation 
is the necessity of extrapolating data from open to laparoscopic colorectal surgery due to scarce and 
inconsistent evidence with other formulas of HA/CMC (e.g. slurry made of film and spray) in 
laparoscopy.33-35 A deviating efficacy in laparoscopy would be highly relevant especially because the 
majority of colorectal resections are being performed by laparoscopy.17 In the deterministic 
sensitivity analysis assumed worse effectiveness of the adhesion barrier (RR 0.61) resulted in an ICER 
of $908 in the open and $1,663 in the laparoscopic cohort, which for laparoscopy is more than a ten-
fold increase compared to base case analysis. 
The time frame to which the model applies was limited to four years, while adhesion related 
complications or repeat surgery may occur many years later.12 However, approximately 70% of ASBO 
occurs within the first 4 years after lower abdominal surgery; regarding repeat surgery there is no 
data available. Using a longer time frame would increase ASBO and repeat surgery rate, thereby 
potentially increasing the clinical benefit and cost-effectiveness of the adhesion barrier strategy. 
Female infertility and chronic visceral pain, which are known consequences of adhesions, were not 
included in the model. Risk for infertility is only applicable to a small and specific group of patients 
undergoing colorectal surgeries at young age. Regarding chronic visceral pain no consistent evidence 
is available, and most costs are generated outside the hospital.4 The incompleteness of the model for 
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these adhesion-related complications may have caused underestimation of adhesion-related costs 
and thus an underestimation of the cost-effectiveness of the use of adhesion barriers. 
The model took into account the costs of repeat surgery depending on presence and not extent and 
severity of adhesions. Evidence shows that laparoscopic approach and use of an adhesion barrier 
reduce adhesions’ incidence, extent and severity (unpublished data).8 Although reduction of extent 
and severity of adhesions potentially decreases adhesiolysis-related complications and costs, 
evidence is insufficient to consider including these variables in the model.5 Excluding the efficacy and 
costs related to reduction in severity and extent may have resulted in an overestimation of the 
adhesion related costs in the laparoscopic cohort, and an underestimation of the benefit of an 
adhesion barrier in both cohorts. 
Due to a higher life expectancy and advances in surgical technology, an increasing number of 
patients undergo abdominal surgery multiple times during lifetime.30 Adhesion formation is the 
most common long term complication of abdominal surgery, and preventing adhesion formation 
from initial abdominal surgery is the critical step in breaking the sequence of complications due to 
adhesions. Despite evidence of reduced adhesion formation when applying adhesion barriers, 
adhesion barriers are seldom used in practice. Doubts about cost-effectiveness and the need for 
adhesion prevention in the minimally invasive era probably underlie this reluctance.9 The present 
cost-effectiveness analysis is based on best available evidence for both open and laparoscopic 
colorectal surgery and can at least for open colorectal surgery take away these doubts. Since the use 
of an adhesion barrier in laparoscopic colorectal surgery involves extra costs, data on quality-
adjusted life-years (QALYs) are required to assess willingness to pay.36 In order to determine QALYs 
for adhesions and the use of adhesion barriers, future research should address patient reported 
outcomes (PROs), such as functional status and quality of life. It is conceivable that adhesion-related 
complications such as ASBO, reoperation associated complications, and chronic visceral pain will 
have a negative impact on PROs.37  
It is concluded that adhesions, adhesive small bowel obstruction and adhesion-related problems at 
repeat abdominal surgery can effectively be reduced with the use of an adhesion barrier in both 
open and laparoscopic colorectal surgery. For open colorectal surgery this will probably result in cost 
savings, and for laparoscopic colorectal surgery this might be accompanied by limited costs. 
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these adhesion-related complications may have caused underestimation of adhesion-related costs 
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Abstract 
Background 
Adhesions develop in more than 90% of patients undergoing an intra-abdominal surgical procedure. 
Adhesion barriers are rarely used despite the high morbidity caused by intra-abdominal adhesions. 
Only one of the currently available adhesion barriers has demonstrated consistent evidence for 
reducing adhesions in visceral surgery. This agent has limitations through poor handling 
characteristics because it is sticky on both sides. C-Qur™ Film is a novel thin film adhesion barrier and 
it is sticky on only one side, resulting in better handling characteristics. The objective of this study is 
to assess efficacy and safety of C-Qur™ Film to decrease the incidence of adhesions after colorectal 
surgery. 
 
Methods/Design 
This is a prospective, investigator initiated, randomized, double-blinded, multicenter trial. Eligible 
patients undergoing colorectal resection requiring temporary loop ileostomy or loop/split colostomy 
by laparotomy or hand assisted laparoscopy will be included in the trial. Before closure, patients are 
randomized 1:1 to either the treatment arm (C-Qur™ Film) or control arm (no adhesion barrier). 
Patients will return 8 to 16 weeks post-colorectal resection for take down of their ostomy. During the 
ostomy takedown, adhesions will be evaluated for incidence, extent, and severity. The primary 
outcome evaluation will be assessment of adhesions to the incision site. It is hypothesized that the 
use of the C-Qur™ Film underneath the primary incision reduces the incidence of adhesion at the 
incision by 30%. To demonstrate a 30% reduction in the incidence of adhesions, a sample size of 84 
patients (32 + 10 per group (25% drop out)) is required (two-sided test, α = 0.05, 80% power). 
 
Discussion 
Results of this study add to the evidence on the use of anti-adhesive barriers in open and 
laparoscopic ‘hand-assisted’ colorectal surgery. We chose incidence of adhesions to the incision site 
as primary outcome measure since clinical outcomes such as small bowel obstruction, secondary 
infertility and adhesiolysis related complications are considered multifactorial and difficult to 
interpret. Incidence of adhesions at repeat surgery is believed to be the most valuable surrogate 
endpoint for clinically relevant adhesion prevention, since small bowel obstruction and adhesiolysis 
at repeat surgery are not likely to occur when complete adhesion reduction in a patient is 
accomplished.  
 
Trial registration 
ClinicalTrials.gov Identifier NCT01872650, registration date 6 June 2013. 
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Background 
Postoperative adhesions develop in more than 90% of patients undergoing an intra-abdominal 
surgical procedure.1 These adhesions are known to cause small bowel obstruction, secondary 
infertility and pain.2-4 At repeat abdominal surgery, intra-abdominal adhesions necessitate 
adhesiolysis, leading to increased operating times and substantial risk of intra- and postoperative 
complications.5,6 The clinical implications of adhesions carry a significant health and socioeconomic 
burden.7,8 
Adhesions are fibrous bands that connect tissue surfaces where anatomical connections do not 
normally exist. Adhesions are formed after a tissue surface has been injured (abrasion, desiccation, 
dissection, etcetera) and the subsequent process of fibrinolysis is incomplete.9 At present, there are 
several products on the market to combat postsurgical adhesion formation. These are broad 
coverage adhesion barriers, generally consisting of liquids, like icodextrin 4% (Adept™, Baxter, 
Deerfield, IL, USA) adhesion reduction solution. These materials may limit adhesion formation by 
minimizing tissue insult during the surgical procedure when used as an intra-operational lavage. At 
the conclusion of the surgical procedure, instillation of large volumes of liquid acts to separate tissue 
surfaces by hydroflotation, limiting tissue-tissue contact. Broad coverage adhesion prevention has 
the distinct advantage of allowing the surgeon to treat many areas of the intraperitoneal space at 
once. A disadvantage is the lack of control giving adhesion prevention at sites at risk for 
complications of adhesion prevention such as an anastomosis. In addition, side effects of abdominal 
distension and vulvar swelling are commonly encountered in the use of liquids.10 The second group 
of barriers consists of local coverage adhesion barriers: films, sprays, or gels that are applied directly 
to adhesiogenic tissue surfaces to act as a physical barrier that blocks tissue-tissue contact. The 
barrier is generally only effective when it remains at the site of treatment. This requires the barrier to 
either be sutured or glued in place or to have tissue adherent properties. All local coverage adhesion 
barriers require the surgeon to anticipate where adhesions are likely to occur and to apply the 
barrier directly to those sites. These generally include sites where the peritoneum was interrupted 
during the surgical procedure, such as under a laparotomy incision to minimize adhesions between 
the incision site and the viscera.11 
Despite the frequent occurrence of adhesions after surgery and the availability of different adhesion 
barriers, these barriers are rarely used by general surgeons. This discrepancy might be explained by 
an underestimation of the impact of adhesions.12 Also, of all the clinically available adhesion barriers, 
only HA/CMC (hyaluronate/carboxymethylcellulose) barrier film (Seprafilm™, Sanofi, Paris, France) 
has demonstrated consistent evidence for reducing adhesions in visceral surgery. Seprafilm™ has 
limitations through poor handling characteristics because it is sticky on both sides. In a large, 
prospective, randomized controlled multicenter study on the safety of Seprafilm™, significantly more 
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anastomotic leak and leak-associated complications occurred in the Seprafilm™ group due to the 
wrapping of Seprafilm™ around an anastomosis.13 A subgroup analysis of control patients and 
patients without (593 patients) Seprafilm™ wrapped around the anastomosis showed no significant 
difference. Therefore, wrapping the suture or staple line of a fresh bowel anastomosis should be 
avoided. 
Atrium (Atrium Medical Corporation, Maquet Gentinge Group, Hudson, NH, USA) has developed and 
manufactures C-Qur™ Film Adhesion Barrier, a novel thin film adhesion barrier for intraperitoneal 
use in general surgeries. The C-Qur™ Film has been approved for use in humans and received a CE 
mark on 13 May 2011 (CE number 10123365). The evidence on efficacy and safety of the C-Qur film 
originates from research on the C-Qur mesh, a mesh with an omega-3 fatty acid coating used for 
patients with an abdominal ventral hernia. The C-Qur mesh was found to be safe in intraperitoneal 
use and reduces adhesions to the mesh.14 The C-Qur™ Film falls into the category of local coverage 
adhesion barriers. The C-Qur™ Film is an adhesion barrier consisting of a non-adhesive omega-3 fatty 
acid layer on one side and a Na-CMC (sodium-carboxymethylcellulose) tissue adherent coating on the 
other side. It is fully resorbable and designed to adhere to the site of treatment for a time that is 
sufficient to minimize postsurgical adhesion formation and clearance from the site of treatment 
within approximately 60 days. In contrast to Seprafilm™, The C-Qur™ Film is a one-sided adherent, 
resulting in good handling characteristics. It offers the potential patient benefits of reduced adhesion 
formation and corresponding reduction of small bowel obstruction, secondary infertility, pain and 
adhesiolysis at repeat surgery. The aim of this study is to assess the efficacy and safety of C-Qur™ 
Film to decrease the incidence of adhesions after colorectal surgery. 
 
Methods/Design 
The CLIPEUS trial is registered with the ClinicalTrials.gov Identifier NCT01872650. The protocol was 
ethically approved by the official Independent Review Board Nijmegen (2013/470) and registered 
nationally (NL45940.091.13).15 
 
Design 
The CLIPEUS trial is a prospective, investigator-initiated, randomized controlled, double-blinded, 
multicenter trial. Treatment with the C-Qur™ film adhesion barrier will be compared with no 
treatment with an adhesion barrier in patients undergoing colorectal surgery with temporary 
diverting ostomy. The surgeons who have agreed to participate in the study and perform the index 
procedures will be trained in the placement of C-Qur™ Film and in adhesion mapping. 
Patients will be included at the outpatient clinics of the participating centers (Radboud University 
Medical Center, Nijmegen; Catharina Hospital, Eindhoven; Atrium Medical Center, Heerlen; Maxima 
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Medical Center, Veldhoven; Gelderse Vallei Hospital, Ede) by the treating surgeons. During the 
operation, when the definite decision to create a temporary ostomy is made, patients are 
randomized 1:1 to either the treatment arm (C-Qur™ film) or the control arm (standard treatment: 
no adhesion barrier, no placebo). In patients assigned to the treatment arm, the C-Qur™ Film must 
be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be 
adhesiogenic (for example, the dissection site and ostomy site, but not around the anastomosis). The 
number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774 cm2 (Table 1). 
Patients will return 8 to 16 weeks post-colorectal resection to have their diverting ostomy taken 
down. During the takedown, the incidence, extent and severity of the adhesions will be evaluated. 
 
Table 1: Maximum area of coverage and number of sheets 
Code Size (cm) Maximum 
Area (cm2) Number of sheets 
32024 7.5 × 10.0 774 10 
32025 7.5 × 12.5 774 8 
32029 10.0 × 10.0 774 7 
32031 12.5 × 15.0 774 4 
 
 
Patients 
Patients aged 18 years or older who require open or hand-assisted laparoscopic colonic or rectal 
resection for colorectal disease with the formation of a temporary diverting loop ileostomy or 
colostomy and a planned closure within 8 to 16 weeks and who visit the outpatient clinic at one of 
the participating centers will be invited to participate in this trial. 
Inclusion criteria are an incision of 6 cm or longer in case of hand-assisted laparoscopy and signed 
informed consent. 
Exclusion criteria include the following: pregnancy, patients for whom it is known prior to the initial 
procedure that loop ileostomy or colostomy closure between 8 and 16 weeks is not feasible, active 
intra-abdominal infection such as peritonitis, abdominal abscess, anastomotic leakage or fistula 
(interloop abscess in the resection specimen is not an exclusion criterion), endometriosis, known 
allergies to any component of the C-Qur Film device, an additional procedure at the time of loop 
ileostomy or colostomy takedown deemed interfering with adhesion assessment by the treating 
surgeon, intended use of intraoperative lavage/irrigation with any anti-adhesion solutions other than 
lactated ringers and/or saline (for example, dextran, heparin, corticosteroids, icodextrin, any other 
irrigant that is believed to have anti-adhesion properties) or an adhesion barrier other than C-Qur 
Film™, (planned) administration of systemic agents with the intention to prevent adhesion formation 
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within 30 days prior to the index procedure, planned chemotherapy and/or abdominal radiotherapy 
between index surgery and loop ileostomy or colostomy takedown, use of immune system 
suppressants deemed by the surgeon to interfere with wound healing (patients taking daily doses of 
corticosteroids exceeding 20 mg within the prior 30 days are to be excluded; patients requiring 
perioperative corticosteroid supplementation are not to be excluded), impaired immune system 
function or coagulation disorders deemed by the surgeon to interfere with wound healing, a known 
history of severe multiple drug allergies, a life expectancy of less than 6 months because of a medical 
condition or disease state, a medical condition or other serious condition that will interfere with 
compliance and/or ability to complete this study protocol or patients who in the opinion of the 
investigator would not be a good candidate for enrolment, or participation in a study of another 
investigational device or drug. 
 
Figure 1: Segments of the abdominal wall and segments of the abdominal cavity. a. The nine 
segments of the abdominal wall; b. The ten segments of the abdominal cavity. 
a.   b.  
 
Intervention 
All patients will undergo a colorectal resection with the creation of a temporary loop ileostomy or 
loop or split colostomy. During this index operation, adhesions, if any, will be mapped. The incidence, 
location, extent and severity and any treatment of adhesions will be noted. For quantifying the 
extent of adhesions to the abdominal wall and between organs, the abdominal wall is divided into 
nine segments and the abdominal cavity into ten segments (Figure 1). Severity of the adhesions will 
be classified according to the Zühlke classification (Table 2).16 Classification of operative wounds 
based on degree of microbial contamination, number of serosal injuries and number of inadvertent  
1  2 3  
4  5  6  
7  8  9  
10  
Efficacy and safety of the C-Qur™ Film Adhesion Barrier for the prevention of surgical adhesions 
145 
Table 2: Adhesion classification system according to Zühlke 16 
Score Observation 
0 No adhesions 
1 Adhesions that are filmy and easy to separate by blunt dissection 
2 Adhesions where blunt dissection is possible but sharp dissection necessary, beginning vascularization 
3 Lysis of adhesions possible by sharp dissection only, clear vascularization 
4 Lysis of adhesions possible by sharp dissection only, organs strongly attached with severe adhesions, damage of organs hardly 
preventable 
 
enterotomies will also be noted in the source notes and CRF (case report form). 
For patients randomized to the C-Qur™ Film arm, the C-Qur™ Film must be applied to the viscera 
underneath the primary or specimen retrieval incision in case of hand-assisted laparoscopy. 
Preferably, the C-Qur™ Film is also applied to other areas considered to be adhesiogenic, such as the 
peritoneal dissection planes and the ileum or colon at the ostomy site. The number of C-Qur™ Film 
sheets placed in the abdomen is limited to a maximum area of coverage of 774 cm2. In case sheets of 
the largest size (15 cm × 12.5 cm) are used, the maximum is four sheets (Table 1). The application of 
C-Qur™ Film directly to a fresh bowel anastomosis is not allowed. 
 
Control arm 
Patients who are not allocated to the treatment group will receive standard treatment, which means 
no C-Qur™ Film or any other treatment considered to have anti-adhesion properties (for example, 
corticosteroids, dextran, heparin, icodextrin, etcetera) and no placebo will be used. 
 
Outcome measures 
The primary outcome measure will be the incidence of adhesions to the primary incision site or the 
specimen retrieval incision in the case of hand-assisted laparoscopy. 
Secondary outcome measures on effectiveness are the extent and severity of adhesions to the 
primary incision site or specimen retrieval incision, incidence, extent and severity of adhesions at the 
loop ileostomy or loop/split colostomy site and of adhesions at areas potentially injured during the 
initial procedure, duration of ileostomy or loop/split colostomy takedown from the start of the 
takedown to the time the bowel is repositioned in the abdomen, percentage (%) of abdominal wall 
with adhesions, number of C-Qur™ barrier films used, sizes of C-Qur™ barrier films used, areas 
treated with C-Qur™ Films (underneath incision, ostomy bowel loops, other areas injured during 
initial procedure and considered adhesiogenic), reason for not placing film in one or more of the 
areas considered to be adhesiogenic, incidence of chronic abdominopelvic pain, incidence of other 
gastrointestinal complaints, quality of life as assessed by Short Form-36 and DASI, and total direct 
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within 30 days prior to the index procedure, planned chemotherapy and/or abdominal radiotherapy 
between index surgery and loop ileostomy or colostomy takedown, use of immune system 
suppressants deemed by the surgeon to interfere with wound healing (patients taking daily doses of 
corticosteroids exceeding 20 mg within the prior 30 days are to be excluded; patients requiring 
perioperative corticosteroid supplementation are not to be excluded), impaired immune system 
function or coagulation disorders deemed by the surgeon to interfere with wound healing, a known 
history of severe multiple drug allergies, a life expectancy of less than 6 months because of a medical 
condition or disease state, a medical condition or other serious condition that will interfere with 
compliance and/or ability to complete this study protocol or patients who in the opinion of the 
investigator would not be a good candidate for enrolment, or participation in a study of another 
investigational device or drug. 
 
Figure 1: Segments of the abdominal wall and segments of the abdominal cavity. a. The nine 
segments of the abdominal wall; b. The ten segments of the abdominal cavity. 
a.   b.  
 
Intervention 
All patients will undergo a colorectal resection with the creation of a temporary loop ileostomy or 
loop or split colostomy. During this index operation, adhesions, if any, will be mapped. The incidence, 
location, extent and severity and any treatment of adhesions will be noted. For quantifying the 
extent of adhesions to the abdominal wall and between organs, the abdominal wall is divided into 
nine segments and the abdominal cavity into ten segments (Figure 1). Severity of the adhesions will 
be classified according to the Zühlke classification (Table 2).16 Classification of operative wounds 
based on degree of microbial contamination, number of serosal injuries and number of inadvertent  
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Table 2: Adhesion classification system according to Zühlke 16 
Score Observation 
0 No adhesions 
1 Adhesions that are filmy and easy to separate by blunt dissection 
2 Adhesions where blunt dissection is possible but sharp dissection necessary, beginning vascularization 
3 Lysis of adhesions possible by sharp dissection only, clear vascularization 
4 Lysis of adhesions possible by sharp dissection only, organs strongly attached with severe adhesions, damage of organs hardly 
preventable 
 
enterotomies will also be noted in the source notes and CRF (case report form). 
For patients randomized to the C-Qur™ Film arm, the C-Qur™ Film must be applied to the viscera 
underneath the primary or specimen retrieval incision in case of hand-assisted laparoscopy. 
Preferably, the C-Qur™ Film is also applied to other areas considered to be adhesiogenic, such as the 
peritoneal dissection planes and the ileum or colon at the ostomy site. The number of C-Qur™ Film 
sheets placed in the abdomen is limited to a maximum area of coverage of 774 cm2. In case sheets of 
the largest size (15 cm × 12.5 cm) are used, the maximum is four sheets (Table 1). The application of 
C-Qur™ Film directly to a fresh bowel anastomosis is not allowed. 
 
Control arm 
Patients who are not allocated to the treatment group will receive standard treatment, which means 
no C-Qur™ Film or any other treatment considered to have anti-adhesion properties (for example, 
corticosteroids, dextran, heparin, icodextrin, etcetera) and no placebo will be used. 
 
Outcome measures 
The primary outcome measure will be the incidence of adhesions to the primary incision site or the 
specimen retrieval incision in the case of hand-assisted laparoscopy. 
Secondary outcome measures on effectiveness are the extent and severity of adhesions to the 
primary incision site or specimen retrieval incision, incidence, extent and severity of adhesions at the 
loop ileostomy or loop/split colostomy site and of adhesions at areas potentially injured during the 
initial procedure, duration of ileostomy or loop/split colostomy takedown from the start of the 
takedown to the time the bowel is repositioned in the abdomen, percentage (%) of abdominal wall 
with adhesions, number of C-Qur™ barrier films used, sizes of C-Qur™ barrier films used, areas 
treated with C-Qur™ Films (underneath incision, ostomy bowel loops, other areas injured during 
initial procedure and considered adhesiogenic), reason for not placing film in one or more of the 
areas considered to be adhesiogenic, incidence of chronic abdominopelvic pain, incidence of other 
gastrointestinal complaints, quality of life as assessed by Short Form-36 and DASI, and total direct 
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health care costs (30 days-in-hospital healthcare costs during both hospital stays). 
Secondary outcome measures on safety are incidence of postoperative complications. Complications 
are divided into surgical and medical complications. Surgical complications are superficial incisional 
surgical site infections, deep incisional surgical site infections, anastomotic leakage, intra-abdominal 
abscess, peritonitis, unexplained fever, fascia dehiscence, wound dehiscence, postoperative 
hemorrhage, and postoperative ileus (POI). Medical complications are pulmonary embolism, 
pneumonia, urinary tract infection, sepsis, and death. 
Other secondary outcome measures are reoperations, number of re-laparotomies, number of 
inserted central venous lines, other re-operations, first postoperative day of oral food intake, 
parenteral feeding, number of days parenteral feeding required, tube feeding, number of days tube 
feeding required, first postoperative day of passing flatus, first postoperative day of passing stool, 
usage of pain medication, daily VAS (Visual Analog Scale) scores, hospital stay, Intensive Care Unit 
stay, Recovery Unit stay, readmissions within 30 days after discharge, and in-hospital mortality. 
 
Randomization and blinding 
Intra-operatively, the treating surgeon judges whether the patient is eligible for definite inclusion. 
Prior to formation of the temporary loop ileostomy, loop or split colostomy, included patients will be 
randomized. Patients will be randomized in a 1:1 fashion to the C-Qur™ Film arm (treatment arm) or 
the control arm. The randomization will be stratified by operative technique (open or hand-assisted 
laparoscopy). The allocation sequence will be computer-generated through the web-based program 
Alea©. A researcher who does not participate in the data analysis will manage the randomization 
process. This way, the researcher who will perform the data analysis is blinded from treatment 
allocation. Concealment of treatment allocation and blinding of the surgeon performing the index 
procedure is not possible because the patient will either get the intervention or does not get an 
intervention at all. Randomization will be noted in the operation reports, allocation will not. 
The patient and doctor at the surgical ward who will complete the case report form during the post-
operative period is blinded from treatment allocation. To achieve blinding during the data collection 
of outcome parameters, the surgeon who will perform the ostomy takedown procedure, will not be 
the same surgeon as the one who performed the index procedure. Because of the absence of clinical 
notes regarding allocation, however, the initial surgeon is allowed to do the ostomy takedown in 
case of man-power or organizational problems. 
During the postoperative period after the ostomy takedown, the physician at the ward, who will 
collect the data regarding the post-operative parameters, will be blinded from the treatment 
allocation of the patient. The patient will stay blinded for the received treatment. 
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Unblinding protocol 
A Data Safety Monitoring Board (DSMB) meeting for safety assessment will be scheduled once every 
15 patients have been enrolled. The study will be deblinded when there is a higher mortality rate or 
incidence of surgical complications than can be expected from data found in the literature. The 
deblinding will be performed by the same researcher who performs the randomization procedure. 
Patients will be informed on request about the performed procedure only after completing the 
quality-of-life questionnaires 1 year postoperatively. 
 
Data recording and follow-up 
All included patients will preoperatively fill in two questionnaires on quality of life (SF-36, short-form 
36, and DASI, duke activity status index) and one questionnaire on gastro-intestinal complaints (GIC). 
Preoperatively, information on the following will be collected: age, sex, weight, height, American 
Society of Anesthesiologists (ASA) classification, smoking status, Revised Cardiac Risk Index (RCRI), 
chronic obstructive pulmonary disease (COPD)/asthma, diabetes mellitus, primary clinical diagnosis, 
medical/surgical history, number of previous laparotomies, type of previous laparotomies, number of 
previous laparoscopies, type of previous laparoscopies, and medication usage. A physical exam will 
be performed, which includes vital signs and laboratory collection (to include C-reactive protein 
(CRP), chemistry, hematology and coagulation) and a pregnancy test if the patient is premenopausal. 
Classification of operative wounds based on the degree of microbial contamination, the number of 
serosal injuries and the number of inadvertent enterotomies will be noted in the source notes and 
CRF. 
The type of abdominal closure (layered or mass fascia closure) and suture material used will be noted 
in the source notes and CRF. 
Patients in both groups will receive the same postoperative treatment. Until patients are discharged, 
the following parameters will be collected: postoperative complications (superficial incisional surgical 
site infections, deep incisional surgical site infections, anastomotic leakage, intra-abdominal abscess, 
peritonitis, unexplained fever, fascia dehiscence, wound dehiscence, postoperative hemorrhage, 
postoperative ileus (POI), pulmonary embolism, pneumonia, urinary tract infection, sepsis, and 
death), reoperations, first post-operative day of oral food intake, parenteral feeding, number of days 
parenteral feeding required, tube feeding, number of days tube feeding required, first post-operative 
day of passing flatus, first post-operative day of passing stool, usage of medication including pain 
medication, daily VAS-scores, hospital stay, Intensive Care Unit stay and Recovery Unit stay. 
Patients will return 8 to 16 weeks after index surgery to have their ostomy taken down. Clinical 
follow-up to obtain update(s) on adverse events (AE’s), adhesion-related events, changes in 
concomitant medications, the presence/absence of surgical site infection (SSI) and the type of SSI (if 
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health care costs (30 days-in-hospital healthcare costs during both hospital stays). 
Secondary outcome measures on safety are incidence of postoperative complications. Complications 
are divided into surgical and medical complications. Surgical complications are superficial incisional 
surgical site infections, deep incisional surgical site infections, anastomotic leakage, intra-abdominal 
abscess, peritonitis, unexplained fever, fascia dehiscence, wound dehiscence, postoperative 
hemorrhage, and postoperative ileus (POI). Medical complications are pulmonary embolism, 
pneumonia, urinary tract infection, sepsis, and death. 
Other secondary outcome measures are reoperations, number of re-laparotomies, number of 
inserted central venous lines, other re-operations, first postoperative day of oral food intake, 
parenteral feeding, number of days parenteral feeding required, tube feeding, number of days tube 
feeding required, first postoperative day of passing flatus, first postoperative day of passing stool, 
usage of pain medication, daily VAS (Visual Analog Scale) scores, hospital stay, Intensive Care Unit 
stay, Recovery Unit stay, readmissions within 30 days after discharge, and in-hospital mortality. 
 
Randomization and blinding 
Intra-operatively, the treating surgeon judges whether the patient is eligible for definite inclusion. 
Prior to formation of the temporary loop ileostomy, loop or split colostomy, included patients will be 
randomized. Patients will be randomized in a 1:1 fashion to the C-Qur™ Film arm (treatment arm) or 
the control arm. The randomization will be stratified by operative technique (open or hand-assisted 
laparoscopy). The allocation sequence will be computer-generated through the web-based program 
Alea©. A researcher who does not participate in the data analysis will manage the randomization 
process. This way, the researcher who will perform the data analysis is blinded from treatment 
allocation. Concealment of treatment allocation and blinding of the surgeon performing the index 
procedure is not possible because the patient will either get the intervention or does not get an 
intervention at all. Randomization will be noted in the operation reports, allocation will not. 
The patient and doctor at the surgical ward who will complete the case report form during the post-
operative period is blinded from treatment allocation. To achieve blinding during the data collection 
of outcome parameters, the surgeon who will perform the ostomy takedown procedure, will not be 
the same surgeon as the one who performed the index procedure. Because of the absence of clinical 
notes regarding allocation, however, the initial surgeon is allowed to do the ostomy takedown in 
case of man-power or organizational problems. 
During the postoperative period after the ostomy takedown, the physician at the ward, who will 
collect the data regarding the post-operative parameters, will be blinded from the treatment 
allocation of the patient. The patient will stay blinded for the received treatment. 
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Unblinding protocol 
A Data Safety Monitoring Board (DSMB) meeting for safety assessment will be scheduled once every 
15 patients have been enrolled. The study will be deblinded when there is a higher mortality rate or 
incidence of surgical complications than can be expected from data found in the literature. The 
deblinding will be performed by the same researcher who performs the randomization procedure. 
Patients will be informed on request about the performed procedure only after completing the 
quality-of-life questionnaires 1 year postoperatively. 
 
Data recording and follow-up 
All included patients will preoperatively fill in two questionnaires on quality of life (SF-36, short-form 
36, and DASI, duke activity status index) and one questionnaire on gastro-intestinal complaints (GIC). 
Preoperatively, information on the following will be collected: age, sex, weight, height, American 
Society of Anesthesiologists (ASA) classification, smoking status, Revised Cardiac Risk Index (RCRI), 
chronic obstructive pulmonary disease (COPD)/asthma, diabetes mellitus, primary clinical diagnosis, 
medical/surgical history, number of previous laparotomies, type of previous laparotomies, number of 
previous laparoscopies, type of previous laparoscopies, and medication usage. A physical exam will 
be performed, which includes vital signs and laboratory collection (to include C-reactive protein 
(CRP), chemistry, hematology and coagulation) and a pregnancy test if the patient is premenopausal. 
Classification of operative wounds based on the degree of microbial contamination, the number of 
serosal injuries and the number of inadvertent enterotomies will be noted in the source notes and 
CRF. 
The type of abdominal closure (layered or mass fascia closure) and suture material used will be noted 
in the source notes and CRF. 
Patients in both groups will receive the same postoperative treatment. Until patients are discharged, 
the following parameters will be collected: postoperative complications (superficial incisional surgical 
site infections, deep incisional surgical site infections, anastomotic leakage, intra-abdominal abscess, 
peritonitis, unexplained fever, fascia dehiscence, wound dehiscence, postoperative hemorrhage, 
postoperative ileus (POI), pulmonary embolism, pneumonia, urinary tract infection, sepsis, and 
death), reoperations, first post-operative day of oral food intake, parenteral feeding, number of days 
parenteral feeding required, tube feeding, number of days tube feeding required, first post-operative 
day of passing flatus, first post-operative day of passing stool, usage of medication including pain 
medication, daily VAS-scores, hospital stay, Intensive Care Unit stay and Recovery Unit stay. 
Patients will return 8 to 16 weeks after index surgery to have their ostomy taken down. Clinical 
follow-up to obtain update(s) on adverse events (AE’s), adhesion-related events, changes in 
concomitant medications, the presence/absence of surgical site infection (SSI) and the type of SSI (if 
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applicable) will be done during the admission for ileostomy/colostomy takedown. Weight and vital 
signs will be noted and the following laboratory investigations will be repeated: CRP, sodium (Na), 
potassium (K), urea, creatinine, hemoglobin, white blood cell count, platelet count, international 
normalized ratio (INR) and prothrombin time (PT). 
Patients in both groups will undergo the same procedure for ostomy closure. To evaluate the 
adhesions at the loop ileostomy/colostomy site, the incidence, severity and extent of adhesions 
around the ostomy have to be evaluated during takedown. The time required for takedown of the 
ostomy is defined as the time from start of the takedown to the time the bowel is repositioned in the 
abdomen, and this time will be noted on the CRF. The severity of adhesions will be scored according 
to the Zühlke classification (see Table 2). To assess the extent of adhesions, the ostomy is divided in 
four quadrants (Figure 2). The extent of adhesions is scored as the number of quadrants containing 
adhesions (Table 3). After the ileostomy/colostomy takedown is completed, the surgeon will 
introduce a laparoscope at the ostomy site and evaluate the incidence, extent and severity of 
adhesions at the incision site and at other areas potentially injured (and covered) during the initial 
procedure. The severity will be scored according to the Zühlke classification (see Table 2). The extent 
of adhesions underneath the incision site will be scored through estimation of the area covered by 
adhesions as a percentage of the total area underneath the incision. The incidence and severity of 
adhesions at other areas potentially injured during the initial procedure will be scored according to 
the Zühlke classification (see Table 2). 
 
 
Figure 2: Quadrants of the ostomy site 
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Table 3: Classification to score the extent of adhesions covering the stoma 
Score Observation 
0 No adhesions 
1 Adhesions present on up to one quadrant of the stoma circle 
2 Adhesions present on two quadrants of the stoma circle 
3 Adhesions present on three quadrants of the stoma circle 
4 Adhesions present on all four quadrants of the stoma circle 
 
One year after randomization, patients in the treatment and control arm will be approached to fill in 
the same questionnaires on quality of life (SF-36 and DASI) and gastrointestinal complaints (GIC) as 
preoperatively. 
 
Ethics and informed consent 
This study is conducted in concordance with the principles of the Declaration of Helsinki 17 and Good 
Clinical Practice guidelines. The protocol was ethically approved by the official Independent Review 
Board Nijmegen (2013/470) and registered nationally (NL45940.091.13).15 A Data and Safety 
Monitoring Board (DSMB) is established to perform safety surveillance and to perform interim 
analysis on the safety data, as described. 
Patients will be screened in the outpatient clinic for participation in this study by a surgeon in one of 
the hospitals that will contribute to this study. Each patient must meet the inclusion/exclusion 
criteria of this trial. All potentially eligible patients are required to sign an informed consent after 
careful consideration. Patients have to sign the informed consent prior to the index procedure. 
 
Analysis and sample size 
It is hypothesized that the use of the C-Qur™ Film underneath the primary incision reduces the 
incidence of adhesion at the incision by 30%. This hypothesis is based on the supporting 
documentation for Seprafilm™ (treatment) versus Control (no treatment) with an adhesion rate of 
94% in the control group and 64% in the treatment group.18-22 We estimate a total drop out of 25% in 
this study, comprising 10% regular drop out and 15% drop out because of anastomotic leakage. A 
15% drop out because of anastomotic leakages is chosen because it is the upper limit of the 
incidence of this complication. Assuming that the C-Qur™ Film group performs similarly to 
Seprafilm™, a total of 84 patients, (32 + 10 per group (25% drop out)) would be needed in a 
randomized study, with 80% power and two-sided alpha = 0.05 in order to detect a 30% reduction in 
incidence of adhesions. 
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applicable) will be done during the admission for ileostomy/colostomy takedown. Weight and vital 
signs will be noted and the following laboratory investigations will be repeated: CRP, sodium (Na), 
potassium (K), urea, creatinine, hemoglobin, white blood cell count, platelet count, international 
normalized ratio (INR) and prothrombin time (PT). 
Patients in both groups will undergo the same procedure for ostomy closure. To evaluate the 
adhesions at the loop ileostomy/colostomy site, the incidence, severity and extent of adhesions 
around the ostomy have to be evaluated during takedown. The time required for takedown of the 
ostomy is defined as the time from start of the takedown to the time the bowel is repositioned in the 
abdomen, and this time will be noted on the CRF. The severity of adhesions will be scored according 
to the Zühlke classification (see Table 2). To assess the extent of adhesions, the ostomy is divided in 
four quadrants (Figure 2). The extent of adhesions is scored as the number of quadrants containing 
adhesions (Table 3). After the ileostomy/colostomy takedown is completed, the surgeon will 
introduce a laparoscope at the ostomy site and evaluate the incidence, extent and severity of 
adhesions at the incision site and at other areas potentially injured (and covered) during the initial 
procedure. The severity will be scored according to the Zühlke classification (see Table 2). The extent 
of adhesions underneath the incision site will be scored through estimation of the area covered by 
adhesions as a percentage of the total area underneath the incision. The incidence and severity of 
adhesions at other areas potentially injured during the initial procedure will be scored according to 
the Zühlke classification (see Table 2). 
 
 
Figure 2: Quadrants of the ostomy site 
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Table 3: Classification to score the extent of adhesions covering the stoma 
Score Observation 
0 No adhesions 
1 Adhesions present on up to one quadrant of the stoma circle 
2 Adhesions present on two quadrants of the stoma circle 
3 Adhesions present on three quadrants of the stoma circle 
4 Adhesions present on all four quadrants of the stoma circle 
 
One year after randomization, patients in the treatment and control arm will be approached to fill in 
the same questionnaires on quality of life (SF-36 and DASI) and gastrointestinal complaints (GIC) as 
preoperatively. 
 
Ethics and informed consent 
This study is conducted in concordance with the principles of the Declaration of Helsinki 17 and Good 
Clinical Practice guidelines. The protocol was ethically approved by the official Independent Review 
Board Nijmegen (2013/470) and registered nationally (NL45940.091.13).15 A Data and Safety 
Monitoring Board (DSMB) is established to perform safety surveillance and to perform interim 
analysis on the safety data, as described. 
Patients will be screened in the outpatient clinic for participation in this study by a surgeon in one of 
the hospitals that will contribute to this study. Each patient must meet the inclusion/exclusion 
criteria of this trial. All potentially eligible patients are required to sign an informed consent after 
careful consideration. Patients have to sign the informed consent prior to the index procedure. 
 
Analysis and sample size 
It is hypothesized that the use of the C-Qur™ Film underneath the primary incision reduces the 
incidence of adhesion at the incision by 30%. This hypothesis is based on the supporting 
documentation for Seprafilm™ (treatment) versus Control (no treatment) with an adhesion rate of 
94% in the control group and 64% in the treatment group.18-22 We estimate a total drop out of 25% in 
this study, comprising 10% regular drop out and 15% drop out because of anastomotic leakage. A 
15% drop out because of anastomotic leakages is chosen because it is the upper limit of the 
incidence of this complication. Assuming that the C-Qur™ Film group performs similarly to 
Seprafilm™, a total of 84 patients, (32 + 10 per group (25% drop out)) would be needed in a 
randomized study, with 80% power and two-sided alpha = 0.05 in order to detect a 30% reduction in 
incidence of adhesions. 
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Statistics 
In general, for continuous variables, the mean, standard deviation, median, IQR, minimum and 
maximum values will be presented. Groups will be compared using the t-test or Mann-Whitney U 
test, as appropriate, based on the distribution of the data. For categorical variables, the frequencies 
and percentage within each category will be calculated. Groups will be compared using the chi-
square or Fisher’s Exact test, as appropriate, based on the expected counts. All available data will be 
summarized. Demographics, preoperative, perioperative, and postoperative parameters will be 
reported and compared for both groups. Descriptive statistics will be presented to describe the trial 
results. Missing data will be evaluated by the investigators, and appropriate action will be 
undertaken. In case of skewed baseline data between groups, results will be corrected for this data. 
Our primary analysis will focus on the effectiveness and safety of the C-Qur film between the 
treatment group and the control group. A chi-square or Fisher’s Exact test will be performed to 
assess a significant improvement in the incidence, on the Zühlke score of adhesions underneath the 
incision site, underneath the loop ileostomy or loop/split colostomy site, and for the extent of 
adhesions underneath the loop ileostomy or loop/split colostomy site as well. The extent of 
adhesions underneath the incision site and the time needed for takedown of the ileostomy or 
loop/split colostomy will be compared using a t-test. To assess the safety of the C-Qur film the total 
incidence of postoperative complications will be compared using a t-test or a Mann-Whitney U test. 
The mortality and the incidence for each separate complication will be compared using a chi-square 
or Fisher’s Exact test. 
Subgroup analysis will be performed on laparoscopic versus open colorectal resection, and on 
ileostomy versus colostomy for the incidence, extent and severity of adhesions as described above. 
Since data collection of the outcome parameters is not blinded when the same surgeon who 
performed the index procedure also takes down the ostomy, subgroup analysis will be performed for 
patients with and without blinded data collection of outcome parameters. 
 
Reporting 
The CLIPEUS trial findings will be reported in concordance with the Consolidated Standards of 
Reporting Trials (CONSORT) checklist.23 
 
Discussion 
Results of this study add to the evidence on the use of anti-adhesive barriers in open and 
laparoscopic ‘hand-assisted’ colorectal surgery. Although the ultimate objective of adhesion 
prevention is to reduce the clinical consequences of adhesions, we chose incidence of adhesions to 
the incision site as primary outcome measure. Clinical outcomes such as small bowel obstruction, 
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secondary infertility and adhesiolysis related complications are considered multifactorial and difficult 
to interpret.24 Incidence of adhesions at repeat surgery is believed to be the most valuable surrogate 
endpoint for clinically relevant adhesion prevention, since small bowel obstruction and adhesiolysis 
at repeat surgery are not likely to occur when complete adhesion reduction in a patient is 
accomplished. No adhesion under the incision site in particular will benefit patients at re-laparotomy 
or re-laparoscopy. Recent evidence from our group emphasizes the large disease and socioeconomic 
burden of adhesions needing lysis at subsequent abdominal surgery.25 
To be able to evaluate incidence of postoperative adhesions, a second-look surgery model is 
required, also because noninvasive methods such as cine-magnetic resonance imaging (MRI) have 
not been validated measuring adhesion reduction.26 Colorectal resection with temporary loop 
ostomy is an obvious choice, since colorectal surgery is frequently performed and known for its 
relatively high incidence of adhesion-related complications.27 We will include patients undergoing 
resection for benign or malignant indication. Malignancy is the largest indication for colorectal 
resection, and since (disease-free) survival has strongly increased, life time risk of adhesion-related 
complications has increased correspondingly. 
In this study, both laparoscopic and open colorectal resections will be included. In many countries, 
laparoscopic colorectal resection for benign and malignant diseases has gained popularity.28 Thus, 
performing only an open colonic resection study would lower the generalizibility of the results on 
adhesion prevention. Laparoscopic technique is accompanied by less tissue trauma. Hence, it is 
suggested that laparoscopic colorectal surgery results in fewer adhesions. A recently published 
population-based register study specifically addressed readmission rate for clinically apparent 
adhesions after colorectal surgery, comparing the open and laparoscopic approach.29 Of the total of 
187,148 patients included, 11,013 (5.9%) had laparoscopic resection. With a median follow-up of 
31.8 months, overall adhesion-related readmission rate was 8.1%; 8.2% after an open approach 
versus 6.3% after a laparoscopic approach (P <0.001). An important limitation of this study was the 
higher percentage of emergency operations in the open group compared to the laparoscopic group. 
The most common underlying disorder for an emergency laparotomy (that is, peritonitis) has a 
higher adhesion formation propensity. Despite the relative reduction of 23% in the re-admission rate, 
it should be concluded that clinically relevant consequences of adhesions are substantial also after 
laparoscopic surgery. A subgroup analysis for open versus laparoscopic resection will be conducted 
to control for the difference in surgical technique and concomitant adhesion formation. 
For the sake of safe and secure placement of the adhesion barrier, only patients undergoing 
laparoscopic resection with a specimen extraction incision of at least 6 cm will be included in our 
study. This minimal incisional length was chosen based on previous experience with the C-Qur™ Film. 
The availability of different sizes of the film and the tissue adherence only at one site improve the 
Efficacy and safety of the C-Qur™ Film Adhesion Barrier for the prevention of surgical adhesions 
151
Ch
ap
te
r 8
Chapter 8 
150 
Statistics 
In general, for continuous variables, the mean, standard deviation, median, IQR, minimum and 
maximum values will be presented. Groups will be compared using the t-test or Mann-Whitney U 
test, as appropriate, based on the distribution of the data. For categorical variables, the frequencies 
and percentage within each category will be calculated. Groups will be compared using the chi-
square or Fisher’s Exact test, as appropriate, based on the expected counts. All available data will be 
summarized. Demographics, preoperative, perioperative, and postoperative parameters will be 
reported and compared for both groups. Descriptive statistics will be presented to describe the trial 
results. Missing data will be evaluated by the investigators, and appropriate action will be 
undertaken. In case of skewed baseline data between groups, results will be corrected for this data. 
Our primary analysis will focus on the effectiveness and safety of the C-Qur film between the 
treatment group and the control group. A chi-square or Fisher’s Exact test will be performed to 
assess a significant improvement in the incidence, on the Zühlke score of adhesions underneath the 
incision site, underneath the loop ileostomy or loop/split colostomy site, and for the extent of 
adhesions underneath the loop ileostomy or loop/split colostomy site as well. The extent of 
adhesions underneath the incision site and the time needed for takedown of the ileostomy or 
loop/split colostomy will be compared using a t-test. To assess the safety of the C-Qur film the total 
incidence of postoperative complications will be compared using a t-test or a Mann-Whitney U test. 
The mortality and the incidence for each separate complication will be compared using a chi-square 
or Fisher’s Exact test. 
Subgroup analysis will be performed on laparoscopic versus open colorectal resection, and on 
ileostomy versus colostomy for the incidence, extent and severity of adhesions as described above. 
Since data collection of the outcome parameters is not blinded when the same surgeon who 
performed the index procedure also takes down the ostomy, subgroup analysis will be performed for 
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Reporting 
The CLIPEUS trial findings will be reported in concordance with the Consolidated Standards of 
Reporting Trials (CONSORT) checklist.23 
 
Discussion 
Results of this study add to the evidence on the use of anti-adhesive barriers in open and 
laparoscopic ‘hand-assisted’ colorectal surgery. Although the ultimate objective of adhesion 
prevention is to reduce the clinical consequences of adhesions, we chose incidence of adhesions to 
the incision site as primary outcome measure. Clinical outcomes such as small bowel obstruction, 
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secondary infertility and adhesiolysis related complications are considered multifactorial and difficult 
to interpret.24 Incidence of adhesions at repeat surgery is believed to be the most valuable surrogate 
endpoint for clinically relevant adhesion prevention, since small bowel obstruction and adhesiolysis 
at repeat surgery are not likely to occur when complete adhesion reduction in a patient is 
accomplished. No adhesion under the incision site in particular will benefit patients at re-laparotomy 
or re-laparoscopy. Recent evidence from our group emphasizes the large disease and socioeconomic 
burden of adhesions needing lysis at subsequent abdominal surgery.25 
To be able to evaluate incidence of postoperative adhesions, a second-look surgery model is 
required, also because noninvasive methods such as cine-magnetic resonance imaging (MRI) have 
not been validated measuring adhesion reduction.26 Colorectal resection with temporary loop 
ostomy is an obvious choice, since colorectal surgery is frequently performed and known for its 
relatively high incidence of adhesion-related complications.27 We will include patients undergoing 
resection for benign or malignant indication. Malignancy is the largest indication for colorectal 
resection, and since (disease-free) survival has strongly increased, life time risk of adhesion-related 
complications has increased correspondingly. 
In this study, both laparoscopic and open colorectal resections will be included. In many countries, 
laparoscopic colorectal resection for benign and malignant diseases has gained popularity.28 Thus, 
performing only an open colonic resection study would lower the generalizibility of the results on 
adhesion prevention. Laparoscopic technique is accompanied by less tissue trauma. Hence, it is 
suggested that laparoscopic colorectal surgery results in fewer adhesions. A recently published 
population-based register study specifically addressed readmission rate for clinically apparent 
adhesions after colorectal surgery, comparing the open and laparoscopic approach.29 Of the total of 
187,148 patients included, 11,013 (5.9%) had laparoscopic resection. With a median follow-up of 
31.8 months, overall adhesion-related readmission rate was 8.1%; 8.2% after an open approach 
versus 6.3% after a laparoscopic approach (P <0.001). An important limitation of this study was the 
higher percentage of emergency operations in the open group compared to the laparoscopic group. 
The most common underlying disorder for an emergency laparotomy (that is, peritonitis) has a 
higher adhesion formation propensity. Despite the relative reduction of 23% in the re-admission rate, 
it should be concluded that clinically relevant consequences of adhesions are substantial also after 
laparoscopic surgery. A subgroup analysis for open versus laparoscopic resection will be conducted 
to control for the difference in surgical technique and concomitant adhesion formation. 
For the sake of safe and secure placement of the adhesion barrier, only patients undergoing 
laparoscopic resection with a specimen extraction incision of at least 6 cm will be included in our 
study. This minimal incisional length was chosen based on previous experience with the C-Qur™ Film. 
The availability of different sizes of the film and the tissue adherence only at one site improve the 
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placement in narrow spaces. These characteristics provide potentially better handling when 
compared to the commonly used HA/CMC barrier film in open colorectal surgery. 
 
Trial status 
This trial has been approved by the official Independent Review Board Nijmegen (2013/470).15 
Inclusion has not started. 
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Summary 
A colorectal resection is a common surgical procedure and in the majority of cases performed for 
colorectal cancer. Either executed by open or laparoscopic approach, trauma to peritoneal surfaces is 
unavoidable and sometimes extensive. The traumatized tissue often heals with adhesion formation 
which may have negative clinical consequences. Until recently, postoperative small bowel 
obstruction was considered the most important complication of adhesions with risk of reoperation, 
major morbidity and mortality.1 Recent literature makes clear that difficulty at repeat abdominal 
surgery is also a major cause of complications due to dissecting adhesions.2 The studies in this thesis 
address adhesions in colorectal surgery with focus on consequences of adhesions for quality of 
cancer resection, adhesiogenic propensity of laparoscopic compared to open colorectal surgery and 
the potential and expediency to prevent adhesion formation with adhesion barriers in colorectal 
surgery.   
Chapter 1 provides an introduction and outline of this thesis. 
Chapter 2 gives an comprehensive overview of the current knowledge regarding inflammatory 
response of the peritoneum on various pathological triggers, such as surgical trauma, invasive 
pathogens and tumor. Colorectal cancer surgery is associated with all mentioned triggers. Regardless 
of the type of injury to the peritoneal mesothelial cells, an inflammatory response is activated 
attempting to restore the peritoneal surfaces. The peritoneal response comprises four interacting 
pathways, an immunological, a humoral, a coagulation and a neurogenic pathway. Fibrous tissue 
connecting organs, surfaces and structures is commonly the ultimate result.  
In Chapter 3 the impact of adhesiolysis on clinical and histopathological outcome of colorectal 
surgery is presented. Despite the fact that colorectal surgery has been the focus of adhesion 
formation and prevention research in the past decades, the impact of adhesiolysis and associated 
organ injury on the outcome of colorectal surgery has not been investigated in detail before. 
A total of 249 colorectal procedures were selected from an earlier prospective cohort study of 
adhesiolysis-related problems in elective abdominal surgery.3 Relevant patient, surgical and medical 
data were prospectively assessed, before, during and after hospital stay. During colorectal surgical 
procedures detailed information on adhesions, adhesiolysis and inadvertent organ damage was 
collected and recorded real-time in a database by an independent researcher present in the 
operating theatre. Primary outcomes were incidence of adhesions, adhesiolysis time, incidence of 
bowel defects, seromuscular injury, injury to other organs and structures, and incidence of  major 
surgery related complications (MSRC). Secondary outcomes were other morbidity, oncological 
outcome, hospital costs, and incidence of hospital readmission within 30 days after discharge. 
Summary and general discussion 
159 
Adhesions were present in 60.6%, and adhesiolysis was performed in 59.0% of colorectal surgeries. 
Adhesiolysis resulted in enterotomy in 6% of cases, and in significantly more seromuscular bowel 
injuries compared to colorectal surgery without necessity to perform adhesiolysis (27% versus 7%). 
There was no significant difference in other organ injury. Adhesiolysis doubled the incidence of MSRC 
to 30% and was associated with a higher readmission rate of 15%. There was a trend towards a 
longer hospital stay and higher costs in the adhesiolysis group. This study was the first to investigate 
the impact of adhesiolysis on oncological quality of colorectal cancer resection. Data on resection 
margin and number of lymph nodes harvested were extracted from the pathology reports of the 
subgroups of 49 patients who underwent a rectal resection and 71 patients who underwent a colon 
resection for cancer. There were no differences with regard to these histopathological outcomes 
between patients undergoing colorectal cancer surgery with or without adhesiolysis. 
It was concluded that adhesiolysis during colorectal surgery is related to an increased incidence of 
iatrogenic bowel injuries and MSRC. Despite the technical challenges associated with 
adhesiolysis, good histopathological results were obtained in oncological resections. 
In Chapter 4 the impact of prior abdominal surgery on the outcome of colorectal cancer resection 
was evaluated. Due to the frequent presence of postoperative adhesions, ranging between 67 and 
95% 1,4-6, prior abdominal surgery was thought to increase complexity and morbidity of colorectal 
cancer surgery. Adhesiolysis is time consuming, associated with a certain percentage of bowel injury 
and increases postoperative morbidity.3 Cautious approach to the bowel during adhesiolysis to avoid 
injury, might compromise access to the operative field and extent of bowel resection, possibly 
leading to smaller or even incomplete resection margins. A small resection margin has been 
identified as a risk factor for poor lymph node harvest.7 
Data on primary colorectal cancer resections between January 2010 and December 2012, registered 
by all 92 Dutch hospitals performing colorectal cancer surgery, were retrieved from the Dutch 
Surgical Colorectal Audit (DSCA) prospective database.8 Primary outcomes were number of lymph 
nodes harvested, circumferential rectal resection margin (CRM), CRM positivity, and completeness of 
resection in colon cancer. Besides absolute number of lymph nodes harvested, we used cut-offs of 10 
and 12 lymph nodes, based on Dutch and US guidelines.9,10 Secondary outcomes were postoperative 
complications and 30-day mortality. 
9,042 patients (33.8%) with one or more prior abdominal operations, and 17,679 patients (66.2%) 
without prior abdominal operations were eligible for inclusion in the analysis. Mean number of 
lymph nodes was significantly lower in the group with prior abdominal surgery (15.2 versus 15.6 
lymph nodes harvested). After prior abdominal surgery 20.7% had less than 10 lymph nodes in the 
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Data on primary colorectal cancer resections between January 2010 and December 2012, registered 
by all 92 Dutch hospitals performing colorectal cancer surgery, were retrieved from the Dutch 
Surgical Colorectal Audit (DSCA) prospective database.8 Primary outcomes were number of lymph 
nodes harvested, circumferential rectal resection margin (CRM), CRM positivity, and completeness of 
resection in colon cancer. Besides absolute number of lymph nodes harvested, we used cut-offs of 10 
and 12 lymph nodes, based on Dutch and US guidelines.9,10 Secondary outcomes were postoperative 
complications and 30-day mortality. 
9,042 patients (33.8%) with one or more prior abdominal operations, and 17,679 patients (66.2%) 
without prior abdominal operations were eligible for inclusion in the analysis. Mean number of 
lymph nodes was significantly lower in the group with prior abdominal surgery (15.2 versus 15.6 
lymph nodes harvested). After prior abdominal surgery 20.7% had less than 10 lymph nodes in the 
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histopathological specimen compared to 17.8% without prior abdominal surgery (adjusted OR 1.17, 
95% CI 1.09 -1.26). No differences were found regarding completeness of resection, mean CRM and 
CRM positivity, between these groups. There was a small but significant increase in percentage of 
patients with postoperative complications after prior surgery (OR 1.14; 95% CI 1.07-1.21). Subgroups 
of different types of abdominal surgery in history as defined in the DSCA database were analyzed 
regarding number of lymph nodes, the cut-offs 10 and 12 lymph nodes, incomplete resection and 
CRM. No effect on histopathological results was shown for prior upper gastrointestinal and 
urogenital surgery. Prior colorectal surgery was associated with a significantly decreased number of 
lymph nodes in colon specimens, and a significant increase of patients with CRM positivity of rectal 
specimens. Prior hepatobiliary surgery and prior other abdominal surgery were associated with more 
patients having a colonic resection specimen with less than 10 lymph nodes. Prior hepatobiliary 
surgery was also associated with an increased percentage of patients  with less than 12 lymph nodes 
in their rectal resection specimen. The negative effect of prior abdominal surgery on 
histopathological outcome and postoperative morbidity found in this study is small. It is likely that 
more invasive and extensive prior surgery has a higher degree of impact on colorectal cancer 
resection. Unfortunately, data on approach and extent of prior surgery, and number of prior 
operations, were not available in the DSCA database. 
We concluded from this study that abdominal surgery compromises the quality of resection and 
increases postoperative morbidity in patients with primary colorectal cancer. 
It is a general assumption that minimally invasive surgery is associated with less adhesion 
formation.11 Adhesion incidences after open and laparoscopic colorectal surgery were evaluated in 
Chapter 5. In a prospective, observational, multicenter study, the incidence and impact of adhesions 
were compared between patients who underwent liver surgery for colorectal metastases after prior 
open and after prior laparoscopic colorectal cancer resection. Primary outcome was the incidence of 
adhesions to the ventral abdominal wall around the incision(s) made for the previous colorectal 
cancer resection. Secondary outcomes were total incidence of adhesions, extent and Zühlke 
classification of adhesions, performance of adhesiolysis, duration of adhesiolysis, surgical 
complications, serious adverse events, length of stay, and episodes of bowel obstruction in the 
interval between colorectal and liver surgery. 
A total of 90 (59.6%) patients with previous open and 61 (40.4%) patients with previous laparoscopic 
colorectal cancer resection were compared. Mean time interval between surgeries was significantly 
longer in the open group compared to the laparoscopic group. In the open group adhesions to the 
ventral abdominal wall around the primary incision were present in 78.9% of patients, compared to 
37.7% in the laparoscopic group (P<0.001). Incidence of adhesions to the complete ventral 
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abdominal wall and overall incidence of any adhesions were also significantly higher after open 
surgery. Still, incidence of overall adhesions was 62.3% after laparoscopic colorectal resection, and 
incidence of visceral adhesions was not significantly different between the open and laparoscopic 
group. 
This large prospective study is the first to provide complete and clinically relevant information on 
adhesion formation after colorectal cancer surgery by laparoscopic approach. The findings challenge 
the broad opinion that laparoscopy minimizes adhesion formation, and might also be a basis to use 
adhesion barriers in laparoscopic colorectal surgery. 
In Chapter 6 a systematic review and meta-analysis is presented evaluating the evidence of benefits 
and harms of four commercially available adhesion barriers. All randomised clinical trials assessing 
use of oxidised regenerated cellulose, hyaluronate carboxymethylcellulose, icodextrin, or 
polyethylene glycol in abdominal surgery were collected. The use of a barrier was compared with no 
barrier for nine predefined outcomes, graded for clinical relevance. Reoperation for adhesive small 
bowel obstruction was the primary outcome. Secondary outcomes were serious adverse events, total 
incidence of adhesions, reoperation time, small bowel obstruction from any cause, site-specific 
incidence of adhesions, and adhesion score. We assessed systematic error, random error, and design 
error with the error matrix approach. 
The risks of systematic and random errors were low. No trials reported data for the effect of oxidized 
regenerated cellulose or polyethylene glycol on reoperations for adhesive small bowel obstruction. 
Some evidence suggests that hyaluronate carboxymethylcellulose reduces the incidence of 
reoperations for adhesive small bowel obstruction (RR 0.49, 95% CI 0.28–0.88). For icodextrin, 
reoperation for adhesive small bowel obstruction did not differ significantly between groups (RR 
0.33, 95% CI 0.03–3.11). No barriers were associated with an increase in serious adverse events. 
Oxidised regenerated cellulose reduced the incidence of adhesions (relative risk [RR] 0.51, 95% CI 
0.31–0.86). 
We concluded that oxidized regenerated cellulose and hyaluronate carboxymethylcellulose can 
safely reduce clinically relevant consequences of adhesions. 
Doubts about cost-effectiveness and the need for adhesion prevention in the minimally invasive era 
probably underlie the current clinical practice to rarely use adhesion barriers.11 In Chapter 7 a 
decision tree model is presented for the use of an adhesion barrier in open and laparoscopic 
colorectal surgery. 
Current clinical practice (no adhesion barrier) 11 is compared with the use of an adhesion barrier. The 
clinical consequences of adhesions considered in the model are adhesive small bowel obstruction 
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(ASBO) and difficulties at repeat abdominal surgery. The best available evidence from the literature 
and hospital data are used for the probabilities and costs in the model. Hyaluronate 
carboxymethylcellulose (HA/CMC) is the only adhesion barrier with consistent evidence available on 
adhesion prevention and prevention of clinical consequences of adhesions in visceral surgery. 
Although the evidence for HA/CMC does not include laparoscopic surgery, we extrapolated the 
efficacy data of HA/CMC in open colorectal resection to the laparoscopic model. Outcomes of the 
model are effect on incidence of ASBO and incidence of adhesions at repeat abdominal surgery, 
direct healthcare costs, and incremental cost effectiveness ratio of adhesion barrier for one patient 
with adhesions prevented. 
Taking the parameters at their baseline values for the open cohort, the adhesion barrier strategy was 
both cheaper and more effective than the no adhesion barrier strategy. In the laparoscopic cohort 
the adhesion barrier strategy was also more effective, but $40 more expensive per patient treated 
taking a four years follow-up period into account. Incremental cost effectiveness ratio was $135 per 
patient with adhesions prevented in the laparoscopic colorectal surgery group. Probabilistic 
sensitivity analysis showed that the use of an adhesion barrier had a 65% probability of being cost-
reducing in the open cohort, this probability was 37% in the laparoscopic cohort. Threshold analysis 
in the open cohort showed that with costs for the barrier of $732 or more, the use of an adhesion 
barrier would no longer be cost-reducing. The same effect was seen with the reoperation rate set to 
15% or less. In the laparoscopic cohort the thresholds for cost-reduction with an adhesion barrier 
were costs for the adhesion barrier of $589, and a repeat surgery rate of 25%. Worst and best case 
scenario for efficacy of the adhesion barrier were performed by means of analysis with the upper 
and lower limits of the confidence intervals. Worst case scenario resulted in an incremental cost 
effectiveness ratio for one patient with adhesions prevented of $908 in the open and $1,663 in the 
laparoscopic cohort. Best case scenario resulted in applying an adhesion barrier in both open and 
laparoscopic colorectal surgery being cost-reducing. 
Adhesions, adhesive small bowel obstruction and adhesion-related problems at repeat abdominal 
surgery can effectively be reduced with the use of an adhesion barrier, in both open and laparoscopic 
colorectal surgery. For laparoscopic colorectal surgery this might  be accompanied by limited costs, 
and  for colorectal surgery this would probably result in cost savings. 
In Chapter 8 we present the study protocol for a randomized controlled trial on the efficacy and 
safety of a novel adhesion barrier membrane, C-QurTM film, in patients undergoing open or hand-
assisted laparoscopic colorectal resection. The film is available in different sizes and only tissue 
adherent at one side, making it potentially more suitable for placement in narrow spaces compared 
to other barriers. The primary outcome measure is incidence of adhesions to the incision site. 
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Incidence of adhesions is believed to be the most valuable surrogate endpoint for clinically relevant 
adhesion prevention, since small bowel obstruction and adhesiolysis at repeat surgery are not likely 
to occur when complete adhesion prevention is accomplished. The results of this study will give 
valuable information on adhesion formation after laparoscopic compared to open colorectal cancer 
resection, and the effectiveness of the use of an adhesion barrier to prevent adhesion formation. 
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General discussion 
Adhesions  complicating colorectal surgery 
This thesis addresses adhesions as complicating factor during colorectal surgery with two different 
approaches. In chapter 3 the analysis of all cases of colorectal surgery from an earlier prospective 
cohort study of adhesiolysis-related problems in elective abdominal surgery is presented. 
Adhesiolysis during colorectal surgery resulted in bowel injury, doubling of postoperative surgical 
complications, and a higher readmission rate. In chapter 4 analysis of a large nationwide prospective 
database of colorectal cancer resections showed that previous abdominal surgery was also 
associated with an increase of postoperative morbidity. This negative impact of previous abdominal 
surgery is most likely attributable to postoperative adhesion formation, since all types of abdominal 
surgery have a substantial risk of postoperative adhesion formation.1,4-6 The strength of the 
prospective cohort study lies within the completeness of detailed information, in particular on 
adhesions and adhesiolysis, complications, and costs. However, since the cohort was relatively small 
and from a single Dutch university medical center, results cannot be generalized for other hospitals 
or other countries. Moreover, subgroup analysis to identify specific risk factors was not possible due 
to the small number of patients. Main advantage of the nationwide database study is the external 
validity and results can be applied to all patients undergoing primary colorectal cancer resection in 
the Netherlands.12 However, a database study harbors the risk of retrospective, and potentially 
incorrect and/or incomplete data. Despite the magnitude of the group of patients, possibilities for 
subgroup analysis were limited because not all relevant variables were registered in the database. As 
a result, the difference between the two studies in complication rate cannot be investigated and 
explained in detail. Most likely the surgical history of the patients included in the prospective cohort 
study is more extensive than of the patients in the national database, and registration of the 
complications in the prospective study might be more complete. The conclusion from both studies 
that adhesions worsen the early outcome of colorectal surgery, gains strength because it is 
supported by two different study methods. Future research on patient-reported outcomes (PROs), 
such as symptoms, quality of life and functional status, could underline the negative impact of 
adhesions from a patient’s perspective. In abdominal surgery quality of care is traditionally measured 
by mortality and morbidity, and seldom by PROs. Knowing the impact of adhesions on PROs after 
colorectal surgery would aid in shared decision making, especially in elective repeat surgery for 
benign diseases and for colorectal cancer surgery in the elderly.     
The known difficulties caused by adhesions during repeat abdominal surgery led to the hypothesis 
that adhesions could negatively impact oncological quality of resection in colorectal cancer surgery.2,3 
We were the first investigating this potential correlation, and performed this study in the 
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aforementioned prospective cohort with complete and detailed information, and in a large 
nationwide database. The pathology reports of all cases of colorectal cancer resection from the 
prospective cohort study were retrospectively analyzed. The reliability of the pathology reports was 
considered high, since standardized reports for colorectal cancer are used as recommended by the 
National Guidelines for Colorectal Cancer Surgery, following the Dataset for colorectal cancer (2nd 
edition) of the Royal College of Pathologists.13,14 The cohort only comprised 120 patients with 
colorectal cancer resection and there were even smaller numbers of patients in subgroup analyses 
which hampered making definite conclusions. Again, generalizability of the results may be an issue 
since the cohort was from one center, and local standards of resection might have influenced 
histopathological outcomes. However, rates of patients with less than 10 lymph nodes harvested for 
both colon (18.6%) and rectal (26.5%) cancer were comparable with the rates in the Dutch Surgical 
Colorectal Cancer Audit (16% and 32% respectively in 2011).8 The hypothesis that prior abdominal 
surgery, as surrogate parameter for adhesions, is associated with worse oncological quality of 
colorectal resection was confirmed in the database study. The small but significant differences can be 
attributed to the very large number of patients and raises the question whether this difference is 
clinically relevant. 20.7% of patients with prior abdominal surgery compared to 17.8% of patients 
without prior abdominal surgery with less than 10 lymph nodes harvested seems a small difference. 
However, a one-sixth increase of patients exposed to adjuvant systemic therapy or a likely increase in 
patients with local or regional recurrence, should not be ignored. Previous studies have shown that 
an inadequate number of lymph nodes evaluated is associated with impaired outcome 15,16 and CRM 
positivity increases local recurrence risk.17 The lack of data on adhesions and performance of 
adhesiolysis in this database does not permit definitive conclusions on the role of adhesions. Since 
data on prior abdominal operations in the database was limited to a nonspecific anatomical 
classification, it was not possible to create specific subgroups of patients, i.e. open versus 
laparoscopic, or according to severity and extent of prior abdominal surgery. It is likely that more 
invasive and extensive prior surgery will have a higher degree of impact on future colorectal cancer 
resection.3 Apart from a worse oncological quality of colorectal resection, the higher rate of 
postoperative complications in patients with prior abdominal surgery may worsen long-term 
oncological outcome. A patient with prior abdominal surgery has a higher likelihood of developing 
postoperative complications risking a later start of adjuvant chemotherapy or no start at all.18 It is 
usually accepted that adjuvant chemotherapy should begin within 8 weeks after surgery, and 
initiation beyond 3 months after surgery is associated with an increase in cancer specific 
mortality.19,20 Awareness of these negative effects should stimulate surgeons when performing an 
oncological resection in patients with an abdominal surgery in history, to dissect the right planes and 
obtain sufficient amounts of lymph nodes, also in the presence of adhesions. It would be even better 
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to prevent the formation of adhesions by using appropriate adhesion barriers from the beginning at 
the first abdominal surgery. 
 
Adhesions as a result of open or laparoscopic colorectal surgery 
Reported incidences of adhesions after abdominal surgery are based on old studies of open 
abdominal surgery.5,6 Colorectal surgery in particular has consistently been associated with high rates 
of adhesion formation and adhesion related complications.1,2 With introduction of laparoscopic 
surgery and reports of reduced inflammatory response associated with this minimally invasive 
technique it is generally assumed that adhesion formation is minimal and related complications are 
substantially reduced.11,21 However, data on adhesions after laparoscopic colorectal surgery 
supporting this assumption, are scarce and of limited quality. For instance, the claim that 
laparoscopy largely solves the problem of adhesions by reported better fertility rates or less 
adhesions after laparoscopic restorative proctocolectomy, is solely based on adhesion assessment 
limited to specific anatomical sites, and involves selection and publication bias.22,23 In this thesis, 
adhesions after open and laparoscopic colorectal cancer surgery are addressed in a prospective 
multicenter study, and in a decision analytic model. In the first study, adhesion formation is 
compared after previous laparoscopic or open resection of colorectal cancer. The chosen population 
of patients in whom liver surgery was performed for metastases, enabled second look surgery to 
reliably assess both abdominal wall and visceral adhesions. Strong aspect of the study is the 
multicenter approach. The study showed that laparoscopy reduces adhesion formation, mainly to the 
parietal peritoneum. Incidence of adhesions, in particular between viscera, was still more than 60%. 
These findings are of particular importance for repeat surgery. Patients undergoing laparoscopy will 
benefit from a lower incidence of abdominal wall adhesions, which facilitates re-entry and lowers risk 
of organ injury by trocar introduction. The benefit of laparoscopy on clinically relevant endpoints is 
addressed in a decision analytic model. The best available evidence on adhesion formation, adhesive 
small bowel obstruction (ASBO) and adhesions complicating repeat surgery was synthesized, to 
evaluate the adhesion related outcome and health care costs after open and laparoscopic colorectal 
surgery. The probability of ASBO was 6.6% after laparoscopic colorectal surgery, a 24% reduction 
relative to 8.6% ASBO after open colorectal surgery. This reduction corresponds with a large 
population-based epidemiological study and a recent meta-analysis, reporting a 24% (6.3% versus 
8.2% in 2.5 years) reduction of adhesion-related readmissions and a 25% (3% versus 4%) reduction of 
small bowel obstruction in favor of laparoscopic compared to open colorectal surgery.24,25 
Remarkably, the reduction in ASBO and adhesion-related readmissions is less than the 30% reduction 
in adhesion incidence demonstrated in our prospective, multicenter study. The studies collectively 
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reject the assumption that adhesions would no longer be an issue in the laparoscopic era. 
Unfortunately, patients remain at risk for developing small bowel obstruction, or requiring 
adhesiolysis at repeat surgery with associated complications. 
 
Adhesion barriers 
The mainstays of adhesion prevention are minimization of surgical trauma and adhesion barriers.  
Adhesion barriers are seldom used due to perceived high costs, doubts about the effectiveness on 
clinically relevant outcomes, and doubts about the need for adhesion prevention in the laparoscopic 
era.11 Laparoscopy reduces surgical trauma, but the reduction of adhesions associated with a 
laparoscopic approach is limited, as apparent from this thesis. Adhesion prevention in laparoscopy 
raises an issue with existing adhesion barriers. Adhesion barrier membranes, with proven efficacy in 
open colorectal surgery, are difficult to apply in laparoscopic surgery, and there are no consistent 
efficacy data available for this application.26.27 Liquid or gel barriers are more appropriate for 
laparoscopic use, but in the systematic review and meta-analysis no evidence for laparoscopic 
colorectal surgery was shown. Regarding other surgical specialties, there is some evidence on use of 
liquid or gel barriers. The liquid barrier icodextrin 4% was not proven effective in reducing de novo 
adhesions in laparoscopic gynecological surgery, and efficacy of sprayable HA/CMC in laparoscopic 
radical prostatectomy was determined with a weak primary endpoint.28,29 Even if efficacy in other 
specialties was proven, this cannot be extrapolated to colorectal surgery, due to large differences in 
factors that may affect adhesion formation e.g. bacterial contamination, large peritoneal surfaces. 
Altogether we plea for renewed initiatives to develop and study sprays, gels and other soluble agents 
as adhesion barriers in laparoscopic colorectal surgery.30  
In a decision tree model for open and laparoscopic colorectal surgery, the efficacy of HA/CMC film in 
open colorectal surgery was extrapolated to the laparoscopic cohort. The balance between the costs 
of the adhesion barrier, and the potential cost reduction that can be achieved by prevention of 
adhesions and adhesion-related complications, was inventoried. The model showed that adhesive 
small bowel obstruction and adhesion-related problems at repeat abdominal surgery are reduced 
with cost savings in open surgery and limited costs in laparoscopic surgery. Combined with the 62% 
incidence of adhesions and limited reduction in adhesion related complications after laparoscopy, 
these findings warrant effective methods of adhesion prevention in laparoscopy. There are no 
ongoing trials on adhesion barriers in laparoscopic colorectal surgery identified in the available trial 
registries. In chapter 8 of this thesis the study protocol for a novel adhesion barrier film in open and 
hand-assisted laparoscopic colorectal surgery is presented. Advantage of this barrier is that a similar 
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to prevent the formation of adhesions by using appropriate adhesion barriers from the beginning at 
the first abdominal surgery. 
 
Adhesions as a result of open or laparoscopic colorectal surgery 
Reported incidences of adhesions after abdominal surgery are based on old studies of open 
abdominal surgery.5,6 Colorectal surgery in particular has consistently been associated with high rates 
of adhesion formation and adhesion related complications.1,2 With introduction of laparoscopic 
surgery and reports of reduced inflammatory response associated with this minimally invasive 
technique it is generally assumed that adhesion formation is minimal and related complications are 
substantially reduced.11,21 However, data on adhesions after laparoscopic colorectal surgery 
supporting this assumption, are scarce and of limited quality. For instance, the claim that 
laparoscopy largely solves the problem of adhesions by reported better fertility rates or less 
adhesions after laparoscopic restorative proctocolectomy, is solely based on adhesion assessment 
limited to specific anatomical sites, and involves selection and publication bias.22,23 In this thesis, 
adhesions after open and laparoscopic colorectal cancer surgery are addressed in a prospective 
multicenter study, and in a decision analytic model. In the first study, adhesion formation is 
compared after previous laparoscopic or open resection of colorectal cancer. The chosen population 
of patients in whom liver surgery was performed for metastases, enabled second look surgery to 
reliably assess both abdominal wall and visceral adhesions. Strong aspect of the study is the 
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small bowel obstruction (ASBO) and adhesions complicating repeat surgery was synthesized, to 
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relative to 8.6% ASBO after open colorectal surgery. This reduction corresponds with a large 
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8.2% in 2.5 years) reduction of adhesion-related readmissions and a 25% (3% versus 4%) reduction of 
small bowel obstruction in favor of laparoscopic compared to open colorectal surgery.24,25 
Remarkably, the reduction in ASBO and adhesion-related readmissions is less than the 30% reduction 
in adhesion incidence demonstrated in our prospective, multicenter study. The studies collectively 
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reject the assumption that adhesions would no longer be an issue in the laparoscopic era. 
Unfortunately, patients remain at risk for developing small bowel obstruction, or requiring 
adhesiolysis at repeat surgery with associated complications. 
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clinically relevant outcomes, and doubts about the need for adhesion prevention in the laparoscopic 
era.11 Laparoscopy reduces surgical trauma, but the reduction of adhesions associated with a 
laparoscopic approach is limited, as apparent from this thesis. Adhesion prevention in laparoscopy 
raises an issue with existing adhesion barriers. Adhesion barrier membranes, with proven efficacy in 
open colorectal surgery, are difficult to apply in laparoscopic surgery, and there are no consistent 
efficacy data available for this application.26.27 Liquid or gel barriers are more appropriate for 
laparoscopic use, but in the systematic review and meta-analysis no evidence for laparoscopic 
colorectal surgery was shown. Regarding other surgical specialties, there is some evidence on use of 
liquid or gel barriers. The liquid barrier icodextrin 4% was not proven effective in reducing de novo 
adhesions in laparoscopic gynecological surgery, and efficacy of sprayable HA/CMC in laparoscopic 
radical prostatectomy was determined with a weak primary endpoint.28,29 Even if efficacy in other 
specialties was proven, this cannot be extrapolated to colorectal surgery, due to large differences in 
factors that may affect adhesion formation e.g. bacterial contamination, large peritoneal surfaces. 
Altogether we plea for renewed initiatives to develop and study sprays, gels and other soluble agents 
as adhesion barriers in laparoscopic colorectal surgery.30  
In a decision tree model for open and laparoscopic colorectal surgery, the efficacy of HA/CMC film in 
open colorectal surgery was extrapolated to the laparoscopic cohort. The balance between the costs 
of the adhesion barrier, and the potential cost reduction that can be achieved by prevention of 
adhesions and adhesion-related complications, was inventoried. The model showed that adhesive 
small bowel obstruction and adhesion-related problems at repeat abdominal surgery are reduced 
with cost savings in open surgery and limited costs in laparoscopic surgery. Combined with the 62% 
incidence of adhesions and limited reduction in adhesion related complications after laparoscopy, 
these findings warrant effective methods of adhesion prevention in laparoscopy. There are no 
ongoing trials on adhesion barriers in laparoscopic colorectal surgery identified in the available trial 
registries. In chapter 8 of this thesis the study protocol for a novel adhesion barrier film in open and 
hand-assisted laparoscopic colorectal surgery is presented. Advantage of this barrier is that a similar 
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efficacy compared to other barrier films is expected, but its design would offer good handling 
characteristics for placement through small incisions in laparoscopic colorectal surgery. Limitation of 
the study design is that visceral adhesions will not be optimally prevented, since the protocol only 
demands barrier placement underneath the incision, and it is optional at other areas considered to 
be adhesiogenic . Moreover, the progress of the study is hampered because it is unclear whether the 
production of the barrier will be continued. The ambiguity in this study, and the lack of current trials 
on adhesion barriers in laparoscopic colorectal surgery, underlines that there is reluctance to invest 
in development of adhesion barriers.  The limited belief in adhesion barriers among surgeons seems 
a key factor for this reluctance.11 Difficulties encountered in adhesion prevention studies, such as 
need for second look surgery, need for long term follow up and large numbers of patients for 
clinically relevant endpoints, are possible other objections.31 Assessment of visceral slide with 
dynamic magnetic resonance imaging might eliminate the need for second look surgery, but needs 
further validation.32 
Breakthrough measure combating the burden of postoperative adhesions is to increase awareness of 
the problem and solutions to the problem among other stakeholders than doctors. Actions should be 
undertaken to inform patients who will undergo colorectal surgery about their long term risk. 
Insurance companies should be well aware of the long term benefits of adhesion prevention at initial 
surgery and increase incentive to routinely use adhesion barriers in colorectal surgery. Funding 
bodies and companies should recognize postoperative adhesion formation as a important health- 
economic problem and fund research in this area. Preventing adhesion formation from initial 
abdominal surgery is the critical step in breaking the sequence of per- and postoperative 
complications caused by adhesions and a subsequent life-long risk of adhesion-related problems.   
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Colorectale resecties worden veelvuldig verricht. De meest voorkomende indicatie voor een resectie 
is een colorectaal carcinoom. De chirurgische procedure kan door middel van een open of 
laparoscopische benadering worden uitgevoerd. Bij beide benaderingen is schade aan peritoneale 
oppervlakken onvermijdelijk en soms zelfs zeer uitgebreid. Genezing van het beschadigde weefsel 
gaat vaak gepaard met adhesievorming, wat negatieve klinische gevolgen kan hebben. Tot voor kort 
werd postoperatieve dunne darmobstructie, met risico op heroperatie, hoge morbiditeit en 
mortaliteit beschouwd als de belangrijkste complicatie van adhesies. Inmiddels zijn er publicaties 
verschenen waarin juist complicaties tengevolge van adhesiolyse bij abdominale reoperaties 
genoemd worden als meest ernstige gevolg van postoperatieve adhesies. De studies in dit 
proefschrift gaan over adhesies in relatie tot colorectale chirurgie. We hebben onderzoek gedaan 
naar de invloed van adhesies op de kwaliteit van resectie van colorectaal carcinoom, naar 
adhesievorming veroorzaakt door laparoscopische vergeleken met open colorectale chirurgie, en 
naar de mogelijkheid en effectiviteit van het voorkomen van adhesievorming met behulp van adhesie 
‘barriers’. 
Hoofdstuk 1 geeft een inleiding en schetst de hoofdlijnen van dit proefschrift. 
Hoofdstuk 2 geeft een uitgebreid overzicht van de huidige kennis over de reactie van het peritoneum 
op verschillende pathologische prikkels, zoals chirurgisch trauma, invasieve ziekteverwekkers en 
tumor. Al deze prikkels kunnen voorkomen bij  een (resectie van) colorectaal carcinoom. Ongeacht 
het type schade aan de peritoneale mesotheelcellen ontstaat er een ontstekingsreactie als eerste 
begin om de peritoneale oppervlakken weer te herstellen. De peritoneale reactie omvat vier 
geïntegreerde processen: een immunologische, een humorale, een stollings- en een neurogene 
route. Vaak is het uiteindelijke resultaat dat er bindweefsel ontstaat dat oppervlakken van 
verschillende organen en structuren verbindt. 
In hoofdstuk 3 wordt de impact van adhesiolyse op de klinische en de histopathologische uitkomst 
van colorectale chirurgie uiteen gezet. In totaal 249 colorectale procedures werden geselecteerd uit 
een eerdere prospectieve cohortstudie over adhesiolyse gerelateerde problemen in electieve 
abdominale chirurgie. Relevante patiënteigenschappen, chirurgische en medische gegevens werden 
prospectief verzameld voor, tijdens en na het verblijf in het ziekenhuis. Tijdens colorectale 
chirurgische ingrepen werd gedetailleerde informatie over adhesies, adhesiolyse en onbedoelde 
orgaanschade in een databank geregistreerd door een onafhankelijk onderzoeker die aanwezig was 
in de operatiekamer. De primaire uitkomsten waren incidentie van de adhesies, de adhesiolyseduur, 
de incidentie van darmletsels, seromusculair letsel, schade aan andere organen en structuren en de 
incidentie van ernstige, aan de operatie gerelateerde, complicaties. Secundaire uitkomsten waren 
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overige morbiditeit, oncologische uitkomst, ziekenhuiskosten en de incidentie van heropname in het 
ziekenhuis binnen 30 dagen na ontslag. 
Adhesies waren aanwezig in 60,6% van de gevallen en adhesiolyse werd uitgevoerd in 59,0% van de 
colorectale operaties. Adhesiolyse leidde in 6% van de gevallen tot een enterotomie, en tot 
significant meer seromusculair darmletsel vergeleken met colorectale chirurgie zonder noodzaak tot 
adhesiolyse (27% versus 7%). Er was geen significant verschil in andere orgaanschade. Adhesiolyse 
verdubbelde de incidentie van ernstige, aan de operatie gerelateerde, complicaties tot 30% en was 
geassocieerd met een hogere incidentie van heropnames (15%). Er was een trend naar een langere 
opnameduur en hogere kosten in de adhesiolysegroep. Deze studie was de eerste waarin het effect 
van adhesiolyse op oncologische kwaliteit van resectie van colorectaal carcinoom is onderzocht. 
Gegevens over resectiemarge en aantal geoogste lymfklieren werden verkregen uit de 
pathologieverslagen van de subgroepen van 49 patiënten die een rectumresectie en 71 patiënten die 
een colonresectie voor kanker ondergingen. Deze histopathologische resultaten bleken niet 
verschillend tussen patiënten die een resectie met of zonder adhesiolyse ondergingen. 
De conclusie is dat adhesiolyse tijdens colorectale chirurgie samenhangt met een verhoogde 
incidentie van iatrogene darmletsels en ernstige, aan de operatie gerelateerde, complicaties. 
Ondanks de technische uitdagingen waarmee adhesiolyse gepaard kan gaan, werden goede 
histopathologische resultaten verkregen bij oncologische resecties. 
In hoofdstuk 4 wordt de invloed van eerdere abdominale chirurgie op het resultaat van een resectie 
voor een colorectaal carcinoom geëvalueerd. Omdat postoperatieve adhesies veelvuldig voorkomen, 
variërend tussen 67 en 95%, werd gedacht dat eerdere abdominale chirurgie de complexiteit en 
morbiditeit van een operatie voor colorectaal carcinoom verhogen. Adhesiolyse is tijdrovend en 
wordt geassocieerd met darmletsels en verhoogde postoperatieve morbiditeit. Een voorzichtige 
benadering van de darm tijdens adhesiolyse om letsel te voorkomen kan ertoe leiden dat de chirurg 
een beperktere toegang tot het operatiegebied heeft en de omvang van de darmresectie beperkt. Dit 
leidt mogelijk tot kleinere of zelfs onvolledige resectiemarges. Een kleine resectiemarge is een 
risicofactor voor een inadequaat aantal lymfeklieren in het preparaat. 
Gegevens van primaire resecties van colorectaal carcinoom tussen januari 2010 en december 2012, 
geregistreerd door alle 92 Nederlandse ziekenhuizen waar deze operaties werden uitgevoerd, 
werden verkregen uit de Dutch Surgical Colorectal Audit (DSCA) prospectieve database. Primaire 
uitkomsten waren het aantal geoogste lymfeklieren, de rectale circumferentiële resectie marge 
(CRM), CRM positiviteit, en radicaliteit van resectie van het coloncarcinoom. Naast het absolute 
aantal geoogste lymfeklieren, gebruikten we afkapwaarden van 10 en 12 lymfeklieren, gebaseerd op 
de Nederlandse en Amerikaanse richtlijnen. Secundaire uitkomsten waren postoperatieve 
complicaties en mortaliteit binnen 30 dagen. 
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overige morbiditeit, oncologische uitkomst, ziekenhuiskosten en de incidentie van heropname in het 
ziekenhuis binnen 30 dagen na ontslag. 
Adhesies waren aanwezig in 60,6% van de gevallen en adhesiolyse werd uitgevoerd in 59,0% van de 
colorectale operaties. Adhesiolyse leidde in 6% van de gevallen tot een enterotomie, en tot 
significant meer seromusculair darmletsel vergeleken met colorectale chirurgie zonder noodzaak tot 
adhesiolyse (27% versus 7%). Er was geen significant verschil in andere orgaanschade. Adhesiolyse 
verdubbelde de incidentie van ernstige, aan de operatie gerelateerde, complicaties tot 30% en was 
geassocieerd met een hogere incidentie van heropnames (15%). Er was een trend naar een langere 
opnameduur en hogere kosten in de adhesiolysegroep. Deze studie was de eerste waarin het effect 
van adhesiolyse op oncologische kwaliteit van resectie van colorectaal carcinoom is onderzocht. 
Gegevens over resectiemarge en aantal geoogste lymfklieren werden verkregen uit de 
pathologieverslagen van de subgroepen van 49 patiënten die een rectumresectie en 71 patiënten die 
een colonresectie voor kanker ondergingen. Deze histopathologische resultaten bleken niet 
verschillend tussen patiënten die een resectie met of zonder adhesiolyse ondergingen. 
De conclusie is dat adhesiolyse tijdens colorectale chirurgie samenhangt met een verhoogde 
incidentie van iatrogene darmletsels en ernstige, aan de operatie gerelateerde, complicaties. 
Ondanks de technische uitdagingen waarmee adhesiolyse gepaard kan gaan, werden goede 
histopathologische resultaten verkregen bij oncologische resecties. 
In hoofdstuk 4 wordt de invloed van eerdere abdominale chirurgie op het resultaat van een resectie 
voor een colorectaal carcinoom geëvalueerd. Omdat postoperatieve adhesies veelvuldig voorkomen, 
variërend tussen 67 en 95%, werd gedacht dat eerdere abdominale chirurgie de complexiteit en 
morbiditeit van een operatie voor colorectaal carcinoom verhogen. Adhesiolyse is tijdrovend en 
wordt geassocieerd met darmletsels en verhoogde postoperatieve morbiditeit. Een voorzichtige 
benadering van de darm tijdens adhesiolyse om letsel te voorkomen kan ertoe leiden dat de chirurg 
een beperktere toegang tot het operatiegebied heeft en de omvang van de darmresectie beperkt. Dit 
leidt mogelijk tot kleinere of zelfs onvolledige resectiemarges. Een kleine resectiemarge is een 
risicofactor voor een inadequaat aantal lymfeklieren in het preparaat. 
Gegevens van primaire resecties van colorectaal carcinoom tussen januari 2010 en december 2012, 
geregistreerd door alle 92 Nederlandse ziekenhuizen waar deze operaties werden uitgevoerd, 
werden verkregen uit de Dutch Surgical Colorectal Audit (DSCA) prospectieve database. Primaire 
uitkomsten waren het aantal geoogste lymfeklieren, de rectale circumferentiële resectie marge 
(CRM), CRM positiviteit, en radicaliteit van resectie van het coloncarcinoom. Naast het absolute 
aantal geoogste lymfeklieren, gebruikten we afkapwaarden van 10 en 12 lymfeklieren, gebaseerd op 
de Nederlandse en Amerikaanse richtlijnen. Secundaire uitkomsten waren postoperatieve 
complicaties en mortaliteit binnen 30 dagen. 
Nederlandse samenvatting 
176
Nederlandse samenvatting 
176 
9042 patiënten (33,8%) met één of meer eerdere abdominale operaties, en 17.679 patiënten (66,2%) 
zonder voorafgaande abdominale chirurgie kwamen in aanmerking voor inclusie in de analyse. In de 
groep met eerdere abdominale chirurgie was het gemiddelde aantal lymfeklieren significant lager 
(15,2 versus 15,6 lymfeklieren). Na eerdere abdominale chirurgie had 20,7% minder dan 10 
lymfeklieren in het histopathologische preparaat ten opzichte van 17,8% zonder eerdere 
buikoperaties (aangepaste OR 1,17, 95% CI 1,09 -1,26). Er werden geen verschillen gevonden met 
betrekking tot de radicaliteit van resectie, gemiddelde CRM en CRM positiviteit tussen deze groepen. 
Er was een kleine maar significante stijging van het percentage patiënten met postoperatieve 
complicaties na eerdere abdominale chirurgie (OR 1.14; 95% Cl 1,07-1,21).  
Het aantal lymfeklieren, de afkapwaarden 10 en 12 lymfeklieren, de radicaliteit van de resectie en de 
CRM werden geanalyseerd voor subgroepen met een bepaald type/locatie van de abdominale 
chirurgie in de voorgeschiedenis, zoals gedefinieerd in de DSCA-databank. Eerdere chirurgie van de 
bovenste tractus digestivus en eerdere urogenitale chirurgie bleken geen effect te hebben op de 
histopathologische resultaten. Eerdere colorectale chirurgie hing samen met een significant 
verminderd aantal verwijderde lymfeklieren bij resecties voor coloncarcinoom, en een significante 
toename van patiënten met een positieve CRM bij resecties voor het rectum carcinoom. Patiënten 
met een eerdere hepatobiliaire operatie en eerdere overige buikoperaties hadden vaker minder dan 
10 lymfklieren in het colon resectiepreparaat. En eerdere hepatobiliaire operatie was ook 
geassocieerd met een verhoogd percentage patiënten dat minder dan 12 lymfeklieren in het rectum 
resectiepreparaat had. Er bestond een klein negatief effect van eerdere buikoperaties op de 
histopathologische resultaten en postoperatieve morbiditeit. Waarschijnlijk is het effect op de 
resectie van colorectaal carcinoom groter afhankelijk van hoe invasief en uitgebreid de eerdere 
chirurgie is geweest. Helaas waren in de DSCA-databank geen gegevens beschikbaar over de gekozen 
benadering en omvang van eerdere operaties, noch over het aantal eerdere operaties. 
We concluderen uit deze studie dat bij patiënten die een primaire resectie van colorectaal carcinoom 
ondergaan eerdere buikoperaties de oncologische kwaliteit van resectie bedreigen en de 
postoperatieve morbiditeit verhogen. 
In het algemeen wordt aangenomen dat minimaal invasieve chirurgie samenhangt met minder 
adhesieformatie. De incidentie van adhesies na open en laparoscopische colorectale chirurgie werd 
geëvalueerd in hoofdstuk 5. In een prospectieve, observationele, multicenterstudie werden bij 
patiënten die een leveroperatie voor colorectale metastasen ondergingen de incidentie en impact 
van adhesies vergeleken tussen patiënten die voorafgaand een open of een laparoscopische 
colorectale resectie hadden ondergaan. De primaire uitkomstmaat was de incidentie van adhesies 
aan de ventrale buikwand rond de incisie gemaakt voor de eerdere colorectale resectie. Secundaire 
uitkomsten waren totale incidentie van adhesies, omvang en Zühlke-classificatie van adhesies, het 
Nederlandse Samenvatting 
177 
verrichten van adhesiolyse, duur van adhesiolyse, chirurgische complicaties, ernstige complicaties, 
opnameduur en episodes van darmobstructie in de periode tussen colorectale resectie en 
leverchirurgie. 
Een totaal van 90 (59,6%) patiënten met eerdere open en 61 (40,4%) patiënten met eerdere 
laparoscopische resectie van colorectale kanker werden vergeleken. Het gemiddelde tijdsinterval 
tussen de twee operaties was significant groter in de open groep vergeleken met de laparoscopische 
groep. In de open groep waren adhesies aan de ventrale buikwand rond de primaire incisie aanwezig 
in 78,9% van de patiënten, vergeleken met 37,7% in de laparoscopische groep (P <0,001). De 
incidentie van adhesies ergens anders aan de ventrale buikwand en de totale incidentie van adhesies 
(buikwand en/of visceraal) waren ook significant hoger na een open operatie. Echter, nog steeds was 
totale incidentie van adhesies (buikwand en/of visceraal) hoog met 62,3% na een laparoscopische 
colorectale resectie, en de incidentie van viscerale adhesies was niet significant verschillend tussen 
de open en laparoscopische groep. 
Deze grote prospectieve studie is de eerste met volledige en klinisch relevante gegevens over 
adhesies na laparoscopische resectie van colorectaal carcinoom. De bevindingen bevestigen eerdere 
studies dat laparoscopie minder adhesies geeft,  maar weerleggen de algemeen heersende mening 
dat laparoscopie adhesieformatie minimaliseert. Deze bevindingen kunnen de wetenschappelijke 
basis vormen om ook bij laparoscopische colorectale chirurgie adhesiebarriers te gebruiken. 
In hoofdstuk 6 wordt een systematische review en meta-analyse gepresenteerd van het bewijs voor 
de effectiviteit en veiligheid van de vier commercieel verkrijgbare adhesiebarriers. Alle 
gerandomiseerde klinische trials die het gebruik van ‘oxidized regenerated cellulose’, ‘hyaluronate 
carboxymethylcellulose’, ‘icodextrin’, of ‘polyethylene glycol’ in abdominale chirurgie evalueerden, 
werden verzameld. Het gebruik van een barrier werd vergeleken met geen barrier op negen vooraf 
bepaalde eindpunten, geclassificeerd naar klinische relevantie. Heroperatie voor 
adhesiegerelateerde dunne darmobstructie was de primaire uitkomstmaat. Secundaire uitkomsten 
waren ernstige complicaties, de totale incidentie van adhesies, heroperatie tijd, dunne 
darmobstructie ongeacht de oorzaak, locatie-specifieke incidentie van adhesies, en de adhesiescore. 
We beoordeelden systematische fouten, toevallige fouten en ontwerpfouten door middel van een 
nieuwe ‘error-matrix’-aanpak. 
De risico's van systematische en toevallige fouten waren laag. Er waren geen studies naar het effect 
van oxidized regenerated cellulose of polyethylene glycol op reoperaties voor adhesiegerelateerde 
dunne darmobstructie. Er zijn aanwijzingen dat hyaluronate carboxymethylcellulose de incidentie 
van reoperaties voor adhesiegerelateerde dunne darmobstructie vermindert (RR 0,49, 95% CI 0,28-
0,88). Voor icodextrin was er geen significant verschil in reoperatie voor adhesiegerelateerde dunne 
darmobstructie (RR 0,33, 95% CI 0,03-3,11). Het gebruik van geen van de barriers was geassocieerd 
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met een toename van ernstige complicaties. Het gebruik van oxidized regenerated cellulose 
verlaagde de incidentie van adhesies (relatief risico [RR] 0.51, 95% CI 0,31-0,86). 
We concluderen dat is bewezen dat oxidized regenerated cellulose en hyaluronate 
carboxymethylcellulose op een veilige manier het risico op klinisch relevante gevolgen van adhesies 
verminderen. 
In de huidige klinische praktijk worden adhesiebarriers zelden gebruikt. Twijfels over 
kosteneffectiviteit en de noodzaak van adhesiepreventie in het minimaal invasieve tijdperk liggen 
hieraan mogelijk aan ten grondslag. In hoofdstuk 7 wordt een beslisboommodel gepresenteerd voor 
het gebruik van een adhesiebarrier in open en laparoscopische colorectale chirurgie. 
De huidige klinische praktijk (geen adhesie barrier) werd vergeleken met gebruik van een 
adhesiebarrier. De klinische gevolgen van adhesies die in het model werden meegenomen zijn 
adhesiegerelateerde dunne darmobstructie (ASBO) en moeilijkheden bij abdominale reoperatie. Het 
best beschikbare bewijs uit de literatuur en ziekenhuis gegevens werden gebruikt voor de kansen en 
de kosten in het model. Hyaluronate carboxymethylcellulose (HA/CMC) is de enige adhesiebarrier 
waarvan consistente gegevens beschikbaar zijn ten aanzien van adhesiepreventie en preventie van 
klinische gevolgen van adhesies in viscerale chirurgie. Bij gebrek aan bewijs voor HA/CMC in 
laparoscopische chirurgie, werden de werkzaamheid van de HA/CMC in de open colorectale resectie 
geëxtrapoleerd naar het laparoscopische model. Uitkomsten van het model waren het effect op de 
incidentie van ASBO en de incidentie van adhesies bij abdominale reoperaties, de directe kosten van 
de gezondheidszorg, en ‘incremental cost effectiveness’-ratio van de adhesiebarrier voor het 
voorkomen van adhesies bij één patiënt. 
Uitgaande van de ‘baseline’-waarden van de parameters en een vier jaar follow-upperiode was de 
adhesiebarrierstrategie voor het open cohort zowel goedkoper als effectiever dan geen 
adhesiebarrierstrategie. In het laparoscopische cohort was de adhesiebarrierstrategie ook 
effectiever, maar waren de kosten $ 40 hoger per behandelde patiënt. De incremental cost 
effectiveness-ratio was $ 135 per patiënt waarbij adhesies voorkomen werden in de laparoscopische 
colorectale chirurgie-groep. Probabilistische sensitiviteitsanalyse toonde een 65% waarschijnlijkheid 
van kostenvermindering met gebruik van een adhesiebarrier in het open cohort. Die kans was 37% in 
het laparoscopische cohort. Een analyse van de drempelwaarden toonde aan dat in het open cohort 
het gebruik van een adhesiebarrier niet langer kostenreducerend was als de prijs voor de barrier $ 
732 of meer was, of als er een kans op reoperatie van 15% of minder was. In het laparoscopische 
cohort waren de drempels voor kostenreductie met een adhesiebarrier een barrier van $ 589 of 
minder, en een reoperatiekans van 25% of meer. We hebben een slechtste en beste scenario voor de 
effectiviteit van de adhesiebarrier uitgevoerd door middel van een analyse met de boven- en 
ondergrenzen van de betrouwbaarheidsintervallen. Het slechtste scenario resulteerde in een 
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incremental cost effectiveness-ratio per patiënt met uitblijven van adhesies van $ 908 in het open en 
$ 1663 in het laparoscopische cohort. In het beste scenario was gebruik van een adhesiebarrier 
kostenreducerend in zowel open als laparoscopische colorectale chirurgie. 
De conclusie is dat adhesies, adhesiegerelateerde dunne darmobstructie en adhesiegerelateerde 
problemen bij abdominale reoperatie effectief gereduceerd kunnen worden met behulp van een 
adhesiebarrier, in open en laparoscopische colorectale chirurgie. Voor laparoscopische colorectale 
chirurgie kan dit gepaard gaan met beperkte kosten en voor open colorectale chirurgie zal dit 
waarschijnlijk leiden tot kostenbesparing. 
In hoofdstuk 8 presenteren we het protocol voor een gerandomiseerd gecontroleerd onderzoek over 
de werkzaamheid en veiligheid van een nieuwe adhesiebarriermembraan, C-QurTM film, bij patiënten 
die een open of hand-assisted laparoscopische colorectale resectie ondergaan. De film is verkrijgbaar 
in verschillende maten en slechts klevend aan één zijde, wat hem mogelijk geschikter maakt voor 
plaatsing in kleine ruimtes dan andere membraanbarriers. De primaire uitkomstmaat is de incidentie 
van adhesies op de plaats van de incisie. Incidentie van adhesies wordt beschouwd als het meest 
waardevolle surrogaat eindpunt voor klinisch relevante adhesiepreventie, omdat een dunne 
darmobstructie en adhesiolyse bij reoperatie zeer waarschijnlijk niet zullen optreden wanneer 
volledige adhesiepreventie wordt bereikt. Deze studie zal waardevolle prospectieve informatie 
opleveren over adhesieformatie na laparoscopische vergeleken met open colorectale resectie en 
over de effectiviteit van het gebruik van een adhesiebarrier om adhesies te voorkomen. 
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met een toename van ernstige complicaties. Het gebruik van oxidized regenerated cellulose 
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Dankwoord 
 
Dit proefschrift was er nooit gekomen zonder de hulp en steun die ik van veel mensen heb mogen 
ontvangen. Ik wil allen die hieraan hebben bijgedragen graag bedanken en een aantal mensen in het 
bijzonder. 
 
Geachte prof. dr. Van Goor, beste Harry, 
Op de een of andere manier klikt het. Ik heb een enorme waardering voor je creatieve geest en 
doortastendheid, en ik heb in ieder geval altijd wel het gevoel dat ik je begrijp. Gelukkig maar, want 
je vraagt regelmatig of ik het begrijp; overigens een tic die ik van je overgenomen schijn te hebben. 
Het plan dat zo spontaan ontstond voor mij, blijkt nu dan toch ook helemaal te kloppen. Heel veel 
dank voor de inspiratie en steun die je me hebt gegeven en nog altijd geeft. 
 
Geachte prof. dr. De Wilt, beste Hans, 
De afgelopen jaren heb ik me onder jouw leiding zowel wetenschappelijk als klinisch kunnen 
ontwikkelen. Met jouw ontembare energie en enthousiasme hield je me scherp, maar waar nodig 
remde je me ook af. Ik was het daar niet altijd mee eens, maar ik heb zeer gewaardeerd dat we daar 
dan ook altijd goed over konden praten. Heel veel dank voor het vertrouwen dat ik van je heb 
gekregen! 
 
Beste Chema, 
Strik jongen, zonder jou was het niet gelukt. Jij als onderzoeker en ik als jonge klare, schouder aan 
schouder in de strijd tegen adhesies. Je was nooit te beroerd om mij te helpen mijn gedachten te 
ordenen, als de locale Andy Field de statistiek uit te leggen, en niet te vergeten een agenda te 
verzorgen voor het wekelijkse overleg met Harry. Mooi dat we beide nu ons proefschrift af hebben, 
ik ben beniewd naar waar jij het klinisch gaat maken! 
 
Beste Richard, 
Met jouw indrukwekkende wetenschappelijke prestaties en uiteindelijke proefschrift in 2014, heb je 
destijds het uitgangspunt voor mijn proefschrift gevormd. Tezamen met jou hebben we in 2012 mijn 
onderzoeksplannen opgesteld. Ik wil je zeer bedanken voor je waardevolle input, maar meer nog 
aanmoedigen in al je ambities in de adhesieresearch. 
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Geachte prof. dr. Rovers, beste Maroeska, 
Niet alleen heb je me geholpen bij de analyse van de big data, maar vooral ben je mijn Radboud 
Institute of Health Sciences PhD mentor. Om beide redenen hebben we gedurende mijn 
promotietraject regelmatig overleg met elkaar gehad, met ook buiten mijn promotie om mooie 
plannen en samenwerking als resultaat. Dit is een uitgelezen moment om je daarvoor te bedanken, 
en ik kijk uit naar wat er nog komen gaat. 
 
Geachte leden van de manuscriptcommissie en geachte overige leden van de promotiecommissie, 
veel dank voor uw kritische beoordeling van mijn proefschrift en voor uw bereidheid te willen 
opponeren. 
 
Mijn paranimfen, Klaas en Peter, 
Klaas, alvast dank dat je tijdens mijn promotie zo goed naast me zal staan. Heerlijk dat je als vriend 
de afgelopen jaren altijd belangstelling hebt gehouden voor waar ik mee bezig was, en dat je iedere 
keer vroeg of je al moest beginnen met lezen. Ik hoop dat ze een moeilijke vraag aan je stellen! 
Peter, of het nu de laparoscopische HPB chirurgie is of mijn promotie, we helpen elkaar al jaren om 
het tot een succes te maken, en het lijkt nu weer te lukken. Je bent in de loop der (bijna 8) jaren mijn 
beste collega en een vriend geworden. Veel dank daarvoor! 
 
Lieve pap en Annette, 
Jullie hebben altijd belangstelling voor eigenlijk alles in ons leven, en hebben ook bij mijn promotie 
zo meegeleefd, waarvoor veel dank. Pap, je waardevolle adviezen hebben de totstandkoming van dit 
proefschrift mede mogelijk gemaakt. Het belangrijkste is misschien wel dat je me vroeger hebt 
gestimuleerd me te concentreren en langer dan een half uur in een boek te lezen. Het lijkt wat 
opgeleverd te hebben, en ik heb dit proefschrift zelfs met veel plezier geschreven. 
 
Lieve mam, 
Wie staat er altijd voor je klaar? Ik doe er misschien niet zo vaak een beroep op, maar dat is 
misschien wel zo omdat het genoeg is te weten dat het kan. Ik ben heel blij met je liefde en steun. Je 
bent soms kritisch, onder andere ten aanzien van mijn werk, en dat helpt mij in het vinden van een 
goede balans. Ik ben heel blij met jou als moeder.  
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Lieve Wyke, 
Als oudere zus ben je natuurlijk toch mijn voorbeeld geweest. Ontzettend leuk dat, ondanks de totaal 
verschillende routes die we afgelegd hebben, we nu plannen uitwerken voor gezamenlijk onderzoek. 
Bedankt voor de inspiratie, en natuurlijk ook voor je tekstuele commentaar bij dit proefschrift. 
 
Lieve Riske en natuurlijk Fien en Daan, 
Tja schat, we hebben het vaak gehad over wat er in mijn dankwoord zou komen te staan, en vooral 
ook wat er niet in zou staan. Net zoals we het trouwens vaak gehad hebben over de overige inhoud 
van dit boekje. Je oprechte interesse kenmerkt jou en vind ik ongelooflijk lief en fijn. Je bent altijd 
een grote steun voor mij en zonder jou was dit proefschrift er zeker niet gekomen. Dat er nog maar 
een leven lang van alles met jou mag komen! 
En kindjes, papa houdt heel veel van jullie en jullie zijn het allermooiste dat er met mama gekomen 
is. 
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